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ABSTRACT 
The World Health Organisation suggests that falsified and substandard medicines 
(FSMs) constitute approximately 10% of medicines globally with higher figures 
expected in low and middle income countries (LMICs). To combat the proliferation of 
FSMs this study is aimed at developing simple and rapid instrumental methods for the 
identification and quantification of these medicines. Attenuated Total Reflection-Fourier 
Transform Infrared (ATR-FTIR) spectroscopy, Raman spectroscopy and two probe 
Mass Spectrometry (MS) methods were assessed for the rapid screening of tablet 
dosage forms. These systems were chosen because NO solvent extraction of the 
sample was required. Comparison with analyses of the tablets by accepted but more 
time consuming methods (UV-Vis and LC-MS) assessed the quality of the data 
obtained. Analgesic/antipyretic and antimalarial medicines tablet dosage forms are 
commonly falsified and for this study tablets were obtained opportunistically from 
different countries around the world. Reference spectra of appropriate active 
pharmaceutical ingredients (APIs) and excipients were created, for each method, as 
part of the identification process. Currently only Raman and ATR-FTIR delivered 
quantitative results which were based on automated multivariate analysis. 
For tablets with a single API, Raman and ATR-FTIR provided the simplest route to API 
confirmation and for tablets with multiple APIs or APIs present at <10%w/w, in the 
tablet, probe MS methods were superior. Quantitative screening using ATR-FTIR 
required the samples to be weighed and crushed to produce reproducible data. 
Comparison of API confirmation tests between trial methods and LC-MS showed 
complete agreement and the quantitative results were within ±15% of the UV-Vis data.  
Each of the new tests can be completed in under five minutes and a survey of 69 
paracetamol tablets, from around the world, showed that 10% were suspect. 
Subsequent probe MS showed the presence of a second undeclared API in different 
samples. More complex tablet formulations, for example the antimalarials were difficult 
to quantify rapidly. Raman and PCA methods provide a rapid approach to tablet 
identification within a limited range of possibilities. Factors that may affect Raman 
spectra of tablets include the expected API, the API levels, different excipients, colours 
or surface coatings for the tablets.  
The simplicity, speed and cost effectiveness of the proposed analytical methods make 
them suitable for use in LMICs. The potential use of these simple analytical methods in 
addition to already established pharmacopoeia approved (solvent extraction) 
techniques could help provide more comprehensive data about FSMs globally.    
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1.1 Introduction  
Medicines, particularly tablet formulations, may not correspond to the description on 
the packaging. In the literature, such tablets are variously described as: counterfeit, 
falsified or substandard. The currently appropriate choice of descriptions are discussed 
in Chapter 2. 
Falsification of medicines is a growing global problem and a serious crime considering 
the threat they pose to human health. The United Nations Sustainable Development 
Goals for 2030 also includes access to “safe, effective, quality and affordable essential 
medicines” acknowledging the severity of the falsified medicines situation (Petersen et 
al, 2017). The difficulty in controlling the falsified medicines market can be attributed in 
no small measure to the complex medicines distribution network with numerous actors 
involved at different stages of the medicine distribution chain (Martino et al, 2010; 
Dégardin et al, 2014). The huge profits that can be made by the falsifiers of medicines 
could be a driving force for this phenomenon (Martino et al, 2010; Rebiere et al, 2017). 
Counterfeiting of medicines is an age old practice which dates back to the 4th century 
BC with Pedanius Dioscorides being the first to mention counterfeit medicines (Newton 
et al, 2006). However, regulations on the trade of the medicines did not include the 
control of counterfeits until 1988 when resolutions against counterfeit medicines were 
adopted (Newton et al, 2006).  
Over time, falsification of medicines has been on the rise with current estimates 
indicating that about 10% of the medicines sold worldwide are falsified or substandard 
(Dégardin et al, 2014). Industrialisation, globalisation and the increasing access to 
medicines via the internet makes the situation even more alarming. Reports suggest 
that over 50% of the medicines sold via the internet may be counterfeit even in 
developed countries like the United States of America (USA) and United Kingdom 
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(Martino et al, 2010; Jackson et al, 2012). This is alarming and calls for urgent action 
even more so because children may have access to and abuse prescription medicines 
exposing them to these falsified medicines. Falsification of medicines has also been 
identified as a branch of organised crime (Dégardin et al, 2015). 
Medicines presented to a patient are usually a combination of the active ingredient with 
several non-active materials called excipients. The excipients generally have no 
bioactivity but are present to protect, bulk out or make the active pharmaceutical 
ingredient (API) more readily available for bio assimilation. 
Whilst medication formulations may be liquids or solids, there is an industry move 
towards tablet formulations so that the patient can take responsibility for adherence to 
the prescribed regimen. API doses can range from 1-1000mg whilst typical tablet 
overall masses range from 100-1100mg. The API level ranges from < 1%, for some 
tablets, to approximately 90% for paracetamol tablets. The aim of the counterfeiter 
therefore is to produce medicines that would pass as or are similar to the genuine 
formulation even though it is falsified.  
In this thesis, the expression falsified/substandard medicines (FSMs) will be the term 
used for all suspect/ questionable medicines. “Falsified” and “counterfeit” will be used 
interchangeably when referring to medicines that are fraudulently mislabelled or 
misrepresented with respect to their identity or source. This is because they refer to the 
same group of medicines as mentioned earlier. Falsified and substandard medicines 
range from those with incorrect amounts of the Active Pharmaceutical Ingredient (API) 
to those with no API(s) present (Davison, 2011). Unlike the counterfeiting of other 
goods, counterfeit medicines could be potentially life threatening and as such, require 
urgent attention (Mackey and Liang, 2011).  More sophisticated techniques are now 
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employed in the manufacture and packaging of falsified and substandard medicines 
making it increasingly difficult to detect them (Kovacs et al, 2014).  
Trade in falsified and substandard medicines depends on profit margins like any other 
commerce and so will thrive where demand is high and there is shortage of supply. It is 
important to note that even cheap medicines are attractive to falsifiers of medicines 
provided the potential volume of sales is high enough. In addition, trade in falsified and 
substandard medicines is facilitated by the ignorant, the careless, the unscrupulous 
and the criminal and so thrives in regions where the risk of detection is low and the 
technical capacity is weak (WHO, 2017). Limited access to quality medicines that are 
both safe and affordable is another huge challenge especially in low and middle-
income countries. The cost pressures and inadequate supply of medicines at any point 
in the medicines supply chain allows counterfeiters to fill in or take care of the deficit 
with falsified/substandard medicines. There is also the lack of legislation prohibiting the 
manufacture or sale of FSMs in many countries and corruption among officials, which 
allows counterfeiters of medicines to thrive. Penalties for manufacturing FSMs in many 
other cases are weak and therefore encourage the counterfeiters to continue with this 
crime of medicine falsification with unfavourable implications on the legal manufacturer 
and the consumers of the falsified medicines (Dégardin et al, 2015). 
Falsified medicines (whether with incorrect amounts of API(s) or no API(s) present) can 
lead to therapeutic failure. Therapeutic failure due to falsified or substandard medicines 
implies that the patient does not get better, the patient’s condition worsens or ultimately 
the patient/consumer dies. For instance, incorrect amount of API(s) could lead to drug 
resistance reducing the bioactivity of the medicine as well as providing no relief for the 
patient even after administration of the required dose. Drug resistance is a serious 
global challenge especially with antimalarial medicine and antibiotics costing the 
pharmaceutical industry millions of pounds every year. Generally, drug resistance is 
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linked to abuse of medication but falsified and substandard medicines might be 
responsible for even more cases of drug resistance than have been reported. This is 
because drug resistance is identified, only in retrospect, when the patient shows no 
positive response to the prescribed dosage of the medication administered. It is 
therefore difficult to say conclusively whether one or a combination of factors is 
responsible for drug resistance in each case reported. This implies that several cases 
of drug resistance caused by falsified and substandard medicines may be going 
unnoticed and attributed to other factors unless measures are put in place to assess 
medicines from manufacturing level to the point of sale to the final consumer.  Besides 
the health risk associated with therapeutic failure from falsified or substandard 
medicines, there is the additional costs to healthcare suppliers who have to spend 
more funds to provide treatment for the patients in cases where medication did not 
work. 
Irrespective of whether people live in low and middle income or developed countries, 
they can be affected by the sale/distribution of falsified and substandard medicines 
(Dégardin et al, 2015). A typical example would be patients suffering from tuberculosis, 
who have been administered falsified anti-tuberculosis medicines. The patients taking 
falsified anti-tuberculosis medicines could pose a huge health risk to all those they 
come in contact with including tourists from different countries. Falsification of 
medicines also leads to economic losses for both the legal manufacturer of the 
medicine and the consumer/patient purchasing the medication. Due to low cost of 
production, falsified medicines are generally cheaper and more accessible to 
consumers. It is more likely that the demand for the cheaper and more affordable 
falsified medicines will be higher than for the more expensive genuine product. 
Declining demand for genuine medicines would invariably lead to losses for the legal 
manufacturers of the medicine. For the patient/consumer on the other hand, money 
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spent on the falsified medicine would be lost since the falsified/substandard medicine 
does not provide any relief from the debilitating ailment (Deisingh, 2005; Dégardin et al, 
2014). It is therefore important that there are quality checks and assessments for 
medicines at different points throughout the medicines distribution chain. 
Current techniques used in the detection of falsified and substandard medicines involve 
lengthy procedures for analysis and the techniques are very expensive making these 
analyses less feasible in low and middle-income countries where resources are limited 
(Kovacs et al, 2014). Therefore, a simple, rapid and cost effective detection system for 
falsified and substandard medicines would help in addressing this challenge of 
medicine falsification. Different approaches have been employed in the detection of 
counterfeit medicines, the first being visual inspection or physical examination of the 
packaging and then the medicines (Davison, 2011).  
Visual inspection/physical examination of medicines starts with the packaging; are 
there any unique features, which could be covert or overt such as logos, watermarks or 
radio-frequency identification tags? For example, absence of leaflets and/or 
inconsistencies in labelling on packaging compared to authentic tablets could help 
identify falsified medication. Newton et al. (2011) identified falsified antimalarial 
medicines based on observed differences in their packaging. Tablet inspection could 
include noting the length, width, thickness, mass, shape, colour and 
markings/inscriptions on the tablet (Kovacs et al, 2014). Custers et al (2016), in their 
study showed measurements of tablets length and mass helped discriminate genuine 
Viagra® tablets from falsified ones. 
Nowadays, simple visual inspection of the medicines no longer suffices for the 
screening of medicines since the falsifiers of medicines now use more sophisticated 
approaches (Martino et al, 2010; Dégardin et al, 2014). Consequently, more advanced 
analytical techniques are required to detect suspect medicines as fast as possible, to 
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get them out of the market to help curb the threat falsified and substandard medicines 
pose to public health. 
Some simple and easy analytical methods used for screening of medicines include, 
colorimetry, thin-layer chromatography (TLC) and melting point determination 
(Dégardin et al, 2014). These simple analytical methods easily identify the presence or 
absence of the API and/or excipient in the medication, hence, provide quick screening 
of samples. The absence of API(s)/excipients declared on the packaging or the 
presence of API(s)/excipients not declared suggests the medicine might be counterfeit 
and needs further analysis. The drawback with the simpler colorimetric and TLC based 
methods for quick screening of medicines mentioned earlier is that they are qualitative 
based techniques and so will not be able to detect counterfeits where incorrect 
amounts of APIs are present but rather identify the presence or absence of the API 
concerned. Furthermore, some of these simple qualitative methods are specific for 
particular medicines such as the paper test cards for assessing antimalarial tablets 
(Weaver and Lieberman, 2015) implying that different methods will be developed for 
different medicines making the process laborious (Martino et al, 2010). Nevertheless, 
the simple qualitative methods are useful as fast preliminary checks for medicines.  
Other more advanced separation techniques that could be used for further 
quantification of APIs or excipients in medicines are gas chromatography (GC), high 
performance liquid chromatography (HPLC), Ultraviolet Visible (UV-vis) spectroscopy, 
nuclear magnetic resonance (NMR) and mass spectrometry (MS) (Görög, 2015). 
Hyphenated mass spectrometry techniques such as GC-MS and LC-MS have also 
been investigated in the quantification of APIs. Despite the fact that these techniques 
are more robust, much longer sample preparation times are required since APIs and/or 
excipients have to be solvent extracted before analysis. These more advanced 
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techniques are also expensive and require skilled personnel for both analysis and 
interpretation of results (Kovacs et al, 2014).  
Simple techniques requiring little or no sample preparation prior to analysis help to 
speed up analysis time and thus would be apt for the first-line analysis of falsified 
medicines (Kovacs et al, 2014). Cost-effectiveness and portability are also important 
features to consider when choosing methods for screening falsified and substandard 
medicines. Cheaper (cost of production and maintenance) methods will make the 
techniques more accessible to wide range of users globally and therefore facilitate 
quicker analysis at different points in the medicines distribution chain. Portability of the 
equipment is also important in screening for falsified medicines in order to ensure ease 
of use on the field or at the point of sale of the medicines. The speed of analysis, 
cheaper costs, portability and simplicity of the technique employed in the screening of 
medicines will go a long way in facilitating in-field analysis of medicines especially in 
low and middle-income countries (Höllein et al, 2016). 
Taking into account the important features for techniques employed in screening 
falsified medicines (highlighted in the previous paragraph), vibrational spectroscopic 
techniques would be well suited for screening medicines since minimal sample 
preparation is required prior to analysis. With spectroscopic-based methods, the 
excitation of fundamental molecular rotations or vibrations gives rise to unique spectra 
for the individual samples (Been, 2011). Generally, spectroscopic techniques can 
assess both solid and liquid samples and require minimal amount of sample (just 
enough to cover the sampling window) because they are surface based techniques. 
Although the IR system was initially a transmission system, current modifications of the 
system allows the excitation of fundamental vibrations only few micrometres beyond 
the sample surface. Very small amounts of sample needed will in turn reduce exposure 
of the analyst to harmful chemicals or substances in the medicines investigated.   
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Raman and Near Infrared (NIR) spectroscopy have been extensively used for the 
analysis of pharmaceutical tablet (solid dosage) formulations though most 
investigations were qualitative, focusing on identifying the sources of the medicines (de 
Veij et al, 2007; Moffat et al, 2010; Mbinze et al, 2015; Dégardin et al, 2016). Raman 
spectroscopy involves heating the test tablet sample via intense laser radiation that 
could in turn destroy the sample or cover the Raman spectrum. Although no sample 
preparation is needed with Raman spectroscopy and samples can be analysed through 
packaging, there might be challenges obtaining good data/ Raman spectra from solid 
formulations which are poorly homogenised or medicines that fluoresce. Poor Raman 
spectra obtained could be because of the weak Raman effect (scattering the inelastic 
part of light by a sample irradiated by a laser). As such, Raman instrumentation has to 
be highly optimised in order to obtain valuable spectra (Deisingh, 2005). The analyst 
may also be exposed to strong laser radiation which is a health risk. NIR on the other 
hand produces spectra with broad peaks which are less specific and are rather 
indicative of vibrational combination and overtones of oxygen-hydrogen (-OH), 
nitrogen-hydrogen (-NH) and carbon-hydrogen (-CH), not particular functional group 
vibrations or rotations (Moffat et al, 2010; Dégardin et al, 2016). Fourier transform 
infrared (FTIR) has been investigated in the analysis of falsified medicines as it 
eliminates the need for solvent extraction of the APIs/excipients. However, skilled 
personnel are needed for sample preparation using transmission FTIR as this involves 
dispersing about 0.1- 2% w/w of the sample in a KBr matrix and pressing it into a disc 
before analysis. The strength of the IR spectra is dependent on the amount and 
homogeneity of the powder sample dispersed in the matrix. Therefore, ensuring the 
right amount of sample in the matrix is crucial in order to obtain good and well-defined 
FTIR spectra. Sample preparation involving dispersion in a matrix in turn lengthens 
time for analysis (Mallah et al, 2015).   
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The use of Attenuated Total Reflection- Fourier Transform Infrared (ATR-FTIR) 
spectroscopy can address the problems identified with Raman and NIR spectroscopy 
(Custers et al, 2011). The spectral peaks with ATR-FTIR spectroscopy are also more 
specific addressing the challenges of poor specificity with NIR spectroscopy. In 
addition, minimal sample preparation is needed, solid pharmaceutical formulations are 
only crushed before analysis. For a tablet, just enough powder to cover the tip of a 
micro spatula is needed for analysis. The ATR-FTIR spectrum is obtained within a few 
seconds. So far, this technique has been used primarily for qualitative analysis of 
medicines (Ortiz et al, 2013; Custers et al, 2015).  
Apart from the spectroscopic techniques, mass spectrometry (MS) was investigated as 
a technique for the rapid authentication of medicines based on its high accuracy, 
selectivity and quantitative abilities. While the spectroscopic techniques are relatively 
low cost, rapid and are able to detect the presence of the expected API(s), they do not 
provide detailed compositional information pertaining to contaminants or wrong APIs. 
MS is able to detect molecules based on the ionisation of the analyte and sorts the ions 
according to their mass-to-charge ratios (m/z) thereby providing a valuable tool for the 
characterisation of individual components in medicines. The ability of MS to 
characterise individual components in medicines will facilitate the detection of falsified 
medicines that might contain other APIs not declared on the packaging or 
contaminants. Detailed MS data could also aid forensic investigations in linking/tracing 
falsified medicines to their source or countries of origin. On the other hand, MS is only 
capable of detecting analytes that are converted to gas phase ions. Liquid and gas 
chromatography coupled to mass spectrometry (LC-MS and GC-MS respectively) are 
the most commonly used MS techniques by regulatory agencies and laboratories in 
pharmaceutical companies in developed countries (Culzoni et al, 2014). However, LC-
MS and GC-MS are expensive techniques and have limited sample throughput 
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resulting from extensive sample preparation requirements before analysis and actual 
duration of the chromatographic runs. The high cost and limited sample throughput 
using LC-MS and GC-MS implies that these techniques (LC-MS and GC-MS) will not 
be easily accessible in LMICs.  More cost-effective complementary techniques with 
increased sample throughput that can provide reliable answers rapidly are highly 
desirable especially in LMICs.  
Improving sensitivity has been the focus of recent efforts towards miniaturization of 
mass spectrometers to make them more portable (Kumano et al, 2015; Snyder et al, 
2015). Optimisation of these portable mass spectrometry (MS) based techniques could 
be important in the efforts towards detecting falsified and substandard medicines. 
Kumano et al, (2015) recently developed a probe heating method for a portable mass 
spectrometer, for the analysis of solid samples. This method was used in the detection 
of illicit drugs but there was no mention of the use of the probe heating MS method as 
a technique for detection of falsified medicines. Probe heating MS method otherwise 
known as Direct Insertion Probe- Mass Spectrometry (DIP-MS) could occur by electron 
ionisation (conventional hard ionisation) or by ambient (soft) ionisation. Minute amount 
of sample is also required for DIP-MS (just a flick of TLC spotter dipped in sample). 
The conditions influencing fragmentation pattern of samples being analysed include the 
ionisation environment (atmospheric or vacuum) within which ionisation takes place as 
well as the energy (soft or hard) employed during ionisation of the samples.  
MS methods such as Direct Analysis in Real Time (DART) and Desorption 
Electrospray Ionisation (DESI) have been identified as suitable for assessing medicines 
since minimal sample preparation is needed before analysis (Culzoni et al, 2014; 
Rebiere et al, 2017; Zou et al, 2017). DART and DESI-MS are ambient ionisation MS 
methods meaning ionisation occurs in open air and outside of the vacuum environment 
of the mass spectrometer and they generate ions softly (Monge et al, 2013). The high 
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throughput capabilities of DART and DESI-MS make them valuable methods for quick 
and reliable screening of large numbers of both solid and liquid pharmaceutical 
formulations (Culzoni et al, 2014; Bernier et al, 2016). Culzoni et al, (2014) identifies 
DART and DESI as solid-liquid extraction based MS techniques suggesting solid 
samples are dissolved in a solvent prior to analysis. Another, ambient ionisation 
technique used for analysis in recent times is the direct analysis probe also known as 
Atmospheric Solid Analysis Probe (ASAP) but as mentioned earlier (with DIP-MS) its 
potential in the screening of medicines has scarcely been explored. ASAP-MS require 
soft ionisation, allows fast analysis of both solid and liquid samples with quality data 
available within seconds and minimal sample preparation is needed prior to analysis as 
with DART and DESI. In addition to the advantages ASAP-MS shares with other 
ambient MS techniques like DART and DESI, it is also a low cost alternative to the 
other direct analysis MS techniques. Furthermore, ASAP-MS provides a replacement 
for the conventional electron ionisation (EI) vacuum solids probe which involves longer 
sampling time and requires hard ionisation. Therefore, ASAP-MS could potentially be a 
valuable option for the investigation of medicines. 
1.2 Aim of Study 
The purpose of this study was to research into the development of rapid instrumental 
methods addressing both the qualitative and the quantitative analysis of medicines 
since many counterfeit medicines in the international market also contain incorrect 
amounts of the API(s). It is therefore important to go beyond confirming the presence 
or absence of the APIs/ excipients to determine if the medicine contains the APIs in the 
right amounts. The following techniques were investigated: Attenuated Total Reflection 
Fourier Transform Infrared (ATR/FTIR) Spectroscopy, Raman Spectroscopy, 
Atmospheric Solid Analysis Probe-Mass Spectrometry (ASAP-MS), Direct Insertion 
Probe Mass Spectrometry (DIP MS) by electron ionisation (EI), UV Vis spectroscopy 
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and Liquid Chromatography- Mass Spectrometry (LC-MS). Direct Insertion Probe Mass 
Spectrometry by EI and ambient ionisation (ASAP-MS), UV Vis spectroscopy and LC-
MS were used to validate the results based on the ATR/FTIR and Raman 
spectroscopy. In summary, this research proposes: 
 Simple, rapid and robust instrumental methods for the authentication of solid 
pharmaceutical formulations/ medicines  
 The use of data obtained based on developed methods to facilitate forensic 
investigations in tracing falsified medicines to their origin or source. 
Optimised methods were employed in the analysis of analgesic/antipyretic and 
antimalarial tablets available to patients in the UK and worldwide. The results show the 
potential of the spectroscopic and DIP-MS techniques and it is hoped that this will help 
facilitate both qualitative and quantitative detection of falsified medicines (especially in 
the field) and in turn forensic investigations of falsified and substandard medicines 
even in LMICs. 
1.3 Thesis Outline 
This thesis focuses on the investigation of simple and rapid instrumental methods for 
qualitative and quantitative analysis of falsified medicines as mentioned in 1.2. The first 
chapter of this thesis gives an overview and general background of the research 
project including the aim of the study. Chapter 2 provides a theoretical background with 
current literature in the subject highlighting the extent of the problem and analytical 
techniques commonly used for investigating counterfeit medicines.  
Methods based on different analytical techniques were assessed for their potential for 
the rapid detection of counterfeit pharmaceutical tablet formulations. The next three 
chapters focus on rapid qualitative and quantitative analysis of counterfeit medicines. 
Chapter 3 covers the development of novel screening methods for counterfeit 
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medicines based on ATR-FTIR. Chapters 4 and 5 describe methods for the analysis of 
tablet medication using Raman spectroscopy and DIP-MS respectively. DIP-MS by EI 
and ambient ionisation (ASAP-MS) were considered for their potential in the detection 
of counterfeit medicines with very low API concentrations which were difficult to detect 
or not well-resolved with the spectroscopic techniques (ATR/FTIR and Raman).  
Since the optimised rapid methods based on the techniques in Chapters 3-5 were able 
to detect the presence or absence of the APIs, Chapters 6 and 7 outline 
conventional/pharmacopoeia approved solvent extraction methods for quantitative 
determination of tablet medications using UV-Vis spectroscopy and LC-MS 
respectively. These conventional methods were applied in the analysis of the tablet 
medication in order to assess the YES and NO of the data based on the rapid methods 
and to ascertain the potential of the rapid methods in the screening of falsified 
medicines. Chapter 8 compares the different techniques for assessing medicines 
investigated based on data obtained. Finally, the main conclusions and results of this 
research project including future directions of the project are presented in the last 







    
15 | P a g e  
 
1.4 References 
Been, F., Roggo, Y., Degardin, K., Esseiva, P. and Margot, P. (2011) Profiling of 
counterfeit medicines by vibrational spectroscopy. Forensic Science International, 
211(1): 83-100. 
Bernier, M.C., Li, F., Musselman, B., Newton, P.N. and Fernández, F.M. (2016) 
Fingerprinting of falsified artemisinin combination therapies via direct analysis in real 
time coupled to a compact single quadrupole mass spectrometer. Analytical Methods, 
8(36): 6616-6624. 
Culzoni, M.J., Dwivedi, P., Green, M.D., Newton, P.N. and Fernández, F.M. (2014) 
Ambient mass spectrometry technologies for the detection of falsified drugs. Medicinal 
Chemistry Communications, 5(1): 9-19. 
Custers, D., Cauwenbergh, T., Bothy, J.L., Courselle, P., De Beer, J.O., Apers, S. and 
Deconinck, E. (2015) ATR-FTIR spectroscopy and chemometrics: an interesting tool to 
discriminate and characterize counterfeit medicines. Journal of Pharmaceutical and 
Biomedical Analysis, 112: 181-189. 
Custers, D., Vandemoortele, S., Bothy, J.L., De Beer, J.O., Courselle, P., Apers, S. and 
Deconinck, E. (2016) Physical profiling and IR spectroscopy: simple and effective 
methods to discriminate between genuine and counterfeit samples of Viagra® and 
Cialis®. Drug Testing and Analysis, 8(3-4): 378-387. 
Davison, M. (2011) Pharmaceutical anti-counterfeiting: combating the real danger from 
fake drugs. New Jersey: John Wiley & Sons. 
Dégardin, K., Guillemain, A., Guerreiro, N.V. and Roggo, Y. (2016) Near infrared 
spectroscopy for counterfeit detection using a large database of pharmaceutical 
tablets. Journal of Pharmaceutical and Biomedical Analysis, 128: 89-97. 
Dégardin, K., Roggo, Y. and Margot, P. (2015) Forensic intelligence for medicine anti-
counterfeiting. Forensic Science International, 248: 15-32. 
Dégardin, K., Roggo, Y. and Margot, P. (2014) Understanding and fighting the 
medicine counterfeit market. Journal of Pharmaceutical and Biomedical Analysis, 87: 
167-175. 
Deisingh, A.K. (2005) Pharmaceutical counterfeiting. Analyst, 130(3): 271-279. 
de Veij, M., Vandenabeele, P., Hall, K.A., Fernandez, F.M., Green, M.D., White, N.J., 
Dondorp, A.M., Newton, P.N. and Moens, L. (2007) Fast detection and identification of 
counterfeit antimalarial tablets by Raman spectroscopy. Journal of Raman 
Spectroscopy, 38(2): 181-187. 
Görög, S. (2015) Identification in drug quality control and drug research. TrAC Trends 
in Analytical Chemistry, 69: 114-122. 
    
16 | P a g e  
 
Höllein, L., Kaale, E., Mwalwisi, Y.H., Schulze, M.H. and Holzgrabe, U., (2016) Routine 
quality control of medicines in developing countries: Analytical challenges, regulatory 
infrastructures and the prevalence of counterfeit medicines in Tanzania. TrAC Trends 
in Analytical Chemistry, 76: 60-70. 
Jackson, G., Patel, S. and Khan, S. (2012) Assessing the problem of counterfeit 
medications in the United Kingdom. International Journal of Clinical Practice, 66(3): 
241-250. 
Kovacs, S., Hawes, S.E., Maley, S.N., Mosites, E., Wong, L. and Stergachis, A. (2014) 
Technologies for detecting falsified and substandard drugs in low and middle-income 
countries. PLoS One, 9(3): e90601. 
Kumano, S., Sugiyama, M., Yamada, M., Nishimura, K., Hasegawa, H., Morokuma, H., 
Inoue, H. and Hashimoto, Y. (2015) Probe Heating Method for the Analysis of Solid 
Samples Using a Portable Mass Spectrometer. Mass Spectrometry, 4(1): A0038. 
Mackey, T.K. and Liang, B.A. (2011) The global counterfeit drug trade: patient safety 
and public health risks. Journal of Pharmaceutical Sciences, 100(11): 4571-4579. 
Mallah, M.A., Sherazi, S.T.H., Bhanger, M.I., Mahesar, S.A. and Bajeer, M.A. (2015) A 
rapid Fourier-transform infrared (FTIR) spectroscopic method for direct quantification of 
paracetamol content in solid pharmaceutical formulations. Spectrochimica Acta Part A: 
Molecular and Biomolecular Spectroscopy, 141: 64-70. 
Martino, R., Malet-Martino, M., Gilard, V. and Balayssac, S. (2010) Counterfeit drugs: 
analytical techniques for their identification. Analytical and Bioanalytical Chemistry, 
398(1): 77-92. 
Mbinze, J.K., Sacré, P.Y., Yemoa, A., Mbay, J.M.T., Habyalimana, V., Kalenda, N., 
Hubert, P., Marini, R.D. and Ziemons, E. (2015) Development, validation and 
comparison of NIR and Raman methods for the identification and assay of poor-quality 
oral quinine drops. Journal of Pharmaceutical and Biomedical Analysis, 111: 21-27. 
Moffat, A.C., Assi, S. and Watt, R.A. (2010) Identifying counterfeit medicines using 
near infrared spectroscopy. Journal of Near Infrared Spectroscopy, 18(1): 1-15. 
Monge, M.E., Harris, G.A., Dwivedi, P. and Fernández, F.M. (2013) Mass 
spectrometry: recent advances in direct open air surface sampling/ionization. Chemical 
Reviews, 113(4): 2269-2308. 
Newton, P.N., Green, M.D., Fernández, F.M., Day, N.P. and White, N.J. (2006) 
Counterfeit anti-infective drugs. The Lancet Infectious Diseases, 6(9): 602-613. 
Newton, P.N., Green, M.D., Mildenhall, D.C., Plançon, A., Nettey, H., Nyadong, L., 
Hostetler, D.M., Swamidoss, I., Harris, G.A., Powell, K. and Timmermans, A.E. (2011) 
Poor quality vital anti-malarials in Africa-an urgent neglected public health 
priority. Malaria Journal, 10(1): 352. 
Ortiz, R.S., de Cássia Mariotti, K., Fank, B., Limberger, R.P., Anzanello, M.J. and 
Mayorga, P. (2013) Counterfeit Cialis and Viagra fingerprinting by ATR-FTIR 
    
17 | P a g e  
 
spectroscopy with chemometry: Can the same pharmaceutical powder mixture be used 
to falsify two medicines? Forensic Science International, 226(1): 282-289. 
Petersen, A., Held, N. and Heide, L. (2017) Surveillance for falsified and substandard 
medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab. 
PloS One, 12(9): e0184165. 
Rebiere, H., Guinot, P., Chauvey, D. and Brenier, C. (2017) Fighting falsified 
medicines: The analytical approach. Journal of Pharmaceutical and Biomedical 
Analysis, 142: 286-306. 
Snyder, D.T., Pulliam, C.J., Ouyang, Z. and Cooks, R.G. (2015) Miniature and fieldable 
mass spectrometers: recent advances. Analytical Chemistry, 88(1): 2-29. 
Weaver, A.A. and Lieberman, M. (2015) Paper test cards for presumptive testing of 
very low quality antimalarial medications. The American Journal of Tropical Medicine 
and Hygiene, 92(6_Suppl): 17-23. 
Zou, W.B., Yin, L.H. and Jin, S.H. (2017) Advances in rapid drug detection 
technology. Journal of Pharmaceutical and Biomedical Analysis, 147: 81-88. 
World Health Organisation- WHO (2017) WHO Global Surveillance and Monitoring 
System for Substandard and Falsified Medical Products. Geneva: World Health 
Organization. Licence: CC BY-NC-SA 3.0 IGO. Available at: 
http://www.who.int/medicines/regulation/ssffc/publications/GSMS_executive_Summary.
















    


























    
19 | P a g e  
 
2.1 What are falsified and substandard medicines? 
The difficulty in reaching an agreement on a clear-cut, globally accepted definition for 
falsified medicines (or counterfeit medicines as they were called) led to several 
consultations by the World Health Organisation (WHO) (Attaran et al, 2011; Newton et 
al, 2011; Dégardin et al, 2015). Initial amendments by the World Health Organisation 
(WHO) led to the use of the ambiguous term “substandard/ spurious/ falsely-labelled/ 
falsified/ counterfeit (SSFFC) medicines” (WHO, 2016). In defining SSFFC medicines, 
the WHO held on to the public health meaning and the life-threatening potential of 
counterfeit medicines. These amendments of the definition for counterfeit medicines 
helped clarify the difference between counterfeit and substandard medicines. Prior to 
the WHO (2016) definition of counterfeit medicines, Reggi (2007) suggested that all 
counterfeit medicines are substandard medicines but substandard medicines may not 
be termed counterfeits if there is no fraudulent intention. The WHO (2016) defines 
counterfeit and substandard medicines thus:  
 “A counterfeit medicine is one which is deliberately and fraudulently mislabelled with 
respect to identity and/or source. Counterfeiting can apply to both branded and generic 
products and counterfeit products may include products with the correct ingredients or 
with the wrong ingredients, without active ingredients, with insufficient (inadequate 
quantities of ingredient(s) or with fake packaging.” 
“Substandard medicines (also called out of specification (OOS) products) are genuine 
medicines produced by manufacturers authorized by the National Medicines 
Regulatory Authority (NMRA) which do not meet quality specifications set for them by 
National standards” (WHO, 2016). 
There was also the argument that it is difficult to distinguish a counterfeit medicine from 
a substandard one since the only major difference between the counterfeit and 
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substandard medicine is the intent to deceive by the manufacturer (Chika et al, 2011). 
Either way, both counterfeit and substandard medicines are not what they say on the 
packet so would pose a threat to public health.    
On the other hand, counterfeiting of medicines can legally be described as a violation 
of intellectual property (IP). The Agreement On Trade-Related Aspects Of Intellectual 
Property Rights (TRIPS), defines “counterfeit trademark goods” as; 
 “any goods, including packaging, bearing without authorization a trademark which is 
identical to the trademark validly registered in respect of such goods, or which cannot 
be distinguished in its essential aspects from such a trademark, and which thereby 
infringes the rights of the owner of the trademark in question under the law of the 
country of importation” (WTO, 2016).  
Intellectual property (IP) violation is punishable by law. This definition of counterfeit or 
falsified medicines based on IP violation enables the manufacturers of branded 
medicines to have a certain level of protection over their products. However, 
punishments may not be commensurate to the crime, since the public health threat 
posed by counterfeit and substandard medicines is neglected. Moreover, the 
intellectual property approach to defining counterfeit medicines does not take account 
of generic medicines (Shepherd, 2010; Attaran et al, 2011). 
In a bid to highlight more clearly the public health threat posed by these SSFFC 
medicines, the WHO have recently adopted the term “substandard and falsified 
medical products” highlighting the public health threat posed by these medicines at the 
seventieth World Health Assembly (WHO, 2017). The adopted definitions are outlined 
as follows:  
    
21 | P a g e  
 
Substandard medical products or out of specification medical products “are authorised 
medical products that fail to meet either their quality standards or their specifications, or 
both”.  
Falsified medical products refer to “medical products that deliberately/fraudulently 
misrepresent their identity, composition or source”  
Unregistered or unlicensed medical products are those “that have not undergone 
evaluation and/or approval by the national or regulatory authority for the market in 
which they are marketed/distributed or used, subject to permitted conditions under 
national or regional regulation and legislation” (WHO, 2017). 
Although the latest definitions by the WHO help to clarify what a falsified medicine 
really is, there is still no consensus among countries on what constitutes a falsified or 
substandard medicine. Consequently, there is a disparity in the legislation addressing 
falsified and substandard between countries, making a general overview difficult. The 
absence of an international legal framework is indeed a major challenge in curbing the 
proliferation of falsified medicines (Attaran et al, 2011, WHO, 2017).  
2.1.2 Types of falsified and substandard medicines  
Falsified medicines differ in type and quality and this depends mostly on their 
destination or point of purchase. Copies of a pharmaceutical formulation often have the 
same API(s) as the genuine product, and in some cases API(s) are present in the 
same proportion making it more difficult to distinguish between the genuine and 
falsified copies of the pharmaceutical formulation (Seiter, 2009; Dégardin et al, 2014). 
Other falsified medicines contain wrong amounts of APIs, no APIs or even other APIs 
in some cases. Wrong APIs with chemical structures similar to the genuine ones could 
be used (Newton et al., 2008; Rebiere et al, 2017). Other falsified medicines contain a 
wrong API that gives the patient a false sense of relief by dealing with or addressing a 
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symptom rather than the ailment itself.  A typical example is falsified antimalarial 
medicines that reduce the fever in patients with malaria but fail to cure the disease 
itself (Davison, 2011). In some other cases, genuine medicines that are expired or 
degraded are repacked and resold, making them difficult to identify (Mukhopadhyay, 
2007; Davison, 2011). There are also those commonly referred to as “placebo 
counterfeits” made up of just excipients (inactive additives) which may not be harmful 
but do not deliver the desired therapeutic effect. Beyond the medicines themselves, 
falsifiers of medicines also often target the packaging and documentation 
(Vanderdonck, 2007; Dégardin et al, 2014). It can be argued that it is the medicine that 
the patient ingests that puts the individual at risk and not the packaging. In other words, 
fake packaging never killed anyone but taking the wrong medication might. However, 
fake packaging can provide a good opportunity for falsifiers of medicine to “dilute” a 
consignment of genuine medicines obtained illegally or stolen in order to double unit 
volume.  For instance, blister-packed medicines can be taken out of their secondary 
packaging and the blisters (which have not been tampered with) are repacked into fake 
boxes while the genuine boxes are repacked with blisters of the falsified medicine. 
Considering this approach of repacking medicine boxes, the falsifier of medicines 
ensure that unit volume is increased and all consignments also contain both genuine 
and falsified medicines. Authentication of medicines where both genuine and falsified 
medicines are present in the same consignment is then a complex situation where 
there is a possibility of the falsified medicines being overlooked or not even noticed due 
to the presence of genuine medicines in the same lot.  Medicines can be falsified in 
different ways depending on the individual(s) and the manufacturing steps involved. 
These manufacturing steps for falsified medicines could be carried out manually or in a 
pharmaceutical plant on an industrial scale. Therefore, falsification of medicines is not 
a uniform activity and results in products that are very variable and can take different 
forms. In 2012, the WHO considered reported cases of falsified and substandard 
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medicines and their magnitude and grouped them into different categories as shown in 
Table 2.1 below: 
Table 2. 1 Types of falsified medicines and their relative levels based on reported cases  
Products Percentage (%) 
Without active ingredients (APIs) 32 
Wrong ingredients 22 
Incorrect quantities of APIs 20 
Falsified packaging 16 
Impurities and contaminants 9 
Copies of original product  1 
(Source: WHO, 2012) 
Although the data presented in Table 2.1 provides some information about the types of 
falsified medicines reported to the WHO at the time, the WHO acknowledges the data 
is not a clear indicator of the levels of these falsified medicines already in circulation in 
the legal pharmaceutical supply chain (WHO, 2017). Since falsification of medicines is 
usually carried out in hiding, available data about the types and levels of falsified 
medicines would be dependent on how efficient the medicines regulatory agencies are 
in not only detecting but also reporting cases of medicine falsification.  
The oral route of administration of medicines is identified as the most preferred making 
oral dosage forms a prime target for falsifiers of medication (Mackey et al, 2015; Qui et 
al, 2016; Mc Gillicuddy et al, 2017). Mc Gillicuddy et al (2017), in their report of data for 
falsified medicines obtained from the Pharmaceutical Security Institute Counterfeit 
Incident System (PSI CIS) suggest that over 75% of the falsified medicines reported 
were oral dosage formulations with injectable biologic drugs identified as the second 
most reported (about 15%) route of administration for medicines. Therefore, falsifiers 
can target all medicines regardless of the route of administration / delivery.   
Earlier reports indicated that life-saving or therapeutic medicines like those for malaria, 
tuberculosis, microbial infections and human immunodeficiency virus/acquired 
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immunodeficiency syndrome (HIV/AIDS) were the main targets for medicine falsifiers in 
developing countries (Zou et al, 2017). On the other hand, lifestyle medicines such as 
sexual enhancement supplements and medicines used for weight management and 
hair loss were the more likely targets for the industrialized countries (Almuzaini et al, 
2013). With diversification in falsification of medicines, the falsifiers are now targeting 
other sought-after products such as medicines for cardiovascular diseases and even 
expensive cancer medicines (Dégardin et al, 2014; Antignac et al, 2017). Low cost 
medicines are also included in the falsified medicines market because the demand 
exceeds supply in most regions. In recent years, reports of falsified medicines received 
by the WHO Global Surveillance and Monitoring System (GSMS) suggest falsifiers of 
medicines now target almost all therapeutic fields and not just expensive or popular 
brand names (Figure 2.1) (WHO, 2017). 
          
 
Figure 2. 1 Reports of falsified medicines by therapeutic class received by the WHO 
GSMS (2013–2017) (Adapted from WHO, 2017). 
 
The data from the WHO GSMS in Figure 2.1 highlights antimalarial medicines and 
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(Bassat et al, 2016; Krakowska et al, 2016; WHO, 2017). In addition, Figure 2.1 
suggests high demand over-the-counter (OTC) medicines for pain relief have also been 
the target of counterfeiters (Newton et al, 2010; Davison, 2011; WHO, 2017). The 2016 
Advisory Council on the Misuse of Drugs (ACMD) report on diversion and illicit supply 
of medicines identifies painkillers as one of the main group of medicines being supplied 
through illicit means in the UK (ACMD, 2016). One API commonly used as a painkiller 
and for reducing fever is paracetamol. Paracetamol, also known as acetaminophen (4-
acetamidophenol, N-acetyl-p-phenacetin), (Bosch et al, 2006) has been identified as 
the second most widely used API after acetylsalicylic acid and the most commonly 
used medicine in children (Star and Choonara, 2014). Falsifiers have therefore 
targeted paracetamol containing OTC medicines (Davison, 2011, WHO, 2017). An 
example is a case of suspect paracetamol tablets in the Democratic Republic of Congo 
in 2014, reported to the WHO (WHO, 2017). Patients taking the paracetamol tablets 
were complaining of lethargy and were also found to have low blood pressure. Low 
blood pressure due to the paracetamol tablets resulted in slower heartbeat in the foetus 
of pregnant women, potentially hampering its growth. Preliminary testing performed 
locally by the national pharmacovigilance programme confirmed the presence of 
paracetamol in the tablets. However, further tests by WHO in a European laboratory 
showed that although the tablets contained the API paracetamol, it was present in 
wildly different doses ranging from the expected amount of 500mg to as low as 100mg. 
In addition, the tablets contained other ingredients not declared on the packaging such 
as the barbiturate phenobarbital a common treatment for epilepsy, which helps to slow 
down heart rate and breathing. Even more intriguing was the fact that the very 
inconsistent paracetamol tablet formulations all bore the same batch number – a clear 
indication that good manufacturing practices were not followed.   
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Recently, the Philippine President Rodrigo Duterte took a stand against falsified OTC 
medicines in a bid to curb the spread of falsified paracetamol by ordering the arrest of 
those responsible by the police (Reuters News, 2018).  
Furthermore, paracetamol was detected in falsified medicines where the anticipated 
API was missing (de Veij et al, 2007; Khuluza et al, 2016). Paracetamol can be a very 
dangerous chemical if taken incorrectly and unexpected overdoses can occur as a 
result of miss-labelled or substandard (too much API) medicines, leading to toxic 
effects including renal failure and possible death (Star and Choonara, 2014; Buckley et 
al, 2016). A report of a situation in the USA, where 500mg paracetamol tablets were 
actually labelled as 325mg, suggest that people in both industrialised and Low and 
Middle Income Countries (LMICs) are exposed to miss-labelled (falsified) medication 
(Barry, 2015).  
2.1.3 Extent of the falsified/substandard medicines problem worldwide 
In a bid to tackle falsified and substandard medicines, some important questions need 
to be addressed such as:  “how many are there and where can they be found?” These 
questions are disappointingly difficult to answer due to the clandestine nature of the 
falsified and substandard medicines market. Reiterating earlier comments made in 
2.1.2, available information regarding FSMs, based on those discovered and reported, 
implies that a lot more might not be accounted for or documented. Data from the 
Pharmaceutical Security Institute (PSI) show that reported incidents of medicine 
falsification from 127 countries around the world increased from 2018 incidents in 2012 
to 3147 in 2016 (PSI, 2018).  These PSI data for reported incidents of medicine 
falsification highlighted in Fig 2.2 were obtained from seven regions of the world 
indicating that falsification of medicines is not just peculiar to certain regions of the 
world but is a global problem. Consequently, anyone anywhere in the world can be 
exposed to falsified medicines. The data from PSI in 2016 also indicates a 5% increase 
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in reports of falsified and substandard medicines from the previous year (2015) 
worldwide. 
 
Figure 2. 2 Incidents of falsification of medicines in different regions of the world in 2016. 
(PSI, 2016). 
The PSI suggests that the data obtained may indicate increased awareness on the part 
of both the public and law enforcement authorities in regions where higher incidents of 
medicine falsification were reported (PSI, 2018). In other words, reports of higher 
incidents of medicine falsification in a particular region does not necessarily translate to 
poor regulations, weak enforcement programs and a high prevalence of FSMs in that 
region. Rather, it might be an indicator of more efficient regulatory practices within 
those regions.  
Considering reports that falsified medicines occur more frequently in low and middle-
income regions, like Africa and Latin America, more reports of medicine falsification 
would be expected from these regions. This is not necessarily the case, as indicated in 
Fig 2.2 since the data suggests fewer reports coming from Africa. This might be due to 
several issues such as; lack of awareness of FSMs, inadequate records of FSMs, poor 
regulations or simply a case of lack of appropriate equipment to facilitate detection of 
Number of incidents 
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FSMs. Some other governments or regulatory agencies would rather not report cases 
of FSMs because there is the assumption that it gives their countries a bad reputation 
(WHO, 2017). Limited resources and lack of necessary facilities for the authentication 
of medicines in LMICs implies that fewer cases will be reported in these regions. Most 
reports will only be made after there is an adverse reaction to the falsified or 
substandard medicine. Generally, for falsified medicines and their prevalence, it is 
more a case of “the more you look, the more you will find.” Therefore, the figures 
reported for incidents of medicine falsification might be very different and much lower 
than the real figures of falsified medicines in circulation (Mukhopadhyay, 2007; 
Roudaut, 2011). Therefore, it is important that issues regarding the falsified and 
substandard medicines market be understood and the facts noted because they further 
complicate region-to-region comparison for incidents of falsification of medicines 
(Dégardin et al, 2014). 
 
Figure 2. 3 Countries where reports of substandard and falsified medical products were 
received by the WHO GSMS (2013–2017) (Adapted from WHO, 2017). 
Countries in which substandard and falsified medical products have been discovered 
and reported to the WHO GSMS, 2013–2017. 
Not applicable 
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Current estimations of the falsified medicines problem are nevertheless disturbing and 
it is clearly a worldwide problem (Sammons and Choonara, 2017; WHO, 2017). 
Incidents of medicine falsification reported to the WHO from around the world (Fig 2.3) 
further accentuates the global nature of this public heath challenge. It is also important 
to note that, as with the PSI data, unshaded countries in Fig 2.3 do not necessarily 
imply that no FSMs exist in those countries but rather that no reports of FSMs were 
made within the duration for which the WHO compiled the data. As mentioned earlier, 
the number of reports of FSMs is dependent on who is looking out for the products, 
whether they have the appropriate facilities to spot the FSMs, whether they understand 
how to report incidents of FSMs, and whether those reports are documented and 
forwarded to the appropriate regulatory body (WHO, 2017). Some reported cases of 
falsified and substandard medicines are outlined below: 
 United States of America- In 2018 (Los Angeles), thousands of misbranded and 
falsified medicines including Viagra and Diprospan (an injectable anti-
inflammatory medicine) were found to have been sold to the public via 
unlicensed vendors. Among these vendors, selling falsified medicines was a 
storefront supposedly selling candy and piñatas (Macias Jr, 2018). 
 United Kingdom- In 2017, antimalarial medicines (Artemether-Lumefantrine) 
used to treat four patients who had visited Africa did not work suggesting 
resistance of the parasite to the medication or falsification of the medicines 
administered (Gallagher, 2017).   
 Niger- In 2017, a batch of falsified meningitis vaccine was discovered before it 
reached the market. Packaging was different from original and the Brazilian 
manufacturer indicated on the pack does not manufacture the vaccine in 
question (Anderson, 2017).  
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 Malawi - In 2016, tablets containing a mixture of paracetamol and co-
trimoxazole were repackaged and labelled as a brand of the antimalarial 
medicine sufadoxine/pyrimethamine for resale (Khuluza et al, 2016).  
 Democratic Republic of Congo- In 2014, over 1000 people were admitted to 
clinics with symptoms of meningitis neck stiffness. Investigations revealed 
patients had taken tablets thought to be diazepam but actually contained 
haloperidol (an antipsychotic medicine) which can cause involuntary action in 
the arms, neck and face (Baggaley, 2017). 
 Republic of Tanzania- In 2013, Halfan tablets expected to contain halofantrine 
hydrochloride was confirmed to contain no API (Höllein et al, 2016).  
 United States of America- In 2012, falsified Avastin for cancer lacking active 
ingredient affected 19 medical practices in the USA (WHO, 2012). 
 Pakistan- In 2012, over 200 patients died and about 1000 hospitalised after 
taking medicine used to prevent angina attacks (Isotab- containing isosorbide 
mononitrate 20mg) which also contained toxic amounts of the antimalarial API 
pyrimethamine (Arie, 2012; WHO, 2017). 
The reported cases of FSMs above are a pointer to the global dimension of FSMs 
challenge and that medicine falsifiers can target any medicine. A proper understanding 
of the marketing and distribution of medicines worldwide will provide more information 
about the loop holes within the system that allows medicine falsifiers carry out their 
activities unnoticed. Section 2.1.4 provides more detail about the falsified and 
substandard medicines market globally.  
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2.1.4 Overview of the falsified and substandard medicines market 
 
Figure 2. 4 Diagram showing how the falsified and substandard medicines (FSMs) 
market operates within the legal medicines distribution chain. 
Falsification of medicines has evolved into an organised industry with some 
stakeholders (manufacturers, wholesalers, distributors and local retailers or vendors) 
across all levels of the medicine distribution chain involved as highlighted in Fig 2.4. At 
the manufacturing phase, security features on medicines like the label, seal and logo of 
the manufacturer can be copied for use on falsified versions of the same medicine to 
enable preliminary authentication of the product. Some corrupt marketers and 
distributors of medicines are also involved in this syndicate (medicine counterfeiters) 
where they interfere with checks for medicines whether across the border or by the 
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national regulatory agencies. These marketers and distributors of medicines interfere 
with the process by diverting medicines from their normal route. Diversion of medicines 
makes it easier to smuggle medicines into countries avoiding the necessary security 
checks. The hospitals, pharmacies or medicine vendors are normally the last point of 
contact in the medicines distribution chain since they are involved in administering the 
medicines required or prescribed to the patients. Again, Fig 2.4 indicates that falsifiers 
of medicines are still able to carry out their activities through unscrupulous individuals 
working in the hospitals, pharmacies or as medicine vendors especially in regions 
where regulations are lax.  
Falsifiers of medicines strive to complicate the market so that the traffic of FSMs goes 
unnoticed (Roudaut, 2011). Townsend (2009), reports of falsified medicines (including 
anti-psychotic and anti-cancer medicines) that found their way into the NHS, UK which 
were discovered to be manufactured in China with labelling in French and shipped to 
Singapore from where the medicines got to Liverpool and were then sold to the NHS. 
The report by Townsend (2009) clearly highlights the complex nature of the falsified 
and substandard medicines market. This implies that falsification of medicines can 
occur at any point in the medicines distribution chain but must be such that the identity 
of the medicine falsifiers is not revealed. For instance, discarded packaging for genuine 
medicines can be retrieved and reused as packaging for falsified copies of the same 
product while expired or withdrawn stock can be relabelled as safe and within its shelf 
life (Davison, 2011). Reusing genuine packaging of medicines obtained will provide the 
counterfeiters with batch numbers and any other identification data that will enable 
them pass the FSMs as the genuine product during the initial screening of the 
medicines.  
 It is also difficult to establish distribution of FSMs as the information available mostly 
depends on where they are discovered which might be completely different from the 
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original point of manufacture. There is also the issue of underreporting by WHO 
member states (as mentioned earlier) and the lack of supplementary data for incidents 
of falsified and substandard medicines from other organisations.  
With increasing awareness about the threat to public health posed by FSMs, it is 
expected that there will be more reports and more WHO member states will be 
involved in the fight against FSMs but currently, it is not certain if this is the case. 
Figure 2.5 gives a picture of the global distribution of FSMs across the medicine 
distribution chain based on reports available at the time. 
 
Figure 2. 5 Global distribution of medicine falsification- from production to point of sale 
(Adapted from Dégardin et al, 2014). 
Manufacturing of FSMs seems to be concentrated in Asia and particularly in India and 
China as illustrated in Fig 2.5 (Chika et al, 2011; Dégardin et al, 2014). This can be 
attributed to the abundant and cheap workforce in the region. Some parts of Latin 
America are also involved in the manufacture of FSMs (Roudaut, 2011). The Middle 
East (United Arab Emirates) has been identified as a major transit point for the 
distribution of medicines and therefore FSMs as indicated in Fig 2.5. This allows for the 
manufacturers of falsified medicines to conceal their identity and the true origin of the 
product. It is not clear why the United Arab Emirates is highlighted as a major transit 
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point for FSMs but the free trade zones and trade regulations in the region that allow 
movement of such falsified medicines among other products might be the reason for 
using that route as a transit point by falsifiers of medicines. On the other hand, sale of 
falsified medicines is huge in Africa and South-East Asia and also high in Latin America 
(Almuzaini et al, 2013) (Figure 2.5). Most medicines in LMICs in regions like Africa and 
Latin America are imported thereby exposing these regions to the falsifiers of 
medicines. Developed countries like the UK where medicines are imported are also at 
risk. 
With reference to Fig 4.2, specific issues regarding surveillance of medicines in the 
LMICs include lack of security across the medicines distribution chain and poor storage 
conditions. There are not enough facilities to carry out routine checks at borders and 
specialists with proper understanding of security features on medicines are also 
lacking. Furthermore, most medicines are to be stored below 25°C but the average 
temperature in most LMICs (in the tropics) is well above 25°C which could lead to 
degradation of the medicines. As a result, medicine storage will be a challenge these 
countries especially where facilities are not readily available. 
In many LMICs, medicine falsifiers take advantage of the fact that medicines can be 
sold in street markets. In some cases, medicines sold in these street markets are not 
stored under appropriate conditions and medicines are taken out of the original 
packaging before selling to the patients. For instance, tablet medicines in blister packs 
can be taken out of the secondary packaging and sold in plastic zip lock bags so 
patients who are not able to buy the full pack of the medicine can have access to the 
smaller amounts of the medicine they can afford.  Removal of medicines from 
packaging leaves the patient with little or no documentation and no information leaflet 
accompanying the medicine which in turn provides a conducive environment for the 
proliferation of FSMs. Falsifiers of medicines are able to take advantage of situations 
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like this to introduce falsified medicines into the system (Wall, 2016). Medicine falsifiers 
also target the mainstream distribution chain of medicines even in industrialised 
countries though the approach might be different, more subtle and sophisticated since 
the market is highly regulated in these countries. 
Manufacturers of FSMs medicines might opt for sale of these medicines on the internet 
using websites that do not clearly provide the contact details of the seller (Orizio et al, 
2009). The patient therefore stands a huge risk of buying falsified medicines on the 
internet. The anonymity of these websites make it more difficult to identify the 
perpetuators of the crime since it is difficult to track their exact location. A study 
considering the hidden parts of the internet suggests that about 12% of the illegal 
products sold online are pharmaceutical products (Megget, 2016). These websites 
provide unregulated access to prescription medications as well as supplements. 
Reports suggest around 50% of the pharmaceutical products available online could be 
falsified (Dégardin et al, 2014; Lavorgna, 2015; Lee et al, 2017). In the United States of 
America, the number of individuals buying medicines off the internet has grown by 
400% in the last decade bringing with it an increased exposure to FSMs. The survey 
also suggests that in the USA alone, between 19 and 26 million people buy medicines 
online and this figure is on the rise (WHO, 2017). Buying medicines over the internet is 
becoming increasingly popular in LMICs too. An in-depth understanding of the different 
factors that allow falsifiers of medicines to perpetuate the crime is crucial in order to 
address the problem. 
2.1.5 Falsified and substandard medicines: the causes 
Falsification of medicines is a lucrative business and largely risk-free for the falsifiers of 
medicines since they operate within the legal medicine distribution network unlike with 
those involved in the distribution of drugs of abuse/ controlled substances. It is 
therefore more difficult to identify falsifiers of medicine than traffickers of illicit 
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medicines (Dégardin et al, 2014). Reports from the international police organisation 
(INTERPOL) suggests that organised criminal networks formerly involved in the illicit 
drugs market now target legal medicines because of the high profits, low risks of 
detection and prosecution and the fact that the penalties when prosecuted for falsifying 
medicines are much less severe than those incurred for trafficking illicit drugs 
(Dégardin et al, 2014). 
There are a number of reasons for the boom of the falsified medicine market; foremost 
among which is the deficiencies in legislation and enforcement. Deficiencies in 
legislation and enforcement would range from poor ethical practices to greed and 
corruption at all levels of the medicine distribution chain. Countries where regulation 
and enforcement is limited and weak are therefore possible breeding grounds for 
medicine falsifiers (Dégardin et al, 2014). Furthermore, the absence of an international 
legal framework has not helped in addressing the FSMs problem (Martino et al, 2010; 
Rebiere et al, 2017). Corruption is widespread in many LMICs with medicines being 
frequently diverted and pilfered at different levels of the medicines distribution chain. 
The approval of questionable medicines is secured with bribes at profitable prices 
(Berman and Swani, 2010; Mori et al, 2018). Although corruption is rampant in LMICs, 
it is important to note that it also exists in developed countries. There have been calls 
for doctors in the UK to declare their earnings with reports of a significant increase in 
the cash and hospitality given to doctors by pharmaceutical companies and the refusal 
by a third of the doctors to declare their earnings making it suspicious (Bodkin, 2017). 
Other reports in the USA suggest opioid manufacturing pharmaceutical companies 
offered more money to doctors who wrote the most opioid prescriptions; almost 
implying that the doctors were being bribed to help the sale of their medicines (Kessler 
et al, 2018). The aforementioned cases in the UK and USA might not necessarily 
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confirm clear cases of corruption in the countries but are pointers to the fact that these 
developed nations are not immune to corruption. 
Limited access to affordable, safe and effective medicines and poor technical 
capacity/tools for ensuring good manufacturing practices, quality control and 
distribution of medicines are some other factors that would allow FSM manufacturers to 
thrive in a region. Some medicines are prime targets for falsifiers because of the value 
attached to the products and their corresponding high prices. The selected targets are 
either high added-value medicines such as cancer and antiretroviral medicines aimed 
at narrow markets (smaller/specific population) or cheaper medicines such as pain 
killers and antimalarial medicines aimed at broader markets (wider population)  (Reggi, 
2007; Degardin et al, 2014). In other words, high cost or high demand medicines are 
the most targeted by falsifiers of medicines. This makes them even more profitable for 
the falsifiers of those medicines whose production costs is nothing compared to that of 
the legal manufacturers, with nothing spent on research and development or licensing 
(Reggi, 2007; WHO, 2017). Even if the falsifiers of medicine use the right ingredients, 
their quality standards will be much lower. For most medicines, the APIs account for 
bulk of the production costs. For generic medicines, APIs generally make up four-fifth 
of the production cost. Use of lower amounts of the API(s) by medicine falsifiers will 
therefore help to maximise their profit while using just enough API for the medicines to 
pass initial screening tests for the presence of the expected API (Reynolds and Mckee, 
2010; WHO, 2017).  
The high costs of some prescription medicines means they might not be affordable for 
LMICs unless they are able to access donated medicines. Patients (with no insurance 
or in countries where cost of medication is borne by the people) are forced to seek out 
cheaper alternatives because of the high costs of genuine medicines, which are often 
burdened by import duty.  This in turn encourages street-market (in LMICs) or internet 
    
38 | P a g e  
 
distribution and the spread of non-regulated outlet production of falsified medicines 
(Wertheimer and Norris, 2009). Cost pressures also have an implication on the 
production and supply chain for medicines. In a bid to cut costs and maximise profit, 
some manufacturers of medicines go for cheaper alternatives to the actual APIs and 
excipients used in the genuine medicine. As a result, the quality of medicines reaching 
the patient might be compromised.   
Availability or access to medicines is becoming more of a problem in the developed 
countries and patients can be affected by the high cost of medicines especially if they 
have to pay for them. Moon (2017), reports that the outrage over the high cost of 
medicines was identified as one of the very few issues bringing voters together during 
the 2016 elections in the United States of America (USA). The trade-off of affordability 
versus quality of medicines by the patient is largely based on necessity and not on 
choice because people would generally purchase the best medicines they can afford. 
Some FSMs are also sold for the same price as the genuine medicine from the legal 
manufacturer to avoid suspicions as to their origin (Shepherd, 2010).  Consequently, 
the cost of medicines does not guarantee authenticity because both cheap and 
expensive copies of genuine medicines abound in the market.  
When the demand for medicines exceeds the supply, it creates an opportunity for 
medicine falsifiers to provide products to address the deficit. There are several 
situations where demand could exceed supply such as when there is outbreak of 
disease, war/conflict, economic crisis and natural disasters. Access to medicines is 
limited as demand increases in these situations providing a conducive environment for 
falsifiers of medicines to thrive. An example that readily comes to mind is recent plans 
by the UK government to stockpile medicines just in case the UK leaves the EU with no 
deal (Buchan, 2018). Stockpiling of medicines would mean increase in demand for 
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such medicines, which the falsifiers of medicine could readily take advantage of to 
infiltrate the market. 
Rapid communication systems and technological advancement have also boosted links 
between medicine falsifiers at different points in the medicine distribution chain, 
especially across international borders (Reynolds and Mckee, 2010). For instance, 
medicine falsifiers in one country can now provide real time updates to others in 
different countries about the movement of the falsified pharmaceutical products and 
falsified medicines are also accessible to people in parts of the world where the 
facilities are not available to produce them (LMICs). Globalisation of the financial 
markets has aided illegal trade where international transactions can be made in real 
time between counterfeiters of medicines and is now widespread in some countries 
(Reynolds and Mckee, 2010). Industrialised countries have more control measures for 
goods produced within their country than for goods to be exported to other countries. 
Falsified medicines are often exported via free trade zones, with their origin concealed 
or changed with fresh labels (Degardin et al, 2014). The issue is more political in some 
countries where it is perceived there is lack of willingness to tackle the problems 
(Roudaut, 2011). In some parts of Europe, medicines can also be sold at low prices 
and then resold elsewhere at a higher price. This phenomenon, identified as 
“pharmaceutical parallel trade,” leaves intermediaries/middlemen with great profit 
(Orizio et al, 2009). The United Kingdom is the largest import market in Europe with 
70% of the parallel trade. Falsifiers of medicine across Europe and around the world, 
seeking to make more profit can also take advantage of this market by again repacking 
medicines to be resold to countries like the UK where cost of medicine obtained via the 
NHS are higher (Degardin et al, 2014).  
Just as parallel trade is considered Europe’s problem, America’s main problem is 
reimportation. This means that medicines that were previously exported to other 
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countries are brought back to America. This practice allows for the importation of 
medicines that the regulatory authorities can hardly control (Palumbo et al, 2007). 
Producers normally sell the medicines to wholesalers who in turn send them directly to 
hospitals or pharmacies. However, between the producer and the patient, so many 
intermediaries could manipulate medicines (Vanderdonck, 2007). Although the legal 
medicine trade cannot be blamed for the issue of falsification of medicines, it is 
important to note that its globalisation and the complications surrounding the 
distribution of medicines worldwide aid the activities of medicine falsifiers (Shepherd, 
2010).  
2.1.6 Falsified and substandard medicines: the consequences  
The proliferation of falsified and substandard medicines could have far-reaching effects 
not only on the patient taking the medicine but also on the licensed manufacturers and 
the government. Non-compliance with good manufacturing practices allows falsifiers of 
medicine to cut production costs to maximise profit while manufacturing medicines that 
could potentially cause harm to patients (Vanderdonck, 2007; Seiter, 2009). Since 
falsifiers of medicine operate in an unregulated environment, manufacturing FSMs 
might not require much workspace and can often be carried out in small workshops 
usually by unskilled workers. Falsifiers of medicine could also use bigger 
manufacturing plants for large-scale production (Dégardin et al, 2014).  
2.1.6.1 Wrong level of APIs 
If the FSM contains more than the stated amount of the expected API, too high doses 
will usually be toxic or harmful with adverse reactions that could result in the death of 
the patient. When the API is absent or present in amounts lower than expected, the 
medicine does not offer any therapeutic benefit. This could lead to the deterioration of 
the patient’s condition or could ultimately lead to death in certain disease conditions. 
Again, when lower than expected amounts of API are present in FSMs, this could lead 
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to drug resistance, which will weaken the patient’s response to future medication 
(Newton et al, 2010; Kelesidis and Falagas, 2015). A typical example is the case in the 
UK, mentioned in 2.1.3 where patients being treated for malaria did not respond to the 
antimalarial medicine (Artemether-Lumefantrine) administered (Gallagher, 2017). The 
reason for the patients’ non-response to the antimalarial medicine is not yet known but 
could be as a result of absence of the API or a case of resistance to the medicine. The 
adverse effects of FSMs can be fatal if other APIs not declared on the packaging are 
present (Vanderdonck, 2007).  
2.1.6.2 Lack of patient information 
Some FSMs are sold without patient-information leaflets making it easy for patients to 
self-medicate or abuse the medicines. Self-medication with FSMs could be very 
dangerous especially when the falsified medicines within a pack contain varying 
amounts of the expected API. No therapeutic benefit observed after taking medicine 
with lower than expected API might lead to increasing the dosage. However, increasing 
dosage with medicine from the same pack, which contains higher amounts of API than 
the one previously administered, might result in toxicity due to higher than expected 
levels of API in the patient (Degardin et al, 2014).  
No one will want to continue taking a particular medicine if it does not work or has 
adverse effects. This could lead to fear and lack of trust in the medical system which 
goes beyond fear of the medicine itself to lack of trust in those involved in the 
prescription of such medications like the doctors, pharmacists and nurses (Martino et 
al, 2010; Davison, 2011; Degardin et al, 2014). 
2.1.6.3 Economic consequences 
Although the health repercussions on the consumer are the most important, the 
economic impact of falsification of medicines must not be ignored. The European Union 
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Intellectual Property Office (EUIPO) reports that FSMs cost the European Union 
pharmaceutical sector about 10.2 billion every year with about 37,700 jobs lost 
(EUIPO, 2016). Previous reports from the Centre for Medicines in the Public Interest 
estimated the worldwide trade of FSMs to be worth around $75 billion by 2010, 
exceeding the illicit drug market, valued to be $50 billion at the time (Vanderdonck, 
2007). Falsification of medicines engenders costs for society as a whole, especially in 
the developing world where the resources are not readily available (Seiter, 2009; Mori 
et al, 2018).  
Economic losses due to FSMs affect not only the pharmaceutical industry and the 
government but also the patients who suffer losses in income if cost of medicine is 
borne by them. The patient taking these FSMs also loses the money spent in purchase 
costs since the medicines do not work and further help or medical advice is required. 
Falsifiers of medicines tarnish the image of the licensed pharmaceutical industries, and 
so, there is the constant burden of protecting their products against the falsifiers (Jack, 
2007; Berman and Swani, 2010). This burden is in turn transferred to the patients 
buying these medicines as prices are hiked so as to account for the extra costs 
involved in the production and protection of the product. Generally, healthcare systems 
are also affected since there is an increase in social and healthcare costs even in 
countries with health insurance cover. Recent reports by the UK National Health 
Service (NHS) suggest that prescribing common painkillers like paracetamol costs 
about four times the cost of the same medicines over the counter (NHS News, 2017). 
This has led to on-going deliberations about removing such medicines that can be 
purchased over-the-counter, at a lower cost, off the NHS prescription list. This would 
save money and free up more funds for frontline care in the NHS. This will in turn 
transfer the cost of the medicines to the patients and could expose them to falsified 
medicines especially over the internet where there are fewer restrictions. With the 
    
43 | P a g e  
 
steady rise in the number of medicine counterfeiting cases, specialists have even 
warned of a macroeconomic pandemic (downturn in the economies of many nations) if 
effective measures are not taken (Dégardin et al, 2014). According to Wertheimer and 
Norris (2009) and Van Baelen et al (2017), the health and economic challenges due to 
falsification of medicines would be so disastrous that the resources in the health sector 
would be completely overwhelmed if nothing were done to curb the situation. 
2.1.7 Tackling the challenges posed by falsified and substandard 
medicines 
The WHO Programme for International Drug Monitoring (WHO PIDM) refers to “the 
science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problem” as 
Pharmacovigilance- PV (WHO PIDM, 2016). Considering the public health risk 
associated with falsified medicines, it is important that response to this phenomenon be 
rapid and globalised in order to get them out of the market and the global supply chain 
within the shortest possible time (Dégardin et al, 2014). To achieve this, the National 
agencies involved in the regulation and control of medicines need to work towards 
developing easier methods for detection of FSMs especially on the field- hence the 
need for this research. Various information dissemination systems should create 
awareness about FSMs among all stakeholders (from manufacturers to patients) 
involved in the pharmaceutical market. Television, radio, newspaper adverts and even 
social media platforms could provide accurate information on the risks of FSMs and 
even more information on how to detect them, how to avoid them and how to report 
suspect cases of medicine falsification. Consumers should learn what features to look 
out for when purchasing medicines and the dangers of purchasing medicines from 
informal markets. While education and awareness is crucial in the fight against falsified 
medicines, the amount of information available to the public should be just enough for 
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basic first-line screening or visual inspection of medicines in order not to provide 
falsifiers of medicines with enough information to circumvent the system. 
Davison (2011) and Dégardin et al (2014), propose multi-layered protection as an 
effective approach towards safeguarding medicines since they will be more expensive 
and hence, difficult for counterfeiters to replicate. This will involve simple and easily 
detectable features, such as the shape, embossing (raised features), or debossing 
(sunken/lowered features) on the medicine or labels, logos, barcodes and seals on its 
packaging.  
The more overt security features on the medicine and the packaging can be 
supplemented with other covert features known to a select few involved in the 
regulatory process (Fig. 2.6). Figure 2.6 illustrates the “authentication pyramid” with the 
vertical dimension indicating the number of individuals participating at various security 
levels in the authentication of medicines. From the base of the pyramid to the apex, a 
gradation of simple to more complicated authentication techniques/methods are 
employed. Consequently, the number of individuals involved in the authentication 
process decreases going up the pyramid from the base where the general public are 
involved in simple visual inspection tests to the apex where one or two highly skilled 
individuals are involved in more complex authentication forensic investigation. 
It is also evident from the authentication pyramid that pharmacovigilance is improved 
when consumers and those closest to them in the medicines distribution chain (such as 
pharmacists) are provided with simple tools or information for spotting falsified and 
substandard medicines. 
    




                                                                          
 
Figure 2. 6 The Authentication pyramid. More overt security features towards the base of the pyramid allows more individuals to be involved 
in the validation of medicines (Adapted from Davison, 2011). 
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Consumers will therefore be more alert with more information about the medicine being 
administered to them. On the other hand, there is the conflicting factor that wider 
dissemination of security features on products will also make them more vulnerable to 
falsifiers as highlighted earlier. Therefore, a combination of techniques and security 
features is necessary to provide individuals at all levels of the pyramid with various 
ways of medicine authentication. 
Collaboration between government agencies is necessary for effective results since the 
distribution channels for these medicines are very complicated. International 
cooperation between National regulatory agencies will also help in effective border 
control and monitoring which will in turn help in curbing the menace caused by falsified 
and substandard medicines. To this effect, the WHO launched the Global Surveillance 
and Monitoring System (WHO GSMS) in 2013 with the number of participating 
countries currently put at 113 (WHO, 2016). The WHO GSMS was supposed to help in 
linking information on incidents of medicine counterfeiting between countries as well as 
provide more data to enable a better understanding of the extent of the problem 
worldwide. Collaboration between countries could also facilitate prompt arrest and 
prosecution of the counterfeiters of medicine. An example of collaboration between 
countries or regional collaboration is the European Union (EU) medicines verification 
system (EMVS) expected to take effect by February 2019, which will facilitate 
verification of medicines throughout the medicines distribution chain in the region until 
the time the medicine is dispensed to the patient (EU, 2016).  
As is the case with drugs of abuse, legislation with stiff penalties for counterfeiters of 
medicines should be enforced by the National regulatory agencies to serve as a 
deterrent to others. Considering the number of individuals exposed to falsified and 
substandard medicines, it can be argued that counterfeiters of medicines should face 
even stiffer penalties than those involved in drugs of abuse because the drugs of abuse 
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market is smaller with fewer individuals exposed to these addictive substances. The 
FSMs market is much bigger because it affects both therapeutic and lifestyle medicines 
with anyone around the world being susceptible to these medicines. In addition, most 
individuals at the receiving end (consumers) in the drugs of abuse/ legal highs market 
are in it as a matter of choice even though the substances are addictive. Consumers of 
FSMs on the other hand do not have a choice because it is the intent of the 
counterfeiter to deceive the consumers of such medicines being well aware that no one 
will take medicine knowing it is not what it says on the box.  
Efforts towards reducing the cost of production and by extension the burden transferred 
to the consumer in terms of the cost of the medicines should be further explored. 
Import duty on medicines could be subsidised by individual countries. This will help in 
reducing the costs of medicines and making them more affordable. 
Finally, further development of suitable analytical methods for the detection of 
counterfeit medicines within the quickest time possible and closest to the final 
consumers of the medicines (where most counterfeiting would most likely occur) will go 
a long way in addressing this problem. This is because public safety with reference to 
FSMs is dependent on how fast the suspect medicines are detected and taken off the 
market. It is in this regard that this research considers more effective, efficient and 
robust methods for the authentication of FSMs both in-field and in laboratories and also 
in different regions of the globe. Referring back to the authentication pyramid (Fig 2.6), 
we established that at different levels of the medicine distribution chain, the analytical 
method required for screening of medicines are different. The analytical method of 
choice for screening medicines will be dependent on a number of factors such as the 
amount and type of information needed ranging from a quick “YES” or “NO” check to 
comprehensive forensic analysis. Analytical methods for screening FSMs will be the 
focus in the next section. 
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2.2 Analytical methods for screening falsified and substandard 
medicines 
The fight against the falsification of medicines has led to the investigation of several 
analytical methods for the detection of FSMs, which include both spectrometric and 
separation techniques as discussed in detail in successive subsections (Deisingh, 
2005; Martino et al, 2010; Anzanello et al, 2014; Dégardin et al, 2014). As falsifiers of 
medicines get more sophisticated in the act, the pharmaceutical industries and 
agencies have to keep improving their analytical methods with more reliable and up-to-
date techniques in order to detect their activities (Deconinck et al, 2013; Dégardin et al, 
2014).  
Recently, research by Armitage (2018), applied a collection of techniques in the 
assessment of cardiovascular tablet medicines. Rebiere et al (2017), identifies 
sampling of suspect medicines as a vital step because it should give information of a 
representative portion of the test sample analysed.  Information obtained from physical 
and chemical study of medicines could provide a better understanding of medicine 
counterfeiting at different levels. Marini (2010) and Dégardin et al (2014) suggest that 
to initiate prompt action of pharmaceutical companies and other relevant regulatory 
authorities involved in curbing medicine falsification, analytical methods for 
authentication of medicines must first be able to identify or distinguish genuine and 
counterfeit pharmaceutical products. The analytical method for authentication must 
also be able to do so as fast as possible as mentioned earlier in 2.1.7.  
2.2.1 Preliminary Screening for falsified and substandard medicines 
The screening process for falsified and substandard medicines begins with visual 
inspection of the medicines. A detailed study of the label, package and content of the 
suspected medicine yields data that are then compared with that of the genuine 
product. Visual inspection of packaging items, like boxes, leaflet inserts, blister packs, 
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and vials, entails the study of features like holograms, logos, taggants and printing 
(Deisingh, 2005; Rodomonte et al, 2010; Shah et al, 2010; Ortiz et al, 2012). Electronic 
tracking systems using Radio Frequency Identification (RFID) or the Global Positioning 
System (GPS) can be used to track genuine medicines and isolate counterfeit 
medicines (Catarinucci et al, 2012). The RFID is based on a two-way radio 
communication system between an RFID tag on an item being tracked and a receiver 
within range of the tracked item. They can be employed for spot checks by the police or 
border control agencies but the short range of the signal implies they can only be used 
for screening medicines in-field and not for remote tracking (Davison, 2011). On the 
other hand, the GPS tracking system is similar to the satellite navigation systems used 
in cars and phones where satellite signals received by small devices hidden in the 
cargo, truck or the medicine boxes are transmitted to a control centre via cellular phone 
networks. The information received by the GPS system is used to ascertain the 
position or location of the item being tracked in real time. Real-time monitoring of the 
movement of medicines will help provide alerts to regulatory agencies when there is a 
deviation or unplanned stop while medicines are transported along the expected route 
of the medicines distribution chain. Although GPS can function remotely, it is also 
dependent on the strength of the satellite signal, which can be interrupted if the signal 
is impeded along its path. In criminal cases, the system could be jammed so the control 
centre is not able to receive positional information. Tracking systems are more suited 
for monitoring bulk items in transit due to the high cost of production of tracking 
devices. It is therefore important to consider screening methods for small quantities of 
medicines, within the medicines distribution chain from manufacturer to consumer 
(Davison, 2011). 
Physical characteristics of the medicine dosage form, like their colour, weight or shape, 
can be evaluated and compared with reference samples of the medicine though this is 
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not always possible. Nevertheless, physical inspection is not sufficient to identify 
counterfeit and authentic medicines due to increased sophistication by the 
counterfeiters who use technologically advanced equipment to produce almost identical 
copies of genuine medicines (Rodomonte et al, 2010; WHO, 2017). Simple tests, 
consisting for instance in disintegration tests (Martino et al, 2010; Kaale et al, 2016) 
and simple density or viscosity measurements (Dégardin et al, 2014) are cheap and 
quick methods that sometimes prove very effective for the initial screening of 
medicines. Furthermore, with advancement in technology and mobile connectivity, 
unique mobile phone apps are now available for the authentication of medicines by 
scanning the medicines or packaging for particular security features, in order to 
distinguish between genuine and falsified medicines (Steinhubl et al, 2015; Yu et al, 
2016). 
Apart from the various visual inspection methods for screening FSMs, other simple 
analytical techniques have been employed. Table 2.2 highlights techniques like 
colorimetry (Green et al, 2000; Rodomonte et al, 2010; Chikowe et al, 2015), and in 
recent times, the Global Pharma Health Fund (GPHF) MinilabTM (Petersen et al, 2017). 
The GPHF MinilabTM combines thin layer chromatography (TLC) and colorimetric tests 
which has been proven a useful low cost semi quantitative analytical method for an in-
field detection of counterfeit medicines. Due to the ease of use and the inexpensive 
test kits, the GPHF has been the technique of choice for screening falsified and 
substandard medicines in LMICs (Kovacs et al, 2014; Petersen et al, 2017). However, 
Kovacs et al (2014), suggests that the GPHF-Minilab is only able to identify grossly 
substandard medicines containing less than 80% of the expected API. Several studies 
have considered more economical, rapid and efficient methods of screening counterfeit 
medicines for use most especially in LMICs and also at the point of care (Hoellein and 
Holzgrabe, 2014; Koesdjojo et al, 2014; Yemoa et al, 2017). The paper device or paper 
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chromatography cards for detecting antimalarial medicines (Koesdjojo et al, 2014), the 
counterfeit detection device (CD-3) by the FDA (Ranieri et al, 2014; Platek et al, 2016) 
and PharmaCheck (Amifar, 2016) are some of the portable devices developed recently 
for on-site monitoring of FSMs. However, even though these simple tests based on the 
physical or chemical properties of the medicine enable quick preliminary assessment of 
medicines and are inexpensive (with prices ranging from about £1 per test with paper 
test cards to £4000 per unit of the GPHF- Minilab), they are mostly qualitative (Kovacs 
et al, 2014). In addition, they often suffer from a lack of specificity and do not provide 
much information about either the identity or the amount of the API in the medicines 
(Martino et al, 2010; Deconinck et al, 2013; Venhuis et al, 2014). Simple analytical 
methods that are more robust providing both qualitative and quantitative forensic 
information would therefore be valuable for efficient first line screening of medicines. 
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Table 2. 2 Comparison of devices for detecting falsified and substandard medicines 
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Table 2.2 (continued) 
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* Low cost= <£10,000; Medium cost= £10,000- £100,000; High cost= > £100,000 (Kovacs et al., 2014; Rebiere et al, 2017; Zou et al, 2017). 
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2.2.2 Authentication Techniques for Falsified and Substandard Medicines 
The portable technologies mentioned in 2.2.1 like the GPHF- Minilab, PharmaCheck 
and paper chromatography test cards all require sample preparation before analysis 
thereby increasing time of analysis. It is therefore important that techniques that 
combine both speed of analysis with sensitivity and specificity be considered for the 
authentication of medicines. Many analytical tools have proved effective for the 
identification of counterfeit medicines (Talati, 2011; Zou et al, 2017). Appreciating the 
fact that time is of essence in the detection of counterfeit medicines, there has been 
increased use of vibrational spectroscopy for the analysis of suspect materials in recent 
times (Custers et al, 2016; Höllein et al, 2016; Rebiere et al, 2017; Zou et al, 2017).  
Spectroscopic techniques are often preferred for the assessment of falsified and 
substandard medicines because they are fast and require little or no sample 
preparation (Sacré et al, 2010; Kovacs et al, 2014). Although these spectroscopic 
techniques are more expensive than the preliminary screening techniques mentioned 
in 2.2.1 (circa £50,000), they are faster, more robust, sensitive and portable and so can 
be used in the field for analysis. Mid-Infrared (MIR) more commonly known as Fourier-
Transform Infrared (FTIR) Spectroscopy (Farouk et al, 2011), Near Infrared (NIR) 
(Moffat et al, 2010; Assi et al, 2011) and Raman spectroscopy (Dégardin et al, 2011) 
are all individually capable of producing measurements and an interpretation of the 
results within minutes. Direct observation of overlaid spectra or mathematical models 
(chemometrics) can be used for the identification of suspect counterfeit medicines. A 
limitation with these spectroscopic techniques is the dependence on the use of 
reference libraries for the individual APIs and excipients. This implies that the reference 
libraries have to be routinely updated when there are new compounds in the market 
and this could limit their feasibility (Kovacs et al, 2014). 
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 ATR-FTIR involves direct contact of the sample with the ATR crystal meaning samples 
must be taken out of their packages for analysis. Raman spectroscopy is a scattering 
technique whereas FTIR spectroscopy and NIR spectroscopy are both absorption 
techniques (Martino et al, 2010; Zou et al, 2017).  Also NIR imaging data (Puchert et al, 
2010) and Raman microscopy (Kwok and Taylor, 2012) provide direct and simple 
information about the genuineness of the medicine. Field-portable, hand-held 
instruments, which are mostly Raman and NIR spectrometers, can be used for 
screening of the authenticity of the content of the dosage form (Ricci et al, 2008; Hajjou 
et al, 2013). The sensitivity of these hand-held devices has been questioned (Hajjou et 
al, 2013).  
These simple techniques as shown in Table 2.2 help ascertain the quality of the 
pharmaceutical product, with respect to both packaging and dosage form (Martino et al, 
2010; Kovacs et al, 2014). In other words, they provide initial “YES” or “NO” checks on 
medicines. The case is closed if the medicine in question is confirmed to be genuine 
otherwise further chemical analyses have to be performed. 
2.2.3 Confirmatory Techniques for Falsified and Substandard Medicines 
In the event that data for medicines based on the assessment techniques identified in 
2.2.2 are inconclusive, several analytical methods can provide the chemical 
composition of the sample to confirm if it is indeed falsified and not just a false positive 
result. For counterfeits of pharmaceutical solid dosage forms, they can first be 
identified by the measured spectra which is compared to the spectra of the reference 
tablet sample during the detection/authentication step as mentioned in section 2.2.2 
(Lanzarotta et al, 2011; Matousek et al, 2011). Confirmatory techniques are highly 
sensitive but also quite expensive and so are more suited for national regulatory 
laboratories where suspect FSMs identified in the field are taken for confirmation. As 
highlighted in Table 2.2, these confirmatory techniques range from those with medium 
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costs (£10,000-£100,000) like direct insertion probe mass spectrometry (DIP-MS) and 
Ultraviolet Visible (UV-vis) spectroscopy to those with high costs (about £100,000 and 
above) like liquid chromatography and gas chromatography. Mass spectrometry (MS) 
is useful for confirmatory testing of medicines by identification of APIs, excipients as 
well as contaminants. Although the MS techniques are expensive, they can also be 
used in tandem with other techniques. Direct Analysis in Real Time (DART) (Likar et al, 
2011; Chernetsova and Morlock, 2011; Bernier et al, 2016) and Desorption 
Electrospray Ionization (DESI) MS (Fernández, 2006; Culzoni et al, 2014) are ion 
sources that can be used in tandem with MS techniques for the direct analysis of solid 
pharmaceutical dosage forms (Culzoni et al, 2014; Bernier et al, 2016). Like DART and 
DESI, direct insertion probe mass spectrometry (DIP-MS) is another important 
technique that allows the direct analysis of samples without solvent extraction or 
sample preparation. DIP-MS could either be by hard ionisation (electron ionisation) in a 
vacuum or soft ionisation under atmospheric (ambient) conditions (also known as 
atmospheric solids analysis probe mass spectrometry (ASAP- MS)). The application of 
DIP-MS as a fast confirmatory technique in the screening of medicines is discussed in 
detail in chapter 5. 
Chromatographic techniques are also well known for confirmatory assessment of 
medicines and like the other confirmatory techniques, they are expensive and much 
slower than the preliminary screening and authentication techniques with analysis time 
stretching to several hours per sample (Mwalwisi, 2016). Commonly used 
chromatographic techniques range from the cheap and simple thin layer 
chromatography –TLC used as an authentication technique (Sherma, 2007; Yemoa et 
al, 2017) to the more sophisticated and expensive ones like high-performance liquid 
chromatography (HPLC). The chromatographic techniques can be used to confirm or 
validate the results of authentication tests like the spectroscopic techniques. Methods 
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like liquid and gas chromatography coupled with Mass Spectrometry (MS) (Deconinck 
et al, 2012; Custers et al, 2014) might then help in the quantification of active 
pharmaceutical ingredients (APIs) and provide information about possible impurities. 
HPLC has been identified as the most popular instrumental technique for 
pharmaceutical analysis and is noted as a gold standard for the quantitative analysis of 
pharmaceutical formulation contents (Martino et al, 2010; Chikowe et al, 2015; Yemoa 
et al, 2017). Ultraviolet Visible (UV-vis) spectroscopy is another solvent extraction 
based confirmatory technique used mainly for the quantitative determination/ analysis 
of different analytes identified in a particular medicine. Further details of the use of UV-
vis spectroscopy as a confirmatory technique in the assessment of medicines are 
outlined in chapter 6. 
One of the advantages of HPLC over the other techniques is that several detectors can 
be coupled with it. These include ultraviolet (UV), electrochemical, photodiode array 
(PDA) and MS detectors making it more versatile in its ability to detect the contents of 
different pharmaceutical formulations (Cai et al, 2010; Martino et al, 2010).  Nuclear 
Magnetic Resonance (NMR) is also increasingly used for screening counterfeit 
medicines, especially for the identification of high molecular APIs (Holzgrabe and 
Malet-Martino, 2011; Barras, 2013). Chromatographic or NMR methods are necessary 
to determine the composition of liquid products like protein based medicines. 
 The analytical data obtained using these more sophisticated confirmatory methods 
could provide forensic intelligence information about the criminal activities of medicine 
counterfeiters. The analytical profile also provides valuable information about the 
spread and globalisation of medicine counterfeiting and its link to organised crime. As a 
result, a trend can be established by tracing and comparing new falsified medicines 
with former cases. This will help in characterising falsified medicines with respect to 
source/origin (Deconinck et al, 2013; Dégardin et al, 2014) as was the case in 
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September, 2013 when falsified cough medicines found in Paraguay where identified to 
be similar to those detected in Pakistan as mentioned earlier in section 2.1.3 (WHO, 
2017). Assessment of the suspect cough medicines in Paraguay was therefore quicker 
because forensic information was available to the WHO from a similar case of medicine 
falsification in Pakistan. 
All the analytical techniques employed in the analysis of falsified and substandard 
medicines have been proven to enable the detection of these medicines (Table 2.2) but 
no individual technique can be identified as the “magic bullet” to FSMs detection 
(Martino et al, 2010, p.91; Rebiere et al, 2017). Therefore, the choice of the most 
suitable technique to be employed at any given time will depend on the following 
(Martino et al, 2010; Dégardin et al, 2014): 
 Expertise of the operator or analyst 
 Site where analysis is to be performed (developed or low income countries; 
forensic laboratories or field). 
 Time limit for the screening exercise 
 Funds available for the analysis 
 Invasive or non-invasive method (Tampering or not tampering with sealed 
packaging) 
 Purpose of testing/ required information (screening or confirmatory; Qualitative, 
semi-quantitative or quantitative). 
2.3 Conclusion  
Despite all the efforts to address the issue, counterfeit medicines are still a challenge 
globally. This is because the counterfeit medicine market thrives by taking advantage 
of the loopholes in the regulatory system or breaching established guidelines locally or 
internationally. Therefore, safeguarding of medicines or pharmacovigilance remains 
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continually relevant and crucial in order to ensure the safety of the medicines available 
to the general public. Also, because these medicines are a potential public health risk, 
the ease and speed of their detection will be a point to note if this phenomenon is to be 
addressed. With studies showing that more counterfeit medicines are found further 
away from the manufacturer in the distribution chain but closer to the final consumer, it 
is important that more simple, cost effective and quick analytical screening methods be 
developed so as to facilitate the process of authenticating medicines on the field.  
This thesis will investigate the use of ATR-FTIR spectroscopy, Raman spectroscopy 
and DIP-MS. The rationale for these choices is that they are readily available, low cost, 
simple, rapid and can analyse solid mixtures. Although ATR-FTIR spectroscopy and 
Raman spectroscopy have previously been used for screening medicines, this 
research considers novel applications of these techniques in quantifying APIs and 
discrimination of samples based on their constituents. On the other hand DIP-MS has 
not been explored as a screening method for counterfeit solid pharmaceutical 
formulations. Further details about the use of ATR-FTIR spectroscopy, Raman 
spectroscopy and DIP-MS in the investigation of solid pharmaceutical formulations are 
presented in chapters 3, 4 and 5 respectively.  
Chapter 6 and 7 will cover quantitative analysis of counterfeit medicines based on UV-
vis spectroscopy and LC-MS respectively. These pharmacopoeia approved methods 
(UV-vis and LC-MS) are used for validation of results obtained using the rapid methods 
in earlier chapters. Chapter 8 is an assessment of the various techniques employed in 
this study based on speed of analysis, cost, portability, sensitivity and specificity for 
their feasibility in different settings or regions globally. 
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3.1 Introduction 
With the growing prevalence of falsified and substandard medicines globally, the 
provision of simple, fast and cost effective methods of analysis for screening 
these medications would be beneficial especially in low and middle income 
countries (LMICs) (Glass, 2014; Hoellein and Holzgrabe, 2014; Koesdjojo et al, 
2014; Mackey et al, 2015; Otte et al, 2015). Vibrational spectroscopic techniques 
are widely-documented as being suitable analytical methods for the 
authentication of pharmaceuticals (Sacré et al, 2010; Ortiz et al, 2013; Custers et 
al, 2015; Neuberger and Neusüß, 2015; Hoellein et al, 2016). There has also 
been increased interest in the use of handheld devices that combine 
spectroscopic and chemical analyses for screening medicines in the field (Kwok 
and Taylor, 2012; Kovacs et al, 2014; Ranieri et al, 2014; Sukkar, 2014). Raman 
spectroscopy in particular has been applied extensively in the characterization 
and identification of suspected medicines (De Veij et al, 2008; Dégardin et al, 
2011; Neuberger and Neusüß, 2015) and also in quantification of paracetamol 
(Lyndgaard et al, 2013). Furthermore, Near Infrared spectroscopy (NIR) in 
combination with Raman spectroscopy, has been used for authentication of 
counterfeit medicines (Vredenbregt et al, 2006; Sacré et al, 2010). However, 
Neuberger and Neusüß (2015) identifies the limitations of Raman spectroscopy 
in its inability to discriminate between variations in mixing quality. Fourier 
Transform Infrared spectroscopy (FTIR) addresses this limitation as it is 
sensitive to mixing quality and granulation (Farouk et al, 2011). 
There is also the issue of chemical peaks not being well defined or separated 
(poor chemical peak specificity) in NIR spectroscopy making spectra difficult to 
interpret (Roggo et al, 2007; Kovacs et al, 2014). Interest in this area is 
increasing by the day with the development of new equipment such as the 
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combination of optical microscopy with sensitive Raman analysis for forensic and 
analytical testing (Horiba, 2016). 
Most applications of FTIR to pharmaceuticals like other spectroscopic 
techniques include characterisation and identifying the presence or absence of 
APIs and excipients (Sacré et al, 2010; Custers et al, 2015). Conventional FTIR 
with multivariate analysis has also been used for the quantification of APIs in 
antidiabetic drugs (Farouk et al, 2011) and paracetamol (Mallah et al, 2015) in 
solid pharmaceutical dosage forms. This approach requires skilled personnel 
since samples must be prepared as crushed powders finely dispersed in a KBr 
matrix which is then compressed into discs before analysis. This is both tedious 
and time consuming.  
Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-
FTIR) has revolutionized conventional FTIR by eliminating the main challenges 
in the analysis of pharmaceutical solid dosage forms notably the time spent in 
sample preparation: sample extraction or KBr disc preparation and the lack of 
spectral reproducibility. ATR-FTIR is quicker than the pharmacopoeia approved 
methods and conventional FTIR since the samples only need to be powdered 
before analysis (Lawson et al, 2018). The ATR accessory measures the changes 
that occur in a totally internally reflected infrared beam when the beam comes 
into contact with a sample (Fig. 3.1). The spectrum obtained is a fingerprint of 
the analyzed sample indicative of its unique features such as the functional 
groups and the chemical bonds in the sample (PerkinElmer, 2005). 
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Figure 3. 1 Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) 
Schematic (Adapted from Lawson et al, 2014) 
 
The aim of this study was to develop a simple fast and cost effective method 
using ATR- FTIR to distinguish between genuine and falsified or substandard 
tablet medication by identifying and quantifying the stated API in the presence of 
excipients. Tablet dosage forms generally consist of the therapeutic part (API) 
and the inactive part (excipients).  The study also aimed at developing methods 
based on portable techniques that could potentially be used in the field for 
authenticating medicines especially in the LMICs. Due to their widespread use 
paracetamol/acetaminophen and chloroquine in tablet dosage forms, collected 
from different countries, were the primary test samples chosen for analysis. As 
stated earlier in Chapter 2, the increase in demand for a particular medicine 
increases the likelihood of it being counterfeited. Paracetamol is a common 
painkiller used worldwide making it a target for counterfeiters. Chloroquine, a 
typical antimalarial medicine, was chosen because of the high prevalence of 
counterfeit antimalarial in regions which are mostly LMICs (Ansari et al, 2013). 
The WHO World Malaria Report 2017 indicates that 90% of the malaria cases in 
2016 occurred in the WHO African region further highlighting the magnitude of 
the problem in these LMICs (WHO, 2017). If validated rapid screening methods 
for medicines will enable withdrawal of counterfeit tablet medication from the 
market within the shortest possible time, thus reducing the risk to public health.  
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3.2. Materials and Methods 
3.2.1 Reference Chemicals  
Analytical grade APIs (analgesics and antimalarials) were obtained from Sigma 
Aldrich, Dorset, UK. Excipients were obtained from Fisher Scientific Ltd 
Loughborough, UK. The APIs and excipients for analysis are outlined in Table 
3.1.  
Table 3. 1 Active Pharmaceutical Ingredients and Excipients for ATR-FTIR analysis 
Active Pharmaceutical Ingredients (APIs) Excipients 
Paracetamol Calcium stearate 
Chloroquine phosphate Carboxymethyl cellulose 
Aspirin Maize starch  
Amodiaquine dihydrochloride Microcrystalline cellulose 
Artemether Magnesium stearate  
Artesunate Methylcellulose  
Pyrimethamine Potato starch 
Sulfadoxine Sodium starch glycolate 
Caffeine Zinc stearate 
 Mannitol  
 Crosscarmellose sodium 
 Sodium carbonate 
 Sodium starch glycolate 
 
3.2.2 Test tablet samples 
Single and multiple API tablet samples containing paracetamol were obtained 
opportunistically for analysis from a range of sources available to tourists in 
Europe, Asia, Africa and the Caribbean Islands. Sources from which tablet 
samples were obtained include pharmacies, hospitals, tuckshops, supermarkets, 
patent medicine stores and street vendors. Likewise tablet samples containing 
chloroquine from Europe, Asia and Africa were obtained for analysis. 
Paracetamol and chloroquine were the tablet samples of choice because of their 
common use globally as a painkiller/antipyretic and antimalarial medicine 
respectively (as mentioned earlier). Tables 3.2, 3.3 and 3.4 give a summary of 
the country of origin and the expected dose of the paracetamol and chloroquine 
tablets. 
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Table 3. 2 Single API paracetamol tablets analysed, their countries of origin and 
expected amount 








UK (n=2) UK P1T1  UK P1T2 Paracetamol 
500 
Cyprus (n=2) Cyp P1T1 Cyp P1T2 Remedol 
Switzerland (n=2) Swz P1T1  Swz P1T2 Dafalgan 
Spain (n=6) 
Spn P1T1  Spn P1T2 Panadol 
Spn P2T1  Spn P2T2 Paracetamol Teva 650 
Spn P3T1  Spn P3T2 Paracetamol Teva 
1000 
Belgium (n=2) Bel P1T1  Bel P1T2 Paracetamol EG 
India (n=19) 
Ind P1T1 Ind P1T2 P1- Crocin Advance  
500 
Ind P2T1 Ind P2T2 P2- G-mol 
Ind P3T1 Ind P3T2 P3- Paracin 
Ind P3T3 Ind P4T1 P4- Doliprane 
Ind P4T2 Ind P5T1 P5- Calpol 
Ind P5T2 Ind P5T3 P5- Calpol  
Ind P6T1 Ind P6T2 P6- Crocin Advance 
Ind P7T1 Ind P7T2 P7- Crocin Advance 
Ind P8T1 Ind P8T2 Tharfenac 325 
Ind P9T1  Paracip 650 
Pakistan (n=2) Pak P1T1 Pak P1T2 Panadol 
500 
Nepal (n=8) 
Nep P1T1 Nep P1T2 P1- Algina 
Nep P2T1 Nep P2T2 P2- Algina 
Nep P3T1 Nep P3T2 P3- Niko 
Nep P4T1 Nep P4T2 P4- Algina 
China (n=4) 
Chn P1T1 Chn P1T2 P1- Tylenol 
Chn P2T1 Chn P2T2 P2- Eurocetamol 
UAE (n=4) 
UAE P1T1 UAE P1T2 P1- Pmol 
UAE P2T1 UAE P2T2 P2- Adol 
Rwanda (n=6) 
Rwa P1T1 P1- Ubithera 
500 
Rwa P2T1 P2- Paradana 
Rwa P3T1 Rwa P3T2 P3- Pharmaquick 
Rwa P4T1 Rwa P4T2 P4- Eskay 
Ghana (n=4) 
Gha P1T1 Gha P1T2 P1- Ayrton 
Gha P2T1 Gha P2T2 P2- Cetapol 
Nigeria (n=4) 
Nig P1T1 Nig P1T2 P1- Agary 
Nig P2T1 Nig P2T2 P2- Seebest 
Jamaica (n=4) 
Jam P1T1 Jam P1T2 P1- Panadol 
Jam P2T1 Jam P2T2 P2- Panadol 
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Table 3. 4 Chloroquine tablets analysed, their countries of origin and expected amount 













Ind C3T1 500 
Nepal (n=2) 
Nep C1T1 
250 Nep C1T2 
Kenya (n=1) Ken C1T1 
Nigeria (n=1) Nig C1T1 400 
Note: n = number of samples, *C1T1= Pack 1 Tablet 1 and so on. 
3.2.3 Instrumentation 
All spectra were recorded on the Alpha Bruker FTIR spectrometer (Bruker 
Corporation, Germany) equipped with the ATR platinum diamond sampling stage 
to provide robustness and durability. Spectral acquisition was done using OPUS 
software version 7.5 (Bruker Corporation, UK).  
For qualitative analysis of tablet samples, the Spectrum Search facility within the 
OPUS 7.5 software was used for comparing sample spectra to those in local 
reference library. For paracetamol, quantitative measurements were carried out 
using two methods namely: 
Tablet(s) 
API(s) Expected in 
Tablets  
Amount of API expected 
in tablet (mg) 
PC A# 1  
Paracetamol and Caffeine  
Paracetamol-500, 
PC A# 2 Caffeine- 65 
PC B # 1  
Paracetamol and Caffeine 
Paracetamol- 500 
PC B # 2 Caffeine- 65 
PC C# 1  
Paracetamol and Caffeine 
Paracetamol- 500 
PC C# 2 Caffeine- 65 
PAC A#1  
Paracetamol Aspirin, and 
Caffeine 
Paracetamol- 200, Aspirin- 
300, Caffeine- 45 
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 Manual integration of characteristic peaks identified using the integration 
mode facility on the software.  
 Automatic multivariate partial least squares (PLS) calibration by using the 
Quant 2 facility within the software to provide calibration spectra from 
different concentrations (%w/w) of paracetamol prepared in selected 
excipients.   
Quantification of chloroquine was based on Quant 2 methods validated for 
paracetamol providing calibration spectra from different concentrations (% w/w) 
of chloroquine in maize starch. 
3.2.4 Methods 
3.2.4.1 Reference Spectra 
All sample spectra were measured in absorbance mode. A fresh background 
spectrum was measured against air before starting measurements and 
subsequently after every 5 runs. Small amounts of finely ground samples of the 
individual reference materials, paracetamol, chloroquine, other APIs and 
excipients often found in pharmaceutical formulations, were placed on the 
diamond sampling crystal and pressed using a clamp to ensure proper contact. 
Each spectrum was measured by averaging 20 scans over the range 4000-
400cm-1 and spectral resolution for measurement was 2cm-1. Estimated scan 
time for spectral acquisition was 25 seconds. This process was repeated 5 times 
to ensure replicate data was produced. The platinum diamond sampling surface 
was cleaned after each sample using paper tissue with isopropanol and allowed 
to dry. Recorded fingerprint spectra for the reference materials were assessed 
for spectral reproducibility by comparing replicate spectra. Reproducible spectral 
data were used to create a local reference library to help in the identification of 
sample spectra. Identification was based on characteristic peaks chosen by 
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comparing test sample to reference. Members of the same excipient groups, 
starches, stearates and celluloses all had very similar spectra (Fig 3.5). 
Characteristic regions of paracetamol and chloroquine spectra were identified 
where there was little or no interference from other materials.  
3.2.4.2 Preparation of API-excipient calibration mixtures 
3.2.4.2.1 Paracetamol calibration 
Excipients used were representative of different excipient groups commonly 
used in formulation for particular functions. Microcrystalline cellulose (binder, 
disintegrant), maize starch (diluent, binder) and magnesium stearate (lubricant) 
were the excipients selected as examples of excipients commonly used in 
paracetamol formulations (Haywood and Glass, 2011; Rowe, 2012).  
For calibration by manual integration of peaks, different concentrations of 
paracetamol at 20, 30, 40, 60 70, 80 and 90% w/w in magnesium stearate were 
prepared mixing paracetamol and the excipient for 120 seconds. For the 
API/excipient mixtures, a uniform total weight of 200mg was measured each 
time. These concentrations covered the different dosages in common over-the-
counter medicines. Calibration curves based on the recorded spectra of the 
paracetamol/excipient mixtures were prepared by determining the areas under 
the paracetamol peaks where there was no contribution from the excipients 
using the manual Integration facility on the OPUS 7.5 software. The final result 
was the mean of three separate runs per sample.  
The same protocol was followed for preparation of paracetamol/ excipient 
mixture for calibration using the automatic Quant 2 method but concentrations of 
paracetamol at 10.0%, 20.0%, 30.0%, 50.0%, 70.0% and 90.0% w/w in maize 
starch, MCC and magnesium stearate respectively were prepared. Calibration 
data was generated for the different paracetamol concentrations in the three 
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excipients considered. Final results were the mean of five replicate runs per 
sample. 
3.2.4.2.2 Chloroquine calibration 
Quant 2 methods based on validated data from paracetamol analysis were 
adopted for analysis of chloroquine tablets. Different concentrations of 
chloroquine in maize starch (10.0%, 30.0%, 50.0%, 60.0%, 70.0% and 90.0% 
w/w) were prepared by mixing chloroquine in maize starch for 120 seconds. 
Maize starch was used as the only excipient for analysis of chloroquine tablets 
as it was identified to produce more accurate and reproducible results in the 
analysis of paracetamol tablets. Areas under characteristic peaks for chloroquine 
were determined for the calibration curve using the Quant 2 application on the 
software. The automatic Quant 2 application on the software was the only 
approach used for chloroquine analysis since it was quicker and gave more 
reproducible results for paracetamol tablet analysis making it more efficient. 
Furthermore, considering good reproducibility obtained for paracetamol studies 
three separate runs were performed per chloroquine sample. Hence, final results 
were the mean of three separate runs.  
3.2.4.3 Preparation of test tablets- Qualitative analyses  
Individual tablet samples were taken out of their blister packs and placed on to the 
diamond crystal on the sampling head of the ATR unit. Measurement was done using 
the same parameters as with the reference spectra in section 3.2.4.1. Several points 
on each side of the tablet were assessed with spectral data recorded each time in 
order to investigate reproducibility and to check if the presence of the API could be 
confirmed based on the data. 
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3.2.4.4 Preparation of test tablets- Quantitative analyses  
Each tablet was weighed and then ground into fine powder using a mortar and 
pestle until a homogeneous mixture was obtained. Spectra of 5 individual 
powder samples per tablet were recorded. Characteristic peaks identified for 
paracetamol were then employed in assessing the potential of ATR-FTIR in the 
quantification of paracetamol in over-the-counter tablets using the OPUS 7.5 
manual integration and Quant 2 applications respectively.  For quantitative 
analysis of samples by manual integration, different integration modes provided 
by the software were applied as highlighted in Table 3.5. 
Table 3. 5 Integration modes for ATR-FTIR quantitative analysis and functions  
INTEGRATION MODE FUNCTION 
A                 
It performs the integration between the band, 
abscissa and the frequency limits defined. 
B                 
It integrates the area above a straight line 
drawn between the peaks of the two 
frequency limits defined. 
J                  
It measures  the highest absolute peak 
intensity 
K                  
It measures the peak intensity relative to the 
local baseline. 
 
Effect of mixing time on the reproducibility of quantitative data for paracetamol 
tablets was also investigated by comparing quantitative data for selected tablet 
samples after mixing for 60 seconds and 120 seconds respectively. 
For Quant 2 analysis the data was processed via the multivariate analysis 
capability of the OPUS 7.5 Quant 2 software 
Quant 2 methods based on paracetamol analysis were adopted for chloroquine 
analysis.  Spectra of three individual powder samples per tablet were recorded. 
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For both paracetamol and chloroquine analysis;  
Measured levels of API were indicative of the percentage amount of API in 
tablet. The relationship between the results in % w/w and the actual dosage can 
be expressed as:  
Actual Dosage of API in tablet (mg) = R x W 
Where R= Concentration of API in % w/w and W= Total weight of the tablet (mg) 
The levels of paracetamol and chloroquine in tablet medication obtained from the 
UK and several countries around the globe were then determined based on data 
obtained from the calibration mixtures. 
3.3. Results and Discussion 
3.3.1 Reference Spectra 
Reference samples for several APIs were recorded as part of the local ATR-FTIR 
library created. Fig 3.2 (a) and (b) are the reference spectra for paracetamol and 
chloroquine respectively. These spectra saved in the reference library could then be 
used for identification purposes by the Spectrum search capability in the OPUS 7.5 
software. If the spectral fingerprint of a test sample matched the reference wholly or in 
part the sample could be said to contain the same reference material. Reference 
spectra for other APIs are outlined in Figs 3.3 (a, b) and 3.4. (a, b). Fig 3.4(a) and 
3.4(b) are artemether and artesunate which are artemisinin derivatives used as 
antimalarials. The obvious similarity in their spectra suggests that they belong to the 
same family of compounds or that they have similar structure. In addition, Fig 3.5 
shows the spectra of different excipient groups (stearates, celluloses and starches) and 
the similarity between individual spectra within each group. 
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Figure 3. 2 ATR-FTIR reference spectra for (a) paracetamol (b) chloroquine 
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Figure 3. 3 ATR-FTIR reference spectra for (a) caffeine (b) aspirin 
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Figure 3. 4 ATR-FTIR reference spectra for (a) artemether (b) artesunate 
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Figure 3. 5 Comparing members of the same excipient group (a) Stearates: magnesium 
stearate (Blue), calcium stearate (Red), zinc stearate (Black) (b) Celluloses: 
microcrystalline celluose (Blue), carboxymethyl cellulose (Red), methylcellulose (Black) 
(c) Starches:  maize starch (Blue), potato starch (Red), sodium starch glycolate (Black)  
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3.3.2 Qualitative assessment of whole tablet samples 
Data sufficiently reproducible for qualitative identification of paracetamol could 
be obtained from a whole tablet placed on the sampling port of the ATR-FTIR 
instrument. The data for both sides of the tablet are shown in the lower two (blue 
and red) traces in Fig. 3.6. The difference between these traces, whilst being 
qualitative, does not lead to reproducible quantitative data. This can be obtained 
from a crushed sample of the tablet as shown in the upper trace (black) in Fig. 
3.6. Variation in the spectra obtained for the top, bottom and crushed tablet 
could be due to the degree of curvature of the tablet which affects contact with 
the sampling surface, poor homogeneity of the tablet or a combination of both. 
The irreproducibility of data based on whole tablet sample analysis meant that 
data based on the whole tablet was not appropriate for this work.    
Figure 3. 6 Paracetamol crushed (Black), Tablet top (Blue), Tablet bottom (Red) 
3.3.3 Spectral reproducibility 
Overlays of replicate spectra of each reference material indicated that there were 
no detectable differences in peak position between replicate spectra of the same 
sample (Fig 3.7). Initial studies showed some variation in peak intensities 
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between replicate spectra (Fig 3.8) but this was resolved with improved 
homogenisation of samples and proper reproducible covering of the sampling 
surface. Optimised sample preparation methods therefore gave reproducible 
spectral data across the fingerprint range (2000 - 400 cm-1). 
Figure 3. 7 Multiple spectra overlay of paracetamol reference showing reproducibility 
 
Figure 3. 8 Multiple spectra overlay of paracetamol reference showing variation in 
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3.3.4 Identification of active pharmaceutical ingredient (API) 
In order to identify the APIs (paracetamol and chloroquine) in the presence of 
excipients, a reference library containing spectra of reference material was 
created as discussed in 3.3.1. Replicate spectra of the reference samples (API 
and excipients) were recorded and there was no detectable difference in 
absorbance bands and peak data between individual replicates of the same 
material provided instrumental conditions remained constant. Spectral data 
based on both absorbance bands and peak intensities were reproducible. 
3.3.4.1 Fingerprint and characteristic peaks for identification of APIs 
The reproducible reference library formed the basis for identification of over-the-
counter paracetamol tablet medications. Crushed tablet spectra were then 
recorded and compared with those in the reference library and if the peaks in the 
fingerprint region (2000 - 400cm-1) matched, the presence of the API was 
confirmed. Aside from comparing the whole spectra, individual characteristic 
peaks were used to indicate the presence of a specified API in more complex 
tablet samples containing other APIs as well as excipients. This was achieved by 
selecting regions of the IR spectrum where there was little or no interference 
from the excipients. These characteristic peaks/ regions identified were then 
employed in the quantification of the API. 
 For the manual integration method for the determination of paracetamol, 
characteristic peaks employed were identified by simply overlaying 
recorded spectra of the API (paracetamol) with the selected excipient in 
order to identify regions in the spectra with the least interference. Based 
on this, peaks at 1225 cm-1, 1172cm-1, 1108cm-1, 603cm-1 were selected 
for calibration of paracetamol in magnesium stearate mixtures (Fig 3.9). 
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Figure 3. 9 Overlay of ATR-FTIR spectra for identification: Paracetamol reference (red) 
and magnesium stearate (blue). 
 
  For Quant 2 analysis, paracetamol was compared with a more complex 
mixture of three excipients (maize starch, MCC and magnesium stearate). 
For example Figure 3.10(C), a mixture of excipients, shows little 
absorbance over the ranges 2000 - 1750cm-1, 1600 - 1450cm-1 and 1300 
-1100cm-1. A comparison between the spectra for pure paracetamol (Fig 
3.10(A)), a paracetamol tablet (Fig 3.10(B)) and a mixture of common 
excipients used in tablet formulations, (Fig 3.10) shows that peaks at 
1505cm-1 and 1225cm-1 are indicative of the presence of paracetamol in 
the formulation. 
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Figure 3. 10 Comparison of three spectra: (A) pure paracetamol, (B) a paracetamol 
tablet, (C) a mixture of three excipients (maize starch, magnesium stearate and 
microcrystalline cellulose). 
Identification of the presence of paracetamol was possible down to about 5% 
w/w of API in excipient using the two characteristic peaks. The characteristic 
peaks for paracetamol at 1225cm-1 and 1505cm-1 correspond to the –OH in 
plane vibration and –CH3 vibration respectively. The molecular structure of 
paracetamol is show in Fig 3.11. 
 
 
Figure 3. 11 Molecular Structure of Paracetamol (Acetaminophen) 
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Figure 3.12 shows identification of paracetamol based on a comparison of 
spectra from the paracetamol reference and a tablet formulation over the 
fingerprint region 2000 - 400cm-1.   
 
Figure 3. 12 Overlay of ATR-FTIR spectra for identification: Paracetamol reference (red) 
and paracetamol tablet (blue). 
Figure 3.13 further confirms the peak at 1505cm-1 as a characteristic peak for 
paracetamol as it is identified in a complex multi API tablet containing aspirin and 
caffeine in addition to paracetamol 
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Figure 3. 13 Overlay of ATR-FTIR spectra for paracetamol reference (red) and 3-API 
tablet (black).      
Similarly, characteristic peak for chloroquine was identified at 1212cm-1 as 
shown in Fig 3.14.  
 
Figure 3. 14 Overlay of ATR-FTIR spectra for chloroquine reference (blue), magnesium 
stearate (green), MCC (black) and maize starch (red).                               
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3.3.5 Quantification of Active Pharmaceutical Ingredients 
Good grinding and homogenisation were essential in order to obtain well-
defined, reproducible and quantifiable spectra. This was particularly important for 
the quantification of the API in tablet samples Effect of mixing time on 
reproducibility and quantification of data is explained in section 3.3.5.1.1 
Grinding/mixing time was set at a minimum of 120 seconds per test tablet 
sample. 
Different approaches to quantitative analysis of paracetamol were carried out by 
applying the OPUS 7.5 Integration and Quant 2 software applications 
respectively to the spectral data obtained from the calibration samples prepared. 
The OPUS 7.5 integration mode has four different operating functions 
highlighted in Table 3.5: 
3.3.5.1 Quantification of paracetamol by manual integration of peak areas 
During the preparation of the Paracetamol/magnesium stearate calibration mixtures, 
there was difficulty in obtaining an even mix of both samples. The difficulty in mixing 
magnesium stearate could be linked to its use as a lubricant in pharmaceutical 
formulations. Calibration graphs were plotted for each of the selected characteristic 
peaks using the different integration modes on the OPUS software 7.5. The OPUS 7.5 
Integration application provides absorbance values for the area under the curve of 
selected spectral ranges using different modes as mentioned in section 3.2.4.4.  
Absorbance data for 3 replicate samples were recorded for each concentration. Table 
3.6 indicates the calibration equation and the R2 values for all calibration graphs for 
paracetamol in magnesium stearate prepared. Table 3.7 and Figure 3.15 show a 
representative example of the calibration data obtained. 
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Table 3. 6 Calibration curve equations and R2 values using different integration modes 
for paracetamol in magnesium stearate calibration mixtures 
PEAKS (cm-1) MODE A 
 CALIBRATION EQUATION R2 VALUE 
1225 y= 0.14x - 0.708 0.9922 
1172 y= 0.0301x + 0.3367 0.9952 
1108 y= 0.02x + 0.662 0.9879 
 MODE B 
1225 y= 0.0387x – 0.5437 0.9743 
1172 y= 0.0071x – 0.0486 0.9855 
1108 y= 0.0067x + 0.0316 0.9877 
603 y= 0.0277x – 0.3385 0.9927 
 MODE J 
1225 y= 0.0043x – 0.0211 0.9837 
1172 y= 0.002x + 0.0056 0.9905 
1108 y= 0.0014x + 0.0307 0.9864 
 MODE K 
1225 y= 0.0018x – 0.0323 0.9734 
1172 y= 0.0011x – 0.0094 0.9807 
1108 y= 0.0009x + 0.0005 0.9862 
603 y= 0.0018x+ 0.0157 0.9969 
 
Owing to the background effects observed with the peak at 603cm-1, measurements 
could only be taken from the local baseline of the peak. Hence, the calibration 
data for the peak at 603cm-1 is only given in modes B and K.  
Table 3. 7 Absorbance readings for paracetamol in magnesium stearate using mode A 
(Peak 1225cm-1) 
MODE A (PEAK 1225cm-1) 
 
AREA 
  CONCENTRATION (% w/w) Replicate 1 Replicate 2 Replicate 3 MEAN±SD 
90 11.642 11.626 12.175 11.814±0.31 
80 10.621 10.786 10.745 10.717±0.09 
70 9.490 9.078 9.441 9.336±0.23 
60 7.150 7.489 7.209 7.283±0.18 
40 5.252 4.998 4.562 4.937±0.35 
30 3.134 3.077 2.978 3.063±0.08 
20 2.697 2.485 2.332 2.505±0.18 
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Figure 3. 15 Calibration curve for paracetamol in magnesium stearate at 1225cm‾¹ using 
mode A (Data represents the mean±SD of 3 replicate samples). 
Calibration data in Fig 3.15 indicates the reproducibility of the data obtained with a high 
correlation coefficient of 0.99. Similar results were obtained for calibration based on the 
characteristic peaks identified and the different integration modes as highlighted in 
Table 3.6. Correlation coefficients for all calibration curves were between 0.97 and 0.99 
showing linearity of the data. Calibration equations were then used in working out the 
concentration of paracetamol in selected tablets (in % w/w).  
3.3.5.1.1 Effect of grinding/ mixing on the quantification of paracetamol tablet 
samples 
The effect of mixing time for crushed tablet samples on the quantification data for 
paracetamol tablets was assessed by mixing paracetamol tablets for 60 seconds and 
120 seconds respectively   It was observed that good grinding/mixing to obtain fine 
powder was essential in the quantification of the API in the tablet samples. 
Grinding/mixing time of the tablet samples also had an impact on the final results 
obtained as shown graphically in Fig. 3.16a and 3.16b. 
 























Paracetamol Concentration (%  w/w)
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Figure 3. 16 Ratio of measured to expected amounts of paracetamol for 5 replicates 
each of 6 different paracetamol tablets after grinding/mixing (a) for 60 seconds (b) for 
120 seconds 
Results after grinding/mixing for 120 seconds were more precise as indicated by the 
spread of the replicate data for each tablet. 120 seconds was therefore the optimum 
mixing used for analysis. 
3.3.3.1.2 Tablet Sample Analysis using OPUS 7.5 manual Integration  
Individual tablets from selected samples were crushed and subjected to ATR-FTIR 
analysis with quantification by the OPUS Integration application. A representative 
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example of the quantitative paracetamol data for the characteristic peaks is displayed 
in Table 3.8 (% w/w) and Table 3.9 (in mg) for data based on Integration mode A. The 
same tablets were assessed based on the other integration modes (B, J and K) and a 
summary of the data is presented in Table 3.10. Final results for each tablet were the 
mean of results obtained for each integration mode as shown in Table 3.10. 
Table 3. 8 Measured concentration of paracetamol (% w/w) using mode A calibration 


















UK P1T1 76.5 75.6 70.3 74.1±3.4 88.4 
UK P1T2 78.5 75.5 70.4 74.8±4.1 89.7 
Bel P1T1 84.5 82.6 83.5 83.5±1.0 85.8 
Bel P1T2  85.5 83.7 83.8 84.3±1.0 86.0 
Chn P1T1 71.2 69.8 68.6 69.9±1.3 84.7 
Chn P1T2  74.0 73.6 73.6 73.7±0.2 85.4 
Chn P2T1 78.9 78.9 72.1 76.6±3.9 80.7 
Chn P2T2 80.6 81.2 75.4 79.1±3.2 77.2 
Rwa P1T1 76.4 77.4 73.9 75.9±1.8 89.1 
Rwa P2T1 78.2 77.0 73.7 76.3±2.3 87.5 
Rwa P3T1 76.8 86.2 95.6 86.2±9.4 88.1 
Rwa P3T2 75.1 83.0 91.7 83.3±8.3 77.6 
Rwa P4T1 78.8 83.1 78.1 80.0±2.7 86.4 
Rwa P4T2 72.1 80.6 75.6 76.1±4.3 87.3 
Ind P1T1 72.6 72.4 69.1 71.4±2.0 75.6 
Ind P1T2 69.8 68.0 63.3 67.0±3.4 75.0 
Ind P2T1 73.4 82.3 95.9 83.9±11.3 84.0 
Ind P2T2 72.6 84.0 96.2 84.3±11.8 82.1 
Ind P3T1 72.2 78.5 83.0 77.9±5.4 84.9 
Ind P3T2 72.8 77.4 81.1 77.1±4.2 83.7 
Ind P3T3 71.9 75.4 78.5 75.3±3.3 84.1 
Ind P4T1 73.7 79.0 85.6 79.4±6.0 85.9 
Ind P4T2 74.1 81.5 87.4 81.0±6.7 84.4 
Ind P5T1 71.7 70.3 67.0 69.7±2.4 79.5 
Ind P5T2 70.6 69.5 65.2 68.4±2.9 77.0 
Ind P5T3 69.1 68.6 63.8 67.2±2.9 79.9 
Ind P8T1 56.6 29.5 102.5 62.9±36.9 42.7 
Ind P8T2 57.9 29.9 103.3 63.7±37.0 42.5 
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Table 3. 9 Measured amount (in mg) of Paracetamol using Mode A calibration curve for 



















UK P1T1 432.4 427.3 397.5 419±19 500 
UK P1T2 437.2 420.8 392.1 417±23 500 
Bel P1T1 985.4 963.2 973.7 974±11 1000 
Bel P1T2  994.1 973.2 974.3 981±12 1000 
Chn P1T1 420.0 411.6 405.0 412±8 500 
Chn P1T2  432.9 430.8 430.9 432±1. 500 
Chn P2T1 488.9 489.0 446.9 475±24 500 
Chn P2T2 521.7 526.0 488.1 512±21 500 
Rwa P1T1 428.8 434.4 414.7 426±10 500 
Rwa P2T1 446.8 439.9 421.0 436±13 500 
Rwa P3T1 436.1 489.4 542.8 489±53 500 
Rwa P3T2 484.1 535.0 590.5 537±53 500 
Rwa P4T1 455.9 480.7 451.8 463±16 500 
Rwa P4T2 441.5 461.5 432.9 445±15 500 
Ind P1T1 479.6 478.8 456.8 472±13 500 
Ind P1T2 465.3 453.7 422.0 447±22 500 
Ind P2T1 436.6 489.8 570.5 499±67 500 
Ind P2T2 442.1 511.1 585.6 513±72 500 
Ind P3T1 425.5 462.4 489.0 459±32 500 
Ind P3T2 434.8 462.4 484.4 461±25 500 
Ind P3T3 427.2 448.1 466.6 447±20 500 
Ind P4T1 429.1 459.5 498.2 462±35 500 
Ind P4T2 438.9 482.7 517.8 480±40 500 
Ind P5T1 450.9 442.4 421.4 438±15 500 
Ind P5T2 458.4 451.6 423.6 445±18 500 
Ind P5T3 432.1 429.2 399.2 420±18 500 
Ind P8T1 430.9 225.1 780.8 479±281 325 
Ind P8T2 443.2 228.8 790.2 487±283 325 
 
ATR-FTIR quantitative results for paracetamol in modes A, B, J and K are mean results 
of the different fingerprint peaks considered. Ind P8 tablets notably had very high 
standard deviation (SD) values. This huge variation arises mainly from results at Peak 
1108cm-1 with results obtained being more than double the expected amounts. Fig 3.17 
clearly shows the difference in the IR spectra of the reference paracetamol and the Ind 
P8 tablet at peak 1108cm‾¹. This variation could be due to the presence of an excipient 
or a different Active Pharmaceutical Ingredient (API) which absorbs in that region.  This 
limits the use of peak 1108cm-1 in quantitative analysis of paracetamol.  
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Figure 3. 17 Overlay of ATR-FTIR spectra of paracetamol reference (red) and Ind P8 tablet 
(blue). 
Table 3. 10 Summary of the results of quantitative analysis of the Paracetamol tablets 




















UK P1T1 419±19 429±28 450±26 461±53 500 
UK P1T2 417±23 442±32 456±31 476±58 500 
Bel P1T1 974±11 977±78 1036±37 1050±127 1000 
Bel P1T2  981±12 986±79 1049±44 1065±134 1000 
Chn P1T1 412±8 410±36 441±23 450±62 500 
Chn P1T2  432±1 419±39 455±21 456±66 500 
Chn P2T1 475±24 431±24 492±32 468±54 500 
Chn P2T2 512±21 457±24 529±27 494±56 500 
Rwa P1T1 426±10 422±36 447±21 446±56 500 
Rwa P2T1 436±13 440±36 466±25 475±60 500 
Rwa P3T1 489±53 401±28 475±24 418±52 500 
Rwa P3T2 537±53 448±38 524±21 472±63 500 
Rwa P4T1 463±16 437±37 476±22 460±59 500 
Rwa P4T2 445±15 422±37 456±23 440±57 500 
Ind P1T1 472±13 448±42 497±29 489±71 500 
Ind P1T2 447±22 445±41 480±38 487±73 500 
Ind P2T1 499±67 392±40 472±30 400±56 500 
Ind P2T2 513±72 394±44 479±33 409±59 500 
Ind P3T1 459±32 394±38 454±8 421±61 500 
Ind P3T2 460±25 407±40 464±5 439±63 500 
Ind P3T3 447±20 405±40 455±7 435±62 500 
Ind P4T1 462±35 412±37 462±7 435±60 500 
Ind P4T2 480±40 410±43 473±11 436±62 500 
Ind P5T1 438±15 434±39 465.±30 469±68 500 
Ind P5T2 445±18 443±36 477±33 483±68 500 
Ind P5T3 420±18 417±39 449±30 451±63 500 
Ind P8T1 479±281 239±71 499±89 314±84 325 
Ind P8T2 487±283 253±77 510±88 327±87 325 
Note: Quantitative results in modes A, B, J and K are mean results of the different peaks 
considered (1225cm-1, 1172cm-1, 1108cm-1 and 603cm-1). 
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A summary of the results based on different modes indicated that the paracetamol 
amounts in the tablets assessed were mostly within acceptable limits except the Ind P8 
tablets which suggests interference with the peak at 1108cm‾¹ as mentioned earlier. 
The quantitative data is better appreciated as a plot of measured to expected amounts 
of paracetamol versus the individual tablets. These data for all integration modes is 
presented in Figs 3.18-3.21 with tablet samples split into regions. 
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Figure 3. 18 Ratio of measured to expected paracetamol amounts in the tablets using 
integration Mode A for paracetamol in magnesium stearate calibration (a) 10 tablets 
from Europe and Africa (b) 18 tablet samples from Asia 
    
102 | P a g e  
 
 
Figure 3. 19 Ratio of measured to expected paracetamol amounts in the tablets using 
integration Mode B for paracetamol in magnesium stearate calibration (a) 10 tablets 
from Europe and Africa (b) 18 tablet samples from Asia 
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Figure 3. 20 Ratio of measured to expected paracetamol amounts in the tablets using 
integration Mode J for paracetamol in magnesium stearate calibration (a) 10 tablets from 
Europe and Africa (b) 18 tablet samples from Asia 
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Figure 3. 21 Ratio of measured to expected paracetamol amounts in the tablets using 
integration Mode K for paracetamol in magnesium stearate calibration (a) 10 tablets 
from Europe and Africa (b) 18 tablet samples from Asia 
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According to British Pharmacopoeia’s uniformity of dosage units test (BP, 2017), the 
test tablets comply and pass the test if not more than one tablet out of 30 tablets taken 
at random is outside the allowed limits of 85- 115% of the average content. The tablets 
fail the uniformity of dosage units test if more than one tablet is outside of the allowed 
limits of 85-115% of the average API content or if one tablet out of the 30 tablets taken 
at random, is outside the threshold limits of 75-125% of the expected API amounts. 
The FDA (FDA, 2014) also adopted the 75-125% threshold limit recommended by the 
International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH), which is an acceptance criteria harmonised 
between 3 different pharmacopoeias namely: the European Pharmacopoeia (Ph Eur), 
the Japanese Pharmacopoeia and the United States Pharamcopoeia (USP). 
It is clear from Figs 3.18-3.21 that higher values for Ind P8 samples occurred when 
integration modes A and J were employed. Integration modes A and J carry out 
measurements relative to the axis and not the local baseline of the peaks as with 
modes B and K. The measurements relative to the axis might therefore be measuring 
extra background information in addition to the actual data from the peak analysed.  
The data obtained from quantitative analysis of paracetamol via the integration method, 
showed that ATR-FTIR was not only able to identify the presence of the API but also 
quantify paracetamol amounts. This ATR-FTIR method was also able to identify 
suspect tablets (Ind P8) needing further analysis. The results therefore highlight the 
potential of the ATR-FTIR in the screening of medicines. Since the study is aimed at 
developing rapid analytical methods for the identification of falsified medicines, further 
analysis on paracetamol tablets was done using the automated Quant 2 facility on the 
OPUS 7.5 software. This would speed up the process since calibration is automated 
making the process even simpler. Quant 2 study is considered in the next section.   
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3.3.5.2 Quantification of Paracetamol by automated Quant 2 analysis (using a 
multivariate PLS calibration model) 
The OPUS 7.5 Quant 2 application automatically employs a partial least square 
(PLS) regression approach to find the best correlation function between spectral 
and concentration data matrix. In addition to magnesium stearate used for 
calibration of paracetamol by integration, maize starch and MCC were also used 
as excipients for calibration via the Quant 2 method. Unlike with magnesium 
stearate, both maize starch and MCC were easy to mix with paracetamol but the 
lower density of MCC may be an issue when trying to ensure good contact on 
the sampling head.  
The approaches assessed with Quant 2 included the use of the 3 individual 
excipients: MCC, maize starch and magnesium stearate with absorbance area 
measurements collected for: 
 the ranges 1524 - 1493cm-1 and 1236 - 1210cm-1 corresponding to the  
1505cm-1 and 1225cm-1 peaks,  
 the range 1524 – 1210cm-1  
 the whole recorded spectral range 4000 – 400cm-1.  
 
Individual calibration curves for paracetamol in the three different excipients, 
were plotted using the selected spectral ranges.  
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Figure 3. 22 ATR FTIR spectra of Paracetamol in maize starch standards between 
1800-800cm-1 
Calibration graphs containing 10-90% paracetamol in the selected excipients 
were produced from recorded spectra (example in Fig. 3.22) with R2 values 
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Table 3. 11 PLS calibration data for paracetamol in selected excipients and across 
different ranges 





1524 - 1493cm-1 0.038 0.999 0.9996 
Paracetamol in 
maize starch 
1236 - 1210cm-1 0.214 0.995 0.9976 
Paracetamol in 
maize starch 
1524 – 1210cm-1 0.027 0.999 0.9997 
Paracetamol in 
maize starch 
















4000 – 400cm-1 0.067 0.999 0.9994 
Paracetamol in 
MCC 
1524 - 1493cm-1 0.191 0.996 0.9982 
Paracetamol in 
MCC 
1236 - 1210cm-1 0.036 0.999 0.9997 
Paracetamol in 
MCC 
1524 – 1210cm-1 0.012 1.000 0.9999 
Paracetamol in 
MCC 
4000 – 400cm-1 0.062 0.999 0.9994 
 
3.3.5.2.1 Methods validation for Quant 2 Analysis 
The performance of the developed calibration data was assessed against a set 
of known typical OTC paracetamol tablets in which the paracetamol level had 
been measured by UV analysis. The tablets were assessed as containing 84% 
w/w paracetamol and the performance of the different ATR-FTIR approaches in 
assessing this value are shown in Table 3.12 and Fig 3.23. As expected the 
magnesium stearate samples show the widest variation with significant 
differences within the MCC samples. Furthermore the data reported for the 
1505cm-1 peak and also when using maize starch as excipient was the most 
consistent through-out all the measurements. This is evident in the data shown 
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in Table 3.12 with lower standard deviation (SD) values for data obtained for the 
peak centred at 1505cm-1 and when using maize starch. 
Table 3. 12 Assessing the performance of Quant 2 calibration methods for paracetamol 
in excipients across different spectral ranges 












PARA/MGST 68.1 82.5 85.2 111.9 18 
PARA/MST 81.3 86 84.7 78.3 3 
PARA/MCC 78.2 75.1 71.3 65.7 5 
SD 7 6 8 24  
 
 
Figure 3. 23 Chart showing measured amounts of paracetamol in tablets based on 
quantification methods using different absorbance bands and excipients. 
As a result of these validation studies, the calibration method based on 
paracetamol in maize starch for the peak centred at 1505cm-1 was used to 
determine the level of paracetamol in the test tablets. A typical calibration curve 
for quantification of paracetamol using data for the peak centred on 1505cm-1 
and covering the range 1524-1493cm-1 is shown in Fig 3.24. The R2 value of 
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0.9996 demonstrates good correlation between the changes in spectral data with 
changes in paracetamol concentration. Figure 3.25 is a comparison of the 
expected (True) paracetamol concentrations with the measured concentrations 
(Fit) showing close correlation for the data obtained using the PLS calibration 
model.    
 
Figure 3. 24 PLS calibration plot over the range 1524-1493cm-1 (with peak centred at 
1505cm-1) 
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Figure 3. 25 Comparison of measured versus expected amounts of paracetamol in 
calibration mixtures based on the range 1524-1493cm-1. 
3.3.5.2.2 Analysis of paracetamol tablet samples using Quant 2 multivariate PLS 
calibration model 
Individual tablets with paracetamol as single API from each of the separate 
samples were crushed and subjected to ATR-FTIR analyses. Quantification of 
paracetamol was based on the calibration for paracetamol in maize starch over 
the range 1524-1493cm-1 as mentioned earlier. The mean results for each 
sample set are recorded in Table 3.13. UV analysis was also conducted for 
validation of the ATR-FTIR paracetamol data (Chapter 6). Most of the ATR-FTIR 
data agreed within the general limits of ±15% of the expected dosage of the 
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paracetamol tablets (BP, 2017) but some significant differences were identified. 
Whilst there was close agreement for many of the samples the ATR-FTIR Quant 
2 approach gave high values for some samples from Belgium (Bel P1T1 and Bel 
P1T2), India (Ind P8T1 and P8T2) and Cyprus (Cyp P1T1 and Cyp P1T2). Low 
levels of API for a tablet sample from Pakistan (Pak P1T1) were also obtained 
from Quant 2 ATR measurements. 
The ATR-FTIR data is displayed as a plot of the ratio of expected to measured 
paracetamol levels versus sample origin as shown in Fig 3.26. This figure clearly 
shows that whilst the majority of tablet samples were within the general 
acceptable limits, seven samples merited further investigation. The first of these, 
the Belgian samples, gave high results using the Quant 2 ATR-FTIR tests but 
results based on quantification by the Integration mode were within allowed limits 
for these tablets. The Belgian samples would therefore be allowed to pass a 
screening test. Two of the Indian samples tested high on both Integration and 
Quant 2 ATR-FTIR methods for quantification but the ATR signal suggested the 
presence of other material in the fingerprint region and would therefore fail a 
screening test. Further investigation of the reason for failure would be required.
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Table 3. 13 Summary of quantitative results using the Quant 2 method for paracetamol 













 UK (n=2) 
UK P1T1 514±15 
500 
UK P1T2 505±15 
 Cyprus (n=2) 
Cyp P1T1 594±14 




Swz P1T1 510±10 
Swz P1T2 505±9 
  
Spn P1T1 514±15 




Spn P2T1 663±19 
650 
Spn P2T2 683±10 
  
Spn P3T1  921±41 
1000 
Spn P3T2 980±20 
 Belgium (n=2) 
Bel P1T1 1196±55 
Bel P1T2 1178±24 
Asia & Middle 
East (n=37) 
India (n=19) 
Ind P1T1  565±23 
500 
Ind P1T2 558±21 
Ind P2T1 462±11 
Ind P2T2 469±16 
Ind P3T1 493±16 
Ind P3T2 500±7 
Ind P3T3 493±9 
Ind P4T1 489±8 
Ind P4T2 481±25 
Ind P5T1 533±20 
Ind P5T2 542±16 
Ind P5T3 509±25 
Ind P6T1 545±6 
Ind P6T2 540±8 
Ind P7T1 530±23 
Ind P7T2 529±15 
Ind P8T1 464±12 
325 
Ind P8T2 472±4 
Ind P9T1  651±17 650 
Pakistan (n=2) 
Pak P1T1  373±14 
500 
Pak P1T2 451±8 
Nepal (n=8) 
Nep P1T1  532±13 
Nep P1T2 526±18 
Nep P2T1 501±17 
Nep P2T2 461±17 
Nep P3T1 535±13 
Nep P3T2 555±7 
Nep P4T1 499±24 
Nep P4T2 536±11 
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Chn P1T1 494±21 
 
Chn P1T2 500±9 
Chn P2T1  516±11 
Chn P2T2 546±6 
UAE (n=4) 
UAE P1T1 527±8 
UAE P1T2  541±17 
UAE P2T1 499±12 






Rwa P1T1 508±9 
500 
Rwa P2T1  525±8 
Rwa P3T1  486±14 
Rwa P3T2 536±11 
Rwa P4T1  533±10 
Rwa P4T2 519±14 
Ghana (n=4) 
Gha P1T1 496±20 
Gha P1T2 510±11 
Gha P2T1 530±5 
Gha P2T2 490±13 
Jamaica (n=4) 
Jam P1T1 481±11 
Jam P1T2  498±15 
Jam P2T1  509±10 
Jam P2T2 517±15 
 
Nigeria (n=4) 
Nig P1T1 488±13  
 Nig P1T2 503±10  
 Nig P2T1 522±11  
 Nig P2T2 519±33  
 
For the tablet sample from Pakistan (Pak P1T1), Quant 2 ATR-FTIR analyses 
showed clear evidence of insufficient levels of paracetamol. The samples from 
Cyprus would also fail a screening test with paracetamol levels higher than is 
generally allowed considering the Quant data in Fig 3.26. It is however important 
to note that the tablets from Cyprus were indicated as having glycerol as an 
excipient which was not the case for the other tablets assessed. Glycerol is not 
commonly used as a pharmaceutical excipient and its FTIR spectrum shows it 
has significant absorbance in the spectral range used for analysis of 
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paracetamol (1524-1493cm-1) (Nanda et al, 2014). This could be the reason for 
the higher than expected ATR-FTIR signals for the Cyprus tablets. 
Consequently, this set of tablets identified as suspect, would require further 
analysis.  
Based on the results obtained from the analysis of single API tablets containing 
paracetamol, ATR-FTIR spectroscopy showed its potential in rapidly identifying 
and quantifying paracetamol in tablet dosage forms. It was also able to identify 
suspect tablets based on the data obtained. 
    




Figure 3. 26 Ratio of measured to expected amounts of Paracetamol in 69 samples of 
tablets from around the world based on calibration for peak at 1505cm-1 (a) 14 tablet 
samples from around Europe (b) 37 tablet samples from Asia and the Middle East (c) 18 
tablet samples from around Africa and the Caribbean Islands. 
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Furthermore, the Quant 2 multivariate PLS calibration model was assessed 
against multiple API tablets containing paracetamol. The tablets were analysed 
using the same protocol for the single API tablets and with the validated 
calibration method for paracetamol in maize starch for the peak centred at 
1505cm-1. Quantitative data obtained for paracetamol are shown Table 3.14. 
Table 3. 14 Measured amounts of paracetamol in multiple API tablets from the UK based on 








Quantitative results for paracetamol in Table 3.14 indicate that paracetamol levels were 
generally within allowed limits for most of the multiple API tablets assessed. However, 
measured paracetamol amount for the 3 API tablet (PAC A#1) was lower than the 
threshold limits (75% of expected content). A comparison of the tablet spectra with 
reference spectra for paracetamol indicates notable absorbance in the spectral region 
being assessed as shown in Fig 3.27. 
Tablet(s) 
Measured amount of 
paracetamol (mg)  
Amount of API expected 
in tablet (mg) 
PC A# 1  502± 21 Paracetamol-500, 
PC A# 2 504±18 Caffeine- 65 
PC B # 1  493±9 Paracetamol- 500 
PC B # 2 490±14 Caffeine- 65 
PC C# 1  469±14 Paracetamol- 500 
PC C# 2 480±10 Caffeine- 65 
PAC A#1  132±7 
Paracetamol- 200, Aspirin- 
300, Caffeine- 45 
    




Figure 3. 27 Comparison of ATR-FTIR spectra for 3 API tablet (blue) with paracetamol 
reference (red) showing absorbance from other material in spectra range assessed. 
Further comparison of the 3-API tablet spectra with the other APIs expected in the 
tablet suggests the material with absorbance in the selected region for measurement is 
aspirin shown in Fig 3.28.  
 
Figure 3. 28 Comparison of ATR-FTIR spectra for 3 API tablet (blue), paracetamol 
reference (red) and aspirin reference (black) identifying peak interfering with 
measurement range to be aspirin 
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Aspirin was also expected in higher concentrations (48% w/w) than paracetamol (32% 
w/w) in the tablet. Therefore quantification using ATR-FTIR might be a challenge in 
multiple API tablets containing more than two APIs especially when the target API is 
present in lower concentrations. However, for the purposes of this research considering 
simple and quick YES or NO assessments of tablet medicines, ATR-FTIR provides a 
valuable option in this regard. 
3.3.5.2.3 Analysis of chloroquine tablet samples using Quant 2 multivariate PLS 
calibration model 
The Quant 2 multivariate PLS calibration model was assessed against chloroquine 
tablets from around the world. Quantification of chloroquine in tablets was based on 
validated methods for paracetamol. Hence, calibration for chloroquine in maize starch 
for the spectral range 1256-1173cm-1 corresponding to the peak at 1212cm-1 (identified 
as characteristic peak) was employed in the assessment of chloroquine tablet samples. 
PLS calibration data for chloroquine is shown in Figs 3.29 and 3.30. The R2 value of 
0.9959 showed good correlation between spectral changes and changes in chloroquine 
concentration. 
 
Figure 3. 29 PLS calibration plot for chloroquine over the range 1256-1173cm-1 (for peak 
at 1212cm-1) using the Bruker OPUS 7.5 Quant 2 software. Data represents three 
replicate samples with maize starch as excipient. 
    




Figure 3. 30 Comparison of measured (Fit) versus expected (True) amounts of 
chloroquine in calibration mixtures over the range 1256-1173cm-1. 
Calibration data obtained was then used in the assessment of tablets containing 
chloroquine with a summary of the quantitative results shown in Table 3.15.  
Table 3. 15 Summary of quantitative results for chloroquine tablet analysis form around 













UK (n=2) UK C1T1 240±5 250 338.8 
UK C1T2 257±23 250 370.4 
Belgium (n=2) Bel C1T1 301±14 250 337.6 
Bel C1T2 288±5 250 332.7 
India (n=5) Ind C1T1 321±11 250 320.5 
Ind C1T2 311±3 250 317.4 
Ind C2T1 348±1 250 311.6 
Ind C2T2 339±7 250 306.5 
Ind C3T1 468±7 500 627.1 
Nepal (n=2) Nep C1T1 308±17 250 314.6 
Nep C1T2 314±2 250 315.0 
Kenya (n=1) Ken C1T1 1517±81 250 501.7 
Nigeria (n=1) Nig C1T1 287±8 400 480.4 
 
Results in Table 3.15 show generally high levels of chloroquine in the tablets except 
with the UK tablets. The tablet from Nigeria also showed values lower than the 
threshold limit. This could be due to differences in the more complex formulation 
compared to the calibration made from binary mixtures. In addition, spectral peaks for 
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chloroquine are not well-defined (separated) as with the paracetamol peaks. This could 
be a challenge when comparing peaks for identification.  
Although results obtained for most of the tablets were generally high, the measured 
values of chloroquine in the tablet sample from Kenya (Ken C1T1) were anomalously 
higher than all the other tablets. The values for Ken C1T1 were about five times the 
total weight of the tablet. The results are better appreciated with a plot of the ratio of 
measured to expected chloroquine amounts in the tablets as shown in Fig 3.31 (a and 
b).   
    




Figure 3. 31 Ratio of measured to expected amounts of chloroquine in tablet samples 
from around the world based on peak over the range 1256-1173cm-1.(for the peak 
centred at 1212cm-1). (a) with Ken C1T1 tablet sample (b) zoomed in excluding Ken 
C1T1 sample 
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Based on the results obtained for the tablet from Kenya (Ken C1T1), the tablet spectra 
was compared with the UK tablet and the chloroquine reference as shown in Fig 3.32. 
 
Figure 3. 32 Comparison of ATR-FTIR spectra for Kenyan chloroquine tablet- Ken C1T1 
(blue), UK chloroquine tablet- UK C1T1 (red) and chloroquine reference (black) 
identifying peak showing differences in Ken C1T1 spectra. 
Figure 3.32 shows marked differences between the FTIR spectra for the chloroquine 
tablet from Kenya and the spectra for the UK tablet and chloroquine reference. 
Consequently, the tablet from Kenya (Ken C1T1) would fail a screening test. It is also 
important to note that the expected concentration of chloroquine for all other 
chloroquine tablets was between 67-82% w/w. On the other hand, chloroquine levels in 
the Kenyan tablet were expected to be about 50% w/w. This difference in expected 
chloroquine levels implies that the Kenyan tablet would have higher excipient levels 
than with the other chloroquine tablets assessed. This could be the reason for the 
difference in spectra. Overall, the Kenyan chloroquine tablet would fail a screening test 
needing further analysis.  
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Although there were limitations in quantifying chloroquine tablets using the ATR-FTIR 
method (as with the 3-API tablet containing paracetamol), the ATR-FTIR method was 
able to identify suspect samples like the Ken C1T1. Identifying the suspect sample is 
priority in the quick screening of medicines and this is the purpose for which the ATR-
FTIR is being assessed.  
One advantage of the approach taken here, recording reference and sample 
spectra over the range 4000-400cm-1 means that the Spectrum Search 
capabilities of the OPUS 7.5 software can be used. This approach should allow 
identification of the compound/s contributing to anomalously high peak areas in 
characteristic spectral ranges for measurement of target APIs as demonstrated 
in this research.  
The limit of quantification (LOQ) of the method is dependent on the type of excipient 
used and the weight of the tablet and so is not fixed for all investigations. 
Consequently, quantification of APIs in the presence of excipients was possible down 
to concentrations between 10-20% w/w. These results were based on the excipients 
considered in the study and the actual weight of the tablets.  
Overall, this novel method developed based on the ATR-FTIR technique has a 
few advantages as it not only identifies the presence or absence of the API but 
also indicates how much of the API could be in the tablet in a short time. It also 
reduces exposure to toxic chemicals used in solvent extraction of the API(s) for 
analysis using conventional pharmacopoeia approved methods. Its portability 
makes it valuable for in-field analysis such as quality control by pharmaceutical 
companies and post marketing surveillance by regulatory bodies. Furthermore, 
its potential in the identification of FSMs with incorrect amounts of API will also 
reduce the public health risk posed by these medications such as antimicrobial 
resistance and ultimately therapeutic failure. The dangers of under dosing or 
    
125 | P a g e  
 
 
exceeding the allowed limits for API(s) in medication especially those with a 
narrow therapeutic range will also be reduced (Blackstone et al, 2014).  
Economically, funds spent on these medications which are toxic or have no 
therapeutic effect will be reduced.  
3. 4 Conclusion 
Based on the rapid ATR-FTIR method examined, this study was able to identify 
10% (7 tablet samples) of the paracetamol tablet samples and 8% (1 tablet) of 
the antimalarial chloroquine tablets as suspect samples needing further analysis. 
These results are also in line with the WHO estimates of the level of FSMs 
globally, highlighting the wide range of samples assessed. 
This study shows that the simple ATR-FTIR approach employed has the 
capacity to rapidly identify and also quantify paracetamol in the presence of 
excipients and other APIs. The whole process of crushing, identifying and 
quantifying a tablet would take about 5 minutes per tablet sample after the 
method has been optimised. However, this is not meant to replace the more 
established and highly sensitive conventional solvent extraction methods but to 
serve as a valuable alternative to the expensive Raman systems as an in-field 
technique for quick screening of medicines. It is also a green technique as the 
elimination of solvent extraction of APIs reduces the amounts of toxic chemicals 
used thus, reducing chemical waste. Furthermore, the technique will enable 
quick withdrawal of counterfeit medicines from the market thereby reducing the 
threat to public health. It is also relatively inexpensive and easy to use compared 
to the pharmacopoeia approved techniques so can also be used in developing 
countries where facilities are not readily available. This approach employed in 
the identification and quantification of paracetamol could potentially be applied in 
the analysis of other APIs in tablet dosage forms. 
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As mentioned in Chapter 2, several techniques can, and have been used for the 
confirmation of FSMs, depending on the type of information needed. Among these 
techniques, Raman spectroscopy is one of the most commonly used for assessing 
FSMs (Dégardin et al, 2011; Kwok and Taylor, 2012; Neuberger and Neusüß, 2015; 
Peters et al, 2016) because it is largely non-destructive and sample measurement can 
be made directly through packaging. In addition, Raman spectroscopy as with other 
spectroscopic techniques like the ATR-FTIR, does not require sample preparation and 
is environmentally friendly. These features of the Raman technique along with 
availability of portable handheld models of the equipment makes it valuable for fast in-
field screening of medicines (Dégardin et al, 2017).  
Raman spectroscopy investigates vibrational transitions in molecules and is similar to 
both mid and near infrared (IR) spectroscopy. However, Raman spectroscopy depends 
on light scattering while IR spectroscopy is hinged on absorption. Monochromatic laser 
light (whether visible or near-IR) is used to irradiate samples in Raman spectroscopy.  
At the same wave number, most of the light with which the sample is irradiated is 
scattered back and this is called Rayleigh scattering (Gala and Chauhan, 2015). 
However, in a very small percentage of cases this light is scattered at wave numbers 
which are slightly higher (anti-Stokes scattering) or, less often, at lower wave numbers 
(Stokes scattering). Collectively, this change from the exact wave number of irradiation 
is known as Raman scattering, although Stokes scattering is more commonly reported 
since anti-Stokes is much weaker. The difference between the wavenumber of the 
incident radiation and the scattered radiation amounts to vibrational energy transitions.  
Consequently, it is this vibrational energy change, indicated at the corresponding 
wavenumber, Raman spectroscopy detects (Strachan et al, 2007; Gala and Chauhan, 
2015). Not only are there vibrational transitions within the molecule but changes 
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between electronic states can also occur giving rise to fluorescence. Fluorescence is 
evident as a non-uniform increase in the base line level in the recorded spectrum. 
Sample fluorescence masks the Raman response and posed a huge challenge for the 
use of Raman spectrometers in the pharmaceutical industry until the advent of novel 
experimental methods such as charge coupled device (CCD)-based experiments and 
Fourier transform (FT) spectrometers.  
Raman scattering is dependent on a change in the electronic polarisability of a 
molecule along with the vibrational mode. Polarisability refers to the electron charge 
being susceptible to having an induced dipole within it. As a result, large polarisability 
changes and in turn strong Raman scattering, are generally linked to molecules with 
delocalised electron systems (for example, aromatic conjugated systems). On the other 
hand, polar molecules exhibit the strongest IR absorption. Therefore, information 
provided by IR and Raman spectroscopy are complementary (Strachan et al, 2007; 
Gala and Chauhan, 2015). 
Several practical features of Raman spectroscopy make it attractive for solid-state 
analysis in the pharmaceutical industry. Most active pharmaceutical ingredients (APIs) 
are aromatics making them strong Raman scatterers. In contrast, many excipients are 
aliphatic and as a result produce much weaker Raman spectra. Thus, Raman 
spectroscopy has its advantages compared to mid- and near-IR spectroscopy when 
studying APIs in formulations, especially in low dosage formulations. Furthermore, 
while it may be very challenging to conduct mid- and near-IR spectroscopic analyses in 
aqueous environments, this will not be the case with Raman spectroscopy since water 
is a very poor Raman scatterer. Consequently, Raman spectroscopy will be suitable for 
solid-state analysis even in the presence of water (Strachan et al, 2007; Gala and 
Chauhan, 2015). 
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Several applications of Raman spectroscopy in pharmaceutical research have been 
evaluated from drug formulation to quality control in the pharmaceutical industry (Izake, 
2010; Gala and Chauhan, 2015).  Kalyanaraman et al (2012) in their review discuss the 
general use of the Raman device in the detection of falsified medicines. Luczak and 
Kalyanaraman (2014), evaluated results for falsified medicines of three products using 
both portable and bench top Raman technologies. A case study assessing the use of 
the Raman handheld device for the authentication of medicines in Nigeria is presented 
by Spink et al (2016). Hajjou et al (2013) evaluated the specificity and precision of the 
handheld Raman device in the screening of six pharmaceutical products including 
analgesics, antimalarial and antidiarrheal medicines. Assi (2016) successfully used 
dual laser handheld Raman spectroscopy for the authentication and chemical 
characterisation of type 5 phosphodiesterase inhibitors with concentrations of API in 
the range 5-15% w/w. 
Raman spectroscopy has its own draw backs such as fluorescence of some samples 
which hampers the accuracy of analytical data and the possibility of samples getting 
burnt due to overheating when illuminated with the laser beam. Assi (2016) suggests 
different laser excitation wavelengths should be explored to identify wavelength at 
which fluorescence is least observed. The difficulty however would be getting a 
balance between the right laser excitation wavelength and sensitivity. Overheating or 
burning of test samples while using Raman spectroscopy is more likely when the 
sample is illuminated with the laser beam on the same spot for a long period. Shin and 
Chung (2013) proposed rotating of test samples during analysis to reduce overheating 
or burning of the sample. Beyond qualitative analysis and general characterisation of 
medicines, Raman spectroscopy has proven useful in the quantitative determination of 
APIs in solid dosage forms. Just as with the optimised methods based on ATR-FTIR in 
Chapter 3, quantitative determination of tablet samples using the Raman device has 
    
134 | P a g e  
 
 
been done mostly in combination with chemometric analysis (Strachan et al, 2007; 
Fransson et al, 2010; Fraser et al, 2013; Shin and Chung, 2013; Griffen et al, 2015). 
Cailletaud et al (2017) in their review and Zheng et al (2014) considered different ways 
of improving sensitivity of the Raman device for low dosage quantification. Tondepu et 
al (2017) considered the use of portable Raman spectroscopy for the qualitative 
analysis and quantification of antiviral and antibiotic drugs but solvent dissolution of 
samples was involved. On the other hand, Rebiere et al (2018) applied Raman 
spectroscopy and chemometric methods in the screening and direct quantification of 
Viagra® and Plavix® test tablet samples  and their results showed the deviation of 
quantitative data from the reference method was between −15% and +24% of the API 
content which was considered acceptable for screening purposes.  
Besides the quantitative abilities of the Raman device, it can also be used in forensic 
analysis of medicines. Neuberger and Neusüß (2015) considered the use of Raman 
spectroscopy in the characterisation of medicines based on differences in the their 
excipients, API amounts and mixing quality but they achieved this by extensive pre-
processing of data including normalisation, baseline correction of the spectra and a 
reduction in spectral range used for analysis. For valuable forensic information to be 
presented in court for instance, it is important that analysis is done using the raw data 
to obtain as much information as possible.  
This chapter explores the potential of Raman spectroscopy in forensic analysis of 
FSMs, its ability to discriminate between different batches of medicines and 
characterise them from raw data obtained without any data pre-processing. This 
research also proposes its potential use in collecting quick valuable forensic 
information tenable in a law court during investigations. 
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4.2 Materials and Method 
4.2.1 Materials 
Pharmaceutical tablet formulations containing paracetamol and the antimalarial 
medicine, chloroquine were obtained for analysis from various locations across the 
globe. Table 4 .1 and 4.2 outlines details of paracetamol and chloroquine tablets 
accessed respectively. 
Table 4. 1 Paracetamol tablets analysed and their origin 
Region 





 UK (n=2) UK P2T1, UK P2T2 
500 
 Cyprus (n=2) Cyp P1T3, Cyp P1T4 
 Belgium (n=2) Bel P2T1, Bel P2T2 
  Spn P1T3, Spn P1T4 
Europe (n=16) Spain (n=6) Spn P2T3, Spn P2T4 650 
  Spn P3T3, Spn P3T4 
1000 
 Belgium (n=2) Bel P1T3, Bel P1T4 
Asia (n=34) 
India (n=14) 
 Ind P11T1, Ind P11T2,  
      Ind P14T1, Ind P14T2,  
 Ind P15T1, Ind P15T2, 
 Ind P16T1, Ind P16T2  
650 
Ind P10T1, Ind P10T2 500 
Ind P12T1, Ind P12T2 300 
Ind P13T1, Ind P13T2 
250+15mg 
Caffeine- Yellow 
Indonesia (n=1) Indn P1T1 
500 
Nepal (n=8) 
Nep P1T3, Nep P1T4,   
Nep P2T3, Nep P2T4,  
Nep P3T3, Nep P3T4,  
Nep P4T3, Nep P4T4 
Thailand (2) Thai P1T1, Thai P1T2 
UAE (n=2) UAE P1T3, UAE P1T4 
China (n=7) 
Chn P1T3, Chn P1T4   
Chn P2T3, Chn P2T4 
500+65mg 
Caffeine- Pink 
Chn P3T1, Chn P3T2, 650 
Chn P4T1 300 
Africa (n=16) 
Rwanda (n=4) 
Rwa P1T2, Rwa P2T2,  
Rwa P3T3, Rwa P4T3 
500 
Ghana (n=4) 
Gha P1T3, Gha P1T4,  
Gha P2T3, Gha P2T4, 
Nigeria (n=4) 
Nig P1T3, Nig P1T4, 
 Nig P2T3, Nig P2T4, 
 South Africa (n=2) SthAfr P1T1, SthAfr P1T2 
 
 Kenya (n=2) Ken P1T1, Ken P1T2 500+65mg Caffeine 
Note: n = number of samples, *P1T1= Pack 1 Tablet 1 and so on. All tablets are white except where colour is indicated 
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Table 4. 2 Chloroquine Tablet Samples analysed and their origin 
Country Tablet Expected Amount (mg) 
UK (3) 
UK C1T3, UK C1T4 
UK C2T1 
250 
Nepal (2) NEP C1T3, NEP C1T4 250 
India (4) 
IND C3T2, IND C3T3 
IND C2T3, IND C2T4 
500 
250 
Nigeria (1) NIG C1T2 400 
Note: n = number of samples, *C1T1= Pack 1 Tablet 1 and so on. All tablets are white except 
where colour is indicated 
4.2.2 Instrumentation 
The Foram 785 HP bench top Raman spectrometer by Foster + Freeman, UK was 
used to collect spectra. The software (Foram 3 by Foster + Freeman) was used to 
control the spectrometer during acquisition of spectral data and analysis. In addition, 
the Foram 3 software package had local spectral libraries (including APIs, and 
excipients) and chemometric algorithms (Metrohm, Runcorn, UK) such as principal 
component analysis (PCA).  
Spectrometer parameters used are outlined below: 
Laser excitation wavelength: 785nm 
Wavenumber range: 300-3000cm−1 
Scan time - 3 seconds 
Detector: Front illuminated charge-coupled device (CCD) 
Laser power output: 2.8mW at 100% laser output 
4.3 Method 
Calibration of the Raman system was done before any tablet sample measurements 
using a polystyrene reference sample. Test samples were measured in three formats: 
 Whole tablets removed from the packaging 
 Powder samples from crushed tablets 
 Tablet samples retained in the original blister packaging. 
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Samples were measured by placing them on the XYZ translation stage which allows 
adjusting the tablet samples in different directions to enable good measurement or well 
defined Raman spectra using the integral video microscope.  Each tablet was 
measured in triplicate from different spots on the tablet surface to improve sample 
representation. All measurements were taken from the plain, unmarked (without 
embossing or debossing) side of the each tablet to ensure the laser beams was 
focussed accurately on the tablet/sample surface. For powders the sample was placed 
on a slide to help position it under the lens. For the ‘in-package’ samples care was 
needed to ensure the laser beam was focussed on the tablet surface and not the 
packaging. Background spectral data from the packaging was also collected. The 5x 
objective lens was used for locating the sample while 20x lenses were used for 
collecting Raman spectra. Raw data was collected for each sample, recorded and 
subsequently background corrected using the inboard software. The raw data was also 
subjected to automatic PCA analysis using the Foram 3 software. 
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4.4 Results and Discussion 
4.4.1 Raman Analysis of Paracetamol Tablet Samples 
 
Figure 4. 1 Raman spectra for all paracetamol tablets assessed- Non Baseline 
Corrected 
Figure 4.1 is an overlay of Raman spectra for all paracetamol tablets assessed. The 
similarity in most of the spectra suggests the presence of the same API in the tablets. 
The only spectra with marked differences from the other tablets are those at the top of 
the figure identified as the spectra for tablet samples Nig P2T3 and Nig P2T4 from 
Nigeria. This difference in spectra could be due to fluorescence (a problem with Raman 
device mentioned earlier) with any of the excipients in the tablets. Therefore, by visual 
observation of spectra as presented in Fig 4.1, the tablet samples could be said to 
contain the same API (paracetamol), with tablets, Nig P2T3 and Nig P2T4 identified as 
being suspect samples needing further analysis. Inspection of Table 4.1 reveals that 
several tablet samples contain both paracetamol and caffeine but these cannot be 
identified in Fig 4.1. Furthermore two of the samples were coloured and these were not 
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differentiated in Fig 4.1. Raman alone is insensitive to small differences which may be 
readily revealed by Principal Component Analysis (PCA) of the raw data.  
4.4.1.1 Principal Component Analysis of Paracetamol Test Tablet Samples 
Figure 4.2 shows a principal component plot of all paracetamol tablets assessed with 
the test tablets separated into different groups based on the spectra presented.  For 
forensic data, it is important that there is minimal manipulation or pre-processing of the 
initial data obtained so raw (non-baseline corrected) spectra for test tablets were used 
for initial PCA study. 
 
Figure 4. 2 PCA for all paracetamol tablets assessed- Non-Baseline Corrected 
The data in Fig 4.2 indicates a similarity between most of the test samples analysed as 
highlighted by the cluster in the middle of the circle. This similarity can be traced to the 
presence of the API, paracetamol in the test tablets. However, more variation is 
observed with data from the PCA study since more tablets (in addition to the 2 
identified by visual observation of spectral data in 4.4.1) are highlighted to be outside 
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the general group in the middle of the circle. It was therefore important to understand 
the basis for the exclusion of the tablets found outside the general group.  
As indicated in Table 4.1, tablets from packs identified as Chn P2 and Ind P13 (in 
general group) are coloured. This could be a basis for discrimination by PCA since all 
other tablets are white. Interestingly, Chn P2 tablets are some of those outside of the 
general group. On the other hand, Ind P13 tablets are highlighted as part of the general 
group suggesting there might be other properties that make them closer related to the 
general group such as having similar excipients in addition to the paracetamol API 
present. Nevertheless, for forensic investigation purposes on the field, coloured 
samples can be spotted by visual observation and so will be removed. Figure 4.3 
shows a principal component plot of all the remaining white paracetamol test tablets.  
Figure 4. 3 PCA for all paracetamol tablet samples except coloured (Chn P2 and Ind 
P13) tablets- Non-Baseline Corrected. 
Figure 4.3 shows once again that most test tablets fall within the same cluster in the 
middle of the circle confirming the similarity in the tablets. With the coloured samples 
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excluded from the white test tablet samples, fewer test tablets were found outside of 
the general group as expected. 
Another basis for exclusion of samples was the presence of other APIs apart from 
paracetamol and as highlighted in Table 4.1, test tablets from the pack Ken P1 
contained caffeine in addition to paracetamol. For this reason, Ken P1 samples were 
again excluded from PCA study with details shown in Fig 4.4. 
 
Figure 4. 4 PCA for all paracetamol tablets in Fig. 4.3 not containing other APIs like 
caffeine (Ken P1) – Non-Baseline Corrected 
Figure 4.4 shows further reduction in the number of outliers based on the PCA study 
with exclusion of the Ken P1 test tablet samples containing caffeine in addition to 
paracetamol.  
Test tablets were then assessed once again in the PCA study with outlier samples from 
Chn P3 and Chn P4 excluded as shown in Fig 4.5a and 4.5b respectively. 
    




Figure 4. 5 (a) PCA for all paracetamol tablets in Fig 4.4 without outlier Chinese samples 
(Chn P3T1 and Chn P3T2) – Non-Baseline Corrected (b) PCA for all paracetamol tablets 
in Fig. 4.5a without outlier Chinese sample (Chn P4T1) – Non-Baseline Corrected 
It is not clear why the Chn P3 and Chn P4 samples are highlighted as significantly 
different from the rest of the tablets assessed. However, it is worthy of note that though 
Chn P3 and Chn P4 tablet samples were obtained from different locations in China and 
    
143 | P a g e  
 
 
were expected to contain different dosages of paracetamol (650 and 300mg 
respectively), they are produced by the same manufacturer. Therefore, there might be 
similarities between Chn P3 and Chn P4 and as such, the basis for the exclusion of 
these tablets by the PCA study might be the same.  
The next exclusion criteria was based on the initial visual inspection of test sample 
spectra which indicated Nig P2 test tablet samples as being different from the others 
and requiring further analysis. These test tablets (Nig P2) were therefore taken off the 
principal component plot as shown in Fig 4.5b resulting in the principal component plot 
in Fig. 4.6. 
 
Figure 4. 6 PCA for all paracetamol tablets without all outliers in Fig 4.2- Non-Baseline 
Corrected 
The principal component plot in Fig 4.6 indicates the remaining test tablet samples 
generally fall within the same group since samples are spread across the circle. The 
few cases spotted outside the circle could be due to slight variation in the spectra 
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recorded from different portions of a tablet since data from the same tablet spectra are 
also found within the circle. 
Generally, PCA study was able to confirm similarity between test tablet samples based 
on the presence of the expected API (paracetamol) and also identify marked 
differences in several tablets; some of which were not identified by visual observation 
of spectra. Raman spectroscopy and chemometrics has been used extensively in the 
quantitative analysis of tablet medicines (as mentioned earlier) so quantitative 
determination of tablet medicines using Raman spectroscopy and chemometrics is not 
addressed in this study.  
4.4.1.2 Comparing Non Baseline Corrected vs Baseline Corrected Data for 
Paracetamol Tablet Samples 
Most studies using Raman spectroscopy involved pre-processing of the Raman spectra 
by either baseline correction or normalisation of the data in order to obtain valuable 
spectral data. To ascertain that valuable forensic data could be obtained without 
manipulating or pre-processing data, raw (non-baseline corrected) spectral data for 
selected test paracteamol tablet samples were compared with pre-processed (baseline 
corrected) spectral data. 
Table 4. 3 Selected paracetamol tablet samples used for comparing non baseline 
corrected vs baseline corrected tablet samples 
Country Tablet 
UK UK P2T1, UK P2T2 
Belgium BEL P1T3, BEL P1T4, 
BEL P2T1, BEL P2T2 
China CHN P3T1, CHN P3T2 
CHN P4T1 
India IND P11T1, IND P11T2 
South Africa STHAFR P1T1, STHAFR 
P1T2 
Nigeria NIG P2T3, NIG P2T4 
 
    




Figure 4. 7 Raman spectra for selected paracetamol tablets including Nig P2 (Red) - 
Baseline Corrected 
Baseline corrected spectral data for all the tablets assessed were similar suggesting 
the presence of the same constituents. In addition, the effect of fluorescence observed 
with the non-baseline corrected spectral data, especially for the for Nig P2 tablets, was 
eliminated with baseline correction. However, even though there are similarities 
between the baseline corrected spectral peaks for Nig P2 tablets (red) and baseline 
corrected spectra for the other tablets, there are still noticeable differences as observed 
between 800 and 1200 wavenumbers (red spectra) in Fig 4.7. 
PCA study for baseline corrected spectra of the selected tablet samples was also 
conducted to check if PCA results were significantly affected by data pre-processing. A 
principal component plot of the selected paracetamol test tablet samples is shown in 
Fig. 4.8. 
    




Figure 4. 8  PCA for selected paracetamol tablets listed in Table 4.3 - Baseline 
Corrected 
PCA study of baseline corrected tablet spectra suggests there was no significant 
difference in PCA results since outlier samples based on baseline corrected spectra 
was generally consistent with results obtained using non baseline corrected samples 
as shown in Fig 4.8. 
    




Figure 4. 9  PCA for selected paracetamol tablets - Baseline Corrected vs Non-Baseline 
Corrected 
Both baseline corrected and non-baseline corrected spectra for the selected 
paracetamol tablets were subjected to PCA study at the same time to check if the 
system could identify differences between raw and pre-processed (manipulated) data. 
Figure 4.9 indicates the system is clearly able to discriminate between baseline 
corrected and non-baseline corrected spectra. It can also be observed that variation 
between baseline corrected spectra is not as pronounced as with non-baseline 
corrected spectra.   
4.4.1.3 Comparing Raman data for whole tablet vs crushed (powder) samples of 
selected paracetamol tablets 
Raman data for selected whole paracetamol tablets (Table 4.4) was compared with 
crushed powder samples of the same tablets to check if this made a huge difference on 
the final outcome. Non baseline corrected spectral data was used for this. 
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Table 4. 4 Selected Paracetamol tablet samples used for comparing tablet vs powder 
data 
Country Tablet 
Belgium BEL P2T1 
Spain  SPN P1T3 
China CHN P2T3 
Nepal NEP P1T3 
UAE UAE P1T3 
Rwanda RWA P3T3, RWA P4T3 
Nigeria NIG P1T1, NIG P2T3 
 
 
Figure 4. 10 Spectra for powder samples of selected paracetamol tablets- Non-Baseline 
Corrected 
Figure 4.10 shows non-baseline corrected spectra for powder samples of the selected 
paracetamol tablets. The same peaks are present in the spectra of the powdered 
samples but at significantly reduced intensity. The effect of fluorescence on the spectra 
for the crushed Nig P2 tablet is not as strong as it was with the whole tablet since 
spectral peaks are better defined. PCA studies were also conducted for the powder 
samples as highlighted in Fig 4.11. 
    




Figure 4. 11 PCA for powder samples of selected paracetamol tablets in Table 4.4- Non- 
Baseline Corrected 
PCA for powder samples in Fig 4.11 shows similarity between most of the tablets 
except Nig P2T3 which was once again identified as an outlier. Therefore, results 
based on powder samples were in agreement with those obtained using the whole 
tablet. This implies that valuable forensic data can be obtained using the whole tablet 
for Raman analysis which will in turn save time of analysis. It is however important to 




    




Figure 4. 12 PCA for whole paracetamol tablets selected in Table 4.4- Non-Baseline 
Corrected 
Figure 4.12 is a principal component plot for selected whole tablets of paracetamol 
outlined in Table 4.4. Interestingly, there is a slight difference observed between the 
principal component plot for whole paracetamol tablets selected and the principal 
component plot for the crushed tablets. Chn P2T3 identified as an outlier using whole 
tablet data in Fig 4.12 is not an outlier when crushed but part of the general group. This 
suggests that the property or constituent of Chn P2T3 which makes the system identify 
it as an outlier in tablet is suppressed or eliminated when it is crushed. This will explain 
similarity with other tablets after it is crushed. It might therefore be important to check 
powder samples of tablets initially identified as outliers to rule out false positives as 
was observed with Chn P2T3.  
The details for the powder samples in Fig 4.11 and whole tablets in Fig. 4.12 are 
compared in a combined principal component plot in Fig. 4.13. 
    





Figure 4. 13 PCA for Powder (Red) vs Whole tablet (Black) Raman data for selected 
paracetamol tablets in Table 4.4 – Non-Baseline Corrected 
Figure 4.13 shows similarities between data based on the whole tablet and powdered 
form of most of the selected tablets. The exceptions are with Chn P2T3 (mentioned 
earlier) and Nig P2T3. Although Nig P2T3 is identified as an outlier when both whole 
tablet and crushed tablet are assessed, it is important to note that the variation 
compared to the other tablets is reduced considerably when the crushed tablet is used. 
4.4.1.4 Comparing Raman data for whole tablets vs non-invasive analysis 
through blister pack for selected paracetamol tablet samples 
Since one of the advantages of the Raman device is its ability to screen samples even 
through packaging, data obtained by direct analysis of whole tablets was compared to 
data obtained without taking the tablets out of their blister packs. Selected paracetamol 
tablet samples were used as outlined in Table 4.5. 
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Table 4. 5 Selected Paracetamol tablet samples used for comparing whole tablet data vs 
data through blister packs  
Country Tablet 
Spain  SPN P1T3 
Nepal NEP P1T3 
UAE UAE P1T3 




Figure 4. 14 Non-transparent side of a blister pack for paracetamol 
Figure 4.14 is an example of a blister pack of paracetamol showing the non-transparent 
side. Raman spectra for the selected paracetamol tablets were collected through the 
non-transparent side of the blister pack and recorded as shown Fig. 4.15. This data 
from the non-transparent (aluminium foil) side of the blister pack was used as 
background reference data when analysing through the transparent side of the blister 
since there is little or no Raman response through the aluminium foil or through 
coating. 
 
    




Figure 4. 15 Spectra for selected paracetamol tablets through the non-transparent side 
(Fig 4.14) of the blister pack – Non Baseline Corrected 
Figure 4.15 shows data collected from the non-transparent side of the blister indicating 
a signal of very low intensity and poorly defined peaks. Signals at this level will pose 
little or no interference with the spectra obtained through the transparent side of the 
blister pack or direct analysis of the whole tablet. The transparent side of the blister 
pack (Fig 4.16) was then assessed for its potential in producing good Raman spectra 
for analysis. 
 
Figure 4. 16 Transparent side of a blister pack for paracetamol 
 
    




Figure 4. 17 Spectra for selected paracetamol tablets through the transparent side (Fig 
4.16) of the blister pack - Non Baseline Corrected 
Figure 4.17 indicates that the transparent side of the blister pack can be used to obtain 
spectra with defined peaks for analysis. However, the peak obtained via the 
transparent side of the blister pack might be weak. The Raman data obtained directly 
for the whole tablet, from powder samples and through the blister pack are compared 
in the next section. 
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4.4.1.5 Comparing Raman spectra collected directly from whole paracetamol 
tablets to spectra obtained through the blister pack and from powder samples 
 
Figure 4. 18 Raman spectra for Paracetamol tablet sample from Nepal (Nep P1T3)(Blue-directly 
from tablet; Yellow- crushed /powder sample; Green- through transparent side of blister pack; Red- 
non transparent side of blister pack) 
 
Figure 4. 19 Raman spectra for Paracetamol tablet sample from Nigeria (P2T3) (Blue-directly 
from tablet; Yellow- crushed /powder sample; Green- through transparent side of blister pack; Red- 
non transparent side of blister pack) 
    




Figure 4. 20 Raman spectra for Paracetamol tablet sample from Spain (P1T3) (Blue-directly from 
tablet; Yellow- crushed /powder sample; Green- through transparent side of blister pack; Red- non 
transparent side of blister pack) 
 
Figure 4. 21 Spectra for Paracetamol tablet sample from UAE (UAE P1T3) (Blue-directly from 
whole tablet; Yellow- crushed /powder sample; Green- through transparent side of blister pack; 
Red- non transparent side of blister pack) 
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Raman spectral data for the tablets assessed in Figures 4.18-4.21 show that the 
intensity of spectral peaks was generally highest for data obtained directly from the 
whole tablet (blue). This could be due to the compactness of the whole tablets. 
Intensities of Raman spectral peaks based on the powder sample (yellow) and through 
the transparent side of the blister pack (green) were not significantly different but less 
intense than those obtained directly from the whole tablet. The amount of information 
needed will therefore determine the approach taken in Raman analysis of test tablets. It 
is also important to note that the Raman response is dependent on the amount of 
analyte in the tablet. Therefore, analysis of low API tablet medicines might be a 
challenge especially with high levels of excipient that could cause fluorescence. 
4.4.2 Raman Analysis of Antimalarial (Chloroquine) Tablets 
The chloroquine tablets outlined in Table 4.6 were subjected to Raman analysis and 
spectral data was recorded as shown in Fig 4.22  
Table 4. 6 Chloroquine Tablet Samples analysed and their origin 
Country Tablet Expected Amount (mg) 
UK UK C1T3, UK C1T4 
UK C2T1 
250 
Nepal NEP C1T3, NEP C1T4 250 
India IND C3T2, IND C3T3 
IND C2T3, IND C2T4 
500 
250 
Nigeria NIG C1T2 400 
 
    




Figure 4. 22 Raman spectra for chloroquine tablet samples- Non Baseline Corrected 
Figure 4.22 shows the Raman spectra of all the chloroquine tablets which contain the 
anticipated characteristic Raman peaks for chloroquine (740, 900, 1110, 1360, 1380 
and 1550 wavenumbers) thus confirming the presence of the same constituent/API 
(chloroquine). The different levels of fluorescence (IndC2 vs Ind C3 suggests different 
excipient concentrations and the variations in the TiO2 peaks (650, 500 and 370 cm-1) 
confirm this. Baseline corrected data for the chloroquine tablets are displayed in Fig 
4.23. 
    




Figure 4. 23 Raman spectra for chloroquine tablet samples- Baseline Corrected 
The baseline corrected spectra for chloroquine tablets in Fig 4.23 eliminates the 
background due to fluorescence in the samples from India with all sample spectra 
closely matched in the overlay further indicating that tablets contain principally the 
same chemical compound (chloroquine). PCA studies were carried out for all 
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4.4.2.1 Principal Component Analysis of Chloroquine Test Tablet Samples 
 
Figure 4. 24 PCA for all chloroquine tablet samples - Non Baseline Corrected 
Based on the PCA data presented in Fig 4.24, four distinct groups are highlighted, 
corresponding to the spectral differences noted for Fig 4.22. Applying the same 
approach used in the PCA study for the paracetamol tablet Nig P2 (which exhibited 
fluorescence but was eliminated by baseline correction), PCA study for baseline 
corrected chloroquine samples was conducted and results recorded (Fig 4.25). 
    




Figure 4. 25 PCA for all chloroquine tablet samples - Baseline Corrected 
PCA for baseline corrected spectra for all chloroquine tablets in Fig 4.25 shows all the 
samples (including Ind C2 and C3) as part of the same group. This suggests that 
fluorescence was the reason for exclusion of the Indian samples in Fig 4.24 but 
baseline correction of the spectra was able to eliminate the effect. Therefore, pre-
processing of Raman spectra by baseline correction (as is commonly used in most 
studies) might be discarding valuable information needed to discriminate between 
tablet samples by the Raman equipment. Figure 4.26 is a combined PCA study 
comparing non baseline corrected data (Fig 4.24) for chloroquine to baseline corrected 
data (Fig 4.25).  
 
 
    




Figure 4. 26 PCA for all chloroquine tablet samples – (Baseline Corrected vs Non 
Baseline Corrected) 
Figure 4.26 shows clearly the difference between non baseline corrected data and 
baseline corrected data for the chloroquine tablets. The figure also shows how baseline 
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of paracetamol in 




UK P2T1 575.1 86.9 
500 
UK P2T2 593.1 84.3 
Cyprus (n=2) 
Cyp P1T3  627.0 79.7 
Cyp P1T4 628.7 79.5 
Belgium (n=2) 
Bel P2T1 584.4 85.6 
Bel P2T2 583.0 85.8 
Spain (n=6) 
Spn P1T3 598.8 83.5 
Spn P1T4 585.8 85.4 
Spn P2T3 863.8 75.2 
650 
Spn P2T4 860.3 75.6 
Spn P3T3 1308.3 76.4 
1000 
Spn P3T4 1310.1 76.3 
Belgium (n=2) 
Bel P1T3 1150.3 86.9 
Bel P1T4 1159.1 86.3 
India (n=14) 
Ind P11T1   806.6 80.6 
650 
Ind P11T2 802.3 81.0 
Ind P14T1 741.5 87.7 
Ind P14T2 748.6 86.8 
Ind P15T1 855.5 76.0 
Ind P15T2 844.0 77.0 
Ind P16T1 778.2 83.5 
Ind P16T2 785.7 82.7 
Ind P10T1 587.7 85.1 
500 
Ind P10T2 586.3 85.3 
Ind P12T1,  440.0 68.2 
300 
Ind P12T2 446.2 67.2 
Ind P13T1 580.7 43.1 250+15mg 
Caffeine- 
Yellow 
Ind P13T2 586.2 42.6 
Indonesia (n=1) Indn P1T1 594.1 84.2 
500 
Nepal (n=8) 
Nep P1T3 599.9 83.3 
Nep P1T4 620.0 80.6 
Nep P2T3 594.6 84.1 
Nep P2T4 612.3 81.7 
Nep P3T3 610.6 81.9 
Nep P3T4 618.5 80.8 
Nep P4T3 593.0 84.3 
Nep P4T4 600.2 83.3 
Thailand (2) Thai P1T1  575.9 86.8 
 Thai P1T2 556.6 89.8 
UAE (n=2) UAE P1T3 605.3 82.6 
 UAE P1T4 609.0 82.1 
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of paracetamol in 




Chn P1T3 592.5 84.4 
 
Chn P1T4   592.9 84.3 
Chn P2T3 629.4 79.4 500+65mg 
Caffeine- Pink Chn P2T4 638.3 78.3 
Chn P3T1 785.9 82.7 
650 
Chn P3T2 784.6 82.8 
Chn P4T1 456.3 65.7 300 
Rwanda (n=4) 
Rwa P1T2 588.3 85.0 
500 
Rwa P2T2 576.8 86.7 
Rwa P3T3 564.7 88.5 
Rwa P4T3 559.4 89.4 
Ghana (n=4) 
Gha P1T3 625.8 79.9 
Gha P1T4 537.7 93.1 
Gha P2T3 543.4 92.0 
Gha P2T4 527.4 94.8 
Nigeria (n=4) 
Nig P1T3 593.2 84.3 
Nig P1T4 584.0 85.6 
Nig P2T3 583.1 85.7 
Nig P2T4 544.0 91.9 
South Africa 
(n=2) 
SthAfr P1T1 602.3 83.0 
SthAfr P1T2 584.9 85.5 
Kenya (n=2) 
Ken P1T1 671.5 74.5 500+65mg 
Caffeine Ken P1T2 673.4 74.3 
Note: n = number of samples, *P1T1= Pack 1 Tablet 1 and so on. All tablets are white except 
where colour is indicated 
 
4.5 Conclusion 
Current work indicates the potential of Raman spectroscopy in providing valuable 
forensic data in the screening of FSMs. Results suggest the use of chemometrics 
(PCA) facilitates the recognition of minor spectral differences which might be difficult to 
detect by simple visual comparison of unique Raman spectral regions or peaks. 
 The factors that may affect the Raman spectra include: 
 The wrong level (concentration) of API  
 The wrong API or more than one API 
 Different excipient mixtures 
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 Surface coatings or colours 
The data recorded in Table 4.7, for European samples, shows that tablets covering 
500, 650 and 1000mg all contain about the same concentration (68-85%) of 
paracetamol on a w/w basis. The spectra are very similar and the PCA signals all 
cluster in the centre of Figure 4.2 Similarly all the other samples with a paracetamol 
concentration within the range 68-85% lie within the central group on Fig 4.2 except for 
the Chn P2 and Ken P1 tablets which both contain a second API and are therefore 
outliers. Of the remaining outliers samples Nig P2 clearly has different excipients 
present and ChnP4 has a reduced concentration of paracetamol (66%). 
One sample, Ind P13 challenges the Raman/PCA methodology reported here. These 
tablets contain 2 APIs, are coloured only contain 250mg of the API and yet appear to 
be bona fide 500mg tablets. 
In addition to the spectroscopic techniques considered in Chapters 3 and 4, the next 
chapter will focus on direct insertion probe mass spectrometry (DIP-MS) and its 
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As established earlier, falsified and substandard medicines pose a huge threat to public 
health not only in many small and middle-income countries but also in developed 
countries as well. In a recent report, key malaria treatment was unable to cure four 
patients in the UK who had all visited Africa suggesting early signs of the parasite 
being resistant to the medication (Gallagher, 2017). The United Nations Office on 
Drugs and Crime has also identified medicine counterfeiting as a global threat (Kaur, 
2015).  
One way to prevent the spread of falsified and substandard medicines as spelt out in 
Chapter 2 is to carry out onsite screening of medicines. This type of screening is 
generally done either by batch number/ bar code searching using special apps on 
mobiles phones or by simple colorimetric or thin layer chromatography (TLC) kits. 
There is also the issue of sensitivity (false positives) and the largely qualitative nature 
of these TLC tests which neglects or doesn’t take into account falsified medicines with 
insufficient amounts of the active ingredient (Rebiere et al, 2017; Zou et al, 2017). In 
addition, it is even more difficult to prevent the spread of clones of particular tablet 
medications especially where chiral compounds are involved with cheaper analogues 
substituted for genuine and more expensive APIs. With the analogues being very 
similar in that they have the same chemical species or functional groups and are 
basically mirror images of each other, they are more difficult to detect (Kovacs et al, 
2014; Rebiere et al, 2017).  
Mass spectrometry has been identified as one of the most popular techniques for 
chemical analysis due to its high accuracy, selectivity and quantitative capabilities 
provided that the analytes in question can be converted efficiently to gas phase ions. 
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While results that are more accurate are obtained using mass spectrometers than with 
conventional immunoassay kits such as the GPHF Minilab and simpler techniques like 
the TLC, mass spectrometers until recently, were considered to be too complex and 
expensive to be used for in situ screening of pharmaceutical formulations. It is in a bid 
to address the challenge posed by using large laboratory based equipment for in-field 
analysis that efforts towards the miniaturisation of mass spectrometers have been on 
the rise in recent times (Kumano et al, 2015).  
5.1.1 Introduction to Mass Spectrometry 
Mass spectrometers need a vacuum system to function and measure the mass to 
charge ratio of ions in order to determine the identity of a sample. For many years 
mass spectrometers have been used, generally in combination with a gas 
chromatograph (GC), to identify the components of mixtures. The identification of the 
components of mixtures which could be in different physical states (solid, liquid or gas) 
have been based on the characteristic fragmentation patterns produced by high energy 
electron impact ionisation processes employed in the mass spectrometer. The GC acts 
both as a separation technique and a means of introducing the samples into the MS. 
Separation of mixtures by GC requires the mixture components to be both readily 
volatile and thermally stable but this is unlikely to be the case for the components of a 
tablet and so an alternative means of introducing a solid sample into the mass 
spectrometer is needed. It was common practice in the 60s and 70s to use a heated 
direct insertion probe (DIP), via a vacuum lock, to introduce samples directly into the 
ion source of a mass spectrometer where the sample was volatilised, ionised and 
analysed. This technique is referred to as DIP-MS and can be applied to crushed tablet 
samples with no other sample preparation required prior to analysis.   Conventionally, 
identifications are based on the characteristic positive ion fragmentation patterns 
    
171 | P a g e  
 
 
produced by the high energy electron impact (EI) ionisation processes used in the 
mass spectrometer. This process can be summarised: 
M + e- (H) = [M+] + 2e- (L) = m1+ + m2+ 
Note e- (H) = high energy electron and e- (L) = low energy electron 
[M+] = excited short-lived molecular ion 
It is also possible for the sample to be ionised by a low energy electron to produce a 
negatively charged molecular ion which is unlikely to fragment. Both approaches have 
been used here and the results compared with data from an example of the new 
atmospheric pressure or ambient ionisation technique (Culzoni et al, 2014, Fernandez 
et al, 2014). In these techniques, the ionisation processes can be represented as:  
M + H+       (M+H)+    where (M+H)+ is known as the pseudomolecular ion. Atmospheric 
pressure or ambient ionisation techniques offer two technical differences to the EI-MS 
process. In these systems ions are created outside of the MS vacuum system, usually 
by the addition of a proton rather than the removal of an electron. Under these 
conditions, the energy transferred to the target molecule is low and therefore little 
fragmentation is observed and the target signal is the anticipated molecular weight 
(Mwt) plus 1 mass unit. 
Exactly what is meant by a molecular ion needs to be clarified. There are three different 
ways to calculate the molecular mass from the empirical formula: 
 Average mass – based on the average atomic weights over all isotopes 
 Monoisotopic mass – based on the mass of the most abundant isotopes 
 Nominal mass – based on the integer mass of the most abundant isotopes 
In mass spectrometry the monoisotopic mass should be used and thus any compound 
containing chlorine, for example, will have two molecular ions separated by 2 mass 
units corresponding to the 35 and 37 isotopes of chlorine. 
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Ambient sampling/ionisation MS has shown great potential (Culzoni et al, 2014, 
Fernandez et al, 2014) with direct analysis in real time (DART) and desorption 
electrospray ionisation (DESI) identified as the most frequently used techniques 
(Bernier et al, 2016). Culzoni et al (2014) asserts that high throughput and very 
sensitive ambient mass spectrometry techniques will enhance the investigation of 
pharmaceutical formulations with little or no sample preparation. Bernier et al (2016) 
employed DART ionisation coupled with a compact single quadrupole mass 
spectrometer in fingerprinting antimalarial tablets and compared them to high-
resolution equipment with both systems producing similar results thereby suggesting its 
possible use on the field. There have also been instances where thermal desorption of 
the sample was followed by ambient ionization. Atmospheric pressure chemical 
ionisation (APCI), dielectric barrier discharge ionisation (DBDI), electrospray ionisation 
and atmospheric pressure photoionization are further examples of ambient ionisation 
methods coupled with thermal desorption (Culzoni et al, 2014).  All these methods 
have proven to be useful but Kumano et al (2015) points out the challenge using bulky 
equipment for a portable spectrometer.   
Efforts to miniaturize mass spectrometers making them more portable have targeted 
improving sensitivity (Snyder et al, 2015; Bernier et al, 2016; Brown et al, 2016; Lawton 
et al, 2017; Li et al, 2017). The weight of the mass spectrometer is predominantly 
attributed to the vacuum pump. As such, reducing the weight of the whole system will 
involve using a smaller pump but this in turn lowers pumping speed which results in 
lower sensitivity for analysis due to the necessary reduction in sample size (Kumano et 
al, 2015).  
Several techniques have been developed to address this lower sensitivity challenge. 
Contreras et al (2008) employed a portable mass spectrometer with a gas 
chromatograph, a toroidal iron trap and an electron ionisation source where a solid 
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phase micro extraction method was used in concentrating the sample. This in turn 
improved sensitivity. Ouyang et al (2009) designed a portable mass spectrometer with 
an electrospray ionisation source and a rectilinear ion trap. They enhanced the 
efficiency of ion transfer (from an ionisation source at atmospheric pressure to a mass 
analyser in a vacuum) by designing a discontinuous atmospheric interface.  
Kumano et al (2015) in their quest to find an alternative to the use of immunoassay kits 
(involving solvent extraction) for the screening of illicit drugs, developed a prototype of 
a portable mass spectrometer. It employs a low-pressure dielectric barrier discharge 
ionisation (LP-DBDI) source which is highly sensitive. To allow for efficient transport of 
the sample vapour to the LP-DBDI source, a vacuum headspace method and a 
discontinuous sample gas introduction technique was used. The spectrometer had the 
ability to detect 0.1 ppm of methamphetamine in a liquid, making it adequately sensitive 
for the screening illicit of drugs. The limitation with this portable mass spectrometer 
however, is that it can only be used for analysis of liquid samples. Kumano et al (2015) 
in their work also suggested that a portable mass spectrometer with solid sampling 
capabilities will be required to and possibly enhance the early detection of illicit drugs 
before they fall into the hands of criminals. To achieve this, they developed a probe 
heating method which they incorporated in the portable mass spectrometer to facilitate 
the screening of solid samples (illicit drugs). This technique (probe heating method), 
they identified as being important for public safety. Li et al (2017) also used portable 
ion mobility spectrometry in the rapid screening of non-steroidal anti-inflammatory 
drugs which were illegally added in anti-rheumatic herbal supplements. Furthermore, 
Ma and Ouyang (2016) are also of the opinion that integrating ambient ionization and 
miniature mass spectrometry systems would facilitate chemical and biological analysis. 
Besides analgesics/ antipyretics, antimalarial medicines have been identified as one of 
the most falsified medicines globally and more prevalent in tropical low and middle 
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income countries (Chaccour et al, 2015). This is because individuals are poor and so 
will settle for cheaper options they can get even if they are not genuine. Karunamoorthi 
(2014), puts the global annual death rate due to falsified antimalarial medicines at 
nearly 660, 000. Chaccour et al, (2015) further indicates that over 584,000 deaths 
occurred in 2013 due to falsified antimalarial medicines with about 453,000 being 
children under 5yrs highlighting the severity of the situation. Different antimalarial 
combination therapies have been in use in malaria endemic countries for  the treatment 
of drug-resistant malaria. Artesunate, artemether, lumefantrine, amodiaquine, 
sulfadoxine and pyrimethamine are key drugs used mostly in combined doses in the 
treatment of multi-drug resistant Plasmodium falciparum malaria (Kaur et al, 2016). 
Reports suggest that counterfeit antimalarials contain either insufficient amounts of API 
or, in some cases, no APIs (Chaccour et al, 2015).  The ignorant consumer of such 
medicines is at substantial risk of not getting any therapeutic relief, becoming resistant 
to the illness and may even die due to ineffective treatment (Karunamoorthi, 2014). 
In a bid to address the challenges encountered with ATR-FTIR outlined in chapter 3 
(such as limit of detection and difficulty in characterising/quantifying mixtures of APIs 
due to complex non well-defined spectra), it was important to consider a more sensitive 
technique for example DIP-MS which is rapid and provides simpler and more 
compound specific information about both API(s) and other components of a tablet 
including impurities/contaminants. DIP-MS also has the potential to be used for in-field 
analysis of pharmaceutical tablet formulations. Until now, DIP-MS has not been 
identified for its use in the identification of falsified and substandard pharmaceutical 
tablet formulations.    
This chapter describes the fast analysis of analgesic/antipyretic and antimalarial tablets 
by direct insertion probe mass spectrometry (DIP-MS). Furthermore, the potential of 
DIP-MS in the analysis of more complex tablets having multiple APIs/excipients and 
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those with API concentrations lower than the detection limits of the ATR-FTIR (e.g. 
antimalarials) were assessed. Tablets were assessed using conventional electron 
ionisation (EI) methods and the results were compared with data from 
ambient/atmospheric ionisation methods (atmospheric solids analysis probe - ASAP® 
mass spectrometry).  
5.2 Principle and Potential Applications of Probe-MS 
5.2.1 DIP-MS 
The apparatus schematic (Fig 5.1) shows the demountable sample probe (DIP) which 
has a heated sample cup in the tip which is inserted into the MS ion source. To analyse 
a sample a small amount (a few milligrams) of the powdered sample is contained in a 
pyrex tube placed in the tip of the direct insertion probe (DIP). The probe is introduced 
into the vacuum system via a vacuum lock and positioned such that the top of the 
sample tube is close to the ionization chamber of the MS as shown in Figure 5.1.   
 
 
Figure 5. 1 Direct Insertion Probe Mass Spectrometry (with high energy electron 
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The tip of the probe is then heated in a temperature controlled mode in order to 
volatilise the different components of the sample; a technique similar to the fractional 
distillation process but with the separation enabled by the dual effect of heat and the 
vacuum.  
The temperature ramp rate chosen is very crucial in order to avoid a situation where 
the sample vaporizes too rapidly and the signal is saturated. As the volatile species are 
ionised by electronic impact the resultant mass spectra are monitored. Electron 
ionisation (EI) method in mass spectrometry has several advantages and 
disadvantages as outlined in Table 5.1.  
Table 5. 1 Advantages and Disadvantages of Electron ionisation (EI) method in mass 
spectrometry 
Advantages Disadvantages 
Sensitive The molecule must be volatile 
Simple The molecule has to be thermally stable 
Fragmentation enables characterisation of 
molecules 
Extensive fragmentation leads to more 
complex data which is difficult to interpret 
(Adapted from Gross, 2011) 
It is important to ensure the molecules have a short residence time in the source so as 
to enhance rapid ionisation and prevent thermolytic degradation. In the DIP-MS, this 
can be achieved by; 
 Very short distance between the tip of the probe and the ionisation source. 
 Ensuring the number of molecules involved in collision with the electron flux is 
small.  
 The turbomolecular pump system, coupled to the mass spectrometer, gives rise 
to a dynamic vacuum in the ionisation chamber in order to sustain high vacuum 
conditions.  
 Molecule collision and recombination are minimised at low pressures (Flego 
and Zannoni, 2012). 
    
177 | P a g e  
 
 
The vacuum helps to lower the boiling temperature of compounds thereby allowing the 
vaporisation of these high-boiling point compounds at temperatures lower than 
expected (their true boiling points). The temperature controlled/programmed probe 
feature provided by DIP-MS enhances its versatility in data analysis because a 
controlled temperature increase allows sequential volatilisation of components in the 
sample. This effect can be seen in the total ion chromatogram - TIC profile (Fig 5.2) 
which plots the combined intensity of all the masses in each MS scan against the time 
and hence probe temperature of the analysis. Once the probe is in position, the mass 
spectrometer is started to carry out repetitive scans, over the selected mass range, as 
the probe tip is heated to volatilise the sample into the MS ion source. The mass 
spectrum from each scan is recorded and the Total Ion Intensity in each scan is plotted 
against time to produce the idealised data in Figure 5.2. In this Figure the horizontal 
axis contains data on time into the analysis, the mass spectral scan number and the 
probe tip temperature. 
 
Figure 5. 2 TIC for UK tablet with multiple APIs/components. 
The peaks in Fig 5.2 are indicative of the vaporisation of individual components 
corresponding to the evolution of different compounds from the tablet formulation as 
the temperature is increased with time. In this example, the maxima of the two 
humps/peaks correspond to 1.0 and 3.5 minutes into the run i.e. probe tip temperatures 
of ca 70oC and 150°C respectively. The flag on the figure indicates the point at which a 
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complete mass spectrum can be retrieved from the data system. This flag can be 
moved to any position on the TIC trace. 
The mass spectrum like the TIC is representative of the total fragmentation patterns of 
all the species vaporised in that instance and may not be directly indicative of the 
fragmentation pattern of a single compound.  
5.2.2 ASAP-MS 
The Atmospheric Solids Analysis Probe – ASAP is an ambient desorption ionisation 
technique typically employed in the analysis of solid samples by MS but is capable of 
analysing a wide range of volatile and semi-volatile analytes (solid and liquid). Little or 
no work up is required before analysis of test samples and so unequivocal results can 
be obtained within 2-3 minutes.  
The ASAP-MS technique is a soft ionisation process producing minimal fragmentation. 
As a result, majority of the ionised species are either the molecular or pseudo 
molecular ion. The mechanism of sample presentation is similar to DIP-MS but in this 
case a flowing stream of heated nitrogen gas is used to selectively vaporise the test 
sample into the ionisation region and the corona discharge triggers ionisation under 
ambient atmospheric pressure conditions as shown in Figure 5.3. The ions produced 
are focussed into the MS to be analysed.  
Just as with the EI method, it is also important that the test sample loaded onto a glass 
sample vial is in close proximity to the ionisation region and the MS inlet to enhance 
sensitivity as well as ensure safety provided by the enclosed source housing. The 
design of the probe (having both fixed and removable sections) allows for rapid sample 
introduction without removing the complete assembly thereby ensuring stable source 
conditions. A corona discharge, atmospheric pressure chemical ionisation (APCI) 
source is used which leads to either charge transfer ionisation from nitrogen radical 
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cations or proton transfer reactions generated from moisture in the sample or ambient 
air.  
 
Figure 5. 3 Direct Insertion Probe Mass Spectrometry (ASAP-MS with low energy 
ionisation under atmospheric pressure) Schematic 
The proposed methods do not need highly sophisticated and expensive high resolution 
mass spectrometers since they are mainly targeted towards screening for the presence 
of the compound(s) stated to be present (Gross, 2011; Flego and Zannoni, 2012). The 
accumulated data can be retrospectively searched for ions (m/z values) characteristic 
of the compounds expected to be present. The process is known as extracted ion 
analysis and is described in Section 5.4.  
5.3 Materials and Methods 
5.3.1 Materials 
Reference samples of paracetamol (acetaminophen), aspirin, caffeine, chloroquine 
diphosphate, sulfadoxine were obtained from Sigma Aldrich, UK and the excipient, 
maize starch was obtained from Fisher Scientific Ltd, Loughborough, UK. 
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Test samples of over the counter paracetamol tablets (Table 5.2) were obtained 
opportunistically from various pharmacy outlets in the UK, across other countries in 
Europe, Africa, Southeast Asia and the Caribbean Islands as detailed in Table 5.2. In 
addition eight (8) analgesic tablets from the UK containing multiple APIs including 
paracetamol, caffeine and aspirin were also obtained for analysis. Six of the multiple 
API tablets were expected to individually contain 2 APIs (paracetamol and caffeine) 
while the other two were indicated as containing 3 APIs (paracetamol, aspirin and 
caffeine) (Table 5.3). 
Table 5. 2 List of analgesic/antipyretic tablets containing paracetamol analysed using EI 





















UK  2 500 
Belgium  2 1000 
Spain  2 500 
Spain  2 650 
Spain  2 1000 
Cyprus  2 500 
Switzerland  2 500 
Pakistan  2 500 
China  4 500 
UAE  4 500 
Rwanda  6 500 
Ghana  4 500 
India  16 500 
India  2 325 
India  1 650 
Jamaica  4 500 
Nepal  8 500 
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Table 5. 3 List of multiple API analgesic/antipyretic tablets from the UK containing 






 A range of over the counter antimalarial tablets (Table 5.4) from the UK, India, 
Zimbabwe and Ghana were subjected to EI DIP-MS analyses in order to determine if 
the appropriate active ingredient could be detected at the therapeutic levels present. 









5.3.2.1 Direct Insertion Probe Mass Spectrometry  
 DIP-MS analysis was performed using the Bruker 450-GC system coupled with a 
quadrupole mass spectrometer detector with electron impact ionization and also having 
a direct insertion probe module.  
The MS operating parameters were:  
Mass range   50-550m/z 
MS Scan rate    33/min 
Source temperature  150ºC 
Electron Ionisation at   70eV or 20eV  
Probe temperature was 40ºC to 350ºC at 30ºC/min. Once 350ºC is reached, cooling 
begins.  
Tablet(s) 
Number of Tablet 
Samples 
API(s) Expected in Tablets  
PC A#1 & 2 2 Paracetamol and Caffeine  
PC B #1 & 2 2 Paracetamol and Caffeine 
PC C# 1& 2  2 Paracetamol and Caffeine 




API(s) Expected in Tablets  
AM. UK A#1 & 2 2 Chloroquine phosphate 
AM. Zimbabwe A#1 & 2 2 Artemether and Lumefantrine 
AM. Zimbabwe B# 1& 2  2 Artesunate and Amodiaquine 
AM. India A#1 & 2 2 Artemether and Lumefantrine 
AM. Ghana A# 1& 2 2 Sulfadoxine and Pyrimethamine 
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5.3.2.2 Atmospheric solids analysis Probe Mass Spectrometry (ASAP-MS) 
ASAP-MS analysis was performed using the Advion Expression compact mass 
spectrometer (CMS) with atmospheric pressure chemical ionisation (APCI) and also 
having an Atmospheric Solids Analysis Probe (a direct insertion probe module). 
Operating parameters for CMS were as follows: 
Ionisation mode:   APCI positive or negative 
Nitrogen gas temperature:  300°C 
Mass range   100-550m/z  
5.3.3 Methods- Sample analysis 
5.3.3.1 DIP-MS 
Crushed tablet powder sample was placed in the sample vial using TLC spotters to 
ensure minimal amount of sample. Sample vial containing analyte affixed to the tip of 
the sampling probe was introduced into the mass spectrometer via a gate valve. This 
valve was only opened when the sample was introduced to maintain the vacuum state 
of the mass spectrometer. Once the sample was in position, the mass spectrometer 
was set to scan and controlled temperature increase on the system caused 
vaporisation of the sample which was then ionised and mass spectral data recorded. A 
blank (empty sample vial) was run after every measurement to avoid any carry over 
from previous run. After each run, cooling time was needed to allow both probe 
temperature and the ion source pressure to drop prior to further scanning. 
For quantitative study using, different concentrations of paracetamol at 1, 2, 5, 10, 20, 
30, 50, 70, and 90% w/w in maize starch were prepared. The data obtained was used 
in preparing a calibration curve (Section 5.4.5) to assess the potential of DIP-MS in 
direct quantification of tablet samples 
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5.3.3.2 ASAP-MS  
First of all, the crushed test tablet sample (powder) was loaded onto the closed end of 
a glass melting point capillary tube by dipping the tip into the sample of interest and 
then placing it into the compact mass spectrometer (CMS) for analysis. For each run, 
after placing the melting point tube in contact with the test powder sample at the rim of 
the sample bottle, excess test powder was removed before inserting the probe into the 
CMS. With the ASAP probe already in the sealed MS source enclosure, and in order 
for MS acquisition to proceed, the flowing stream of heated nitrogen gas was rapidly 
heated to 300°C. Only relatively low temperatures, up to 300°C were applied in order to 
avoid pyrolysis and in-source fragmentation. To minimize any background ions, a 
clean, new and empty glass capillary tube was inserted into the MS and heated up for 
approximately 15seconds. The acquisition of MS data was initiated while the newly 
heated capillary tube was still inserted into the source in order to obtain reference 
background scans. When collection of MS data for the blank glass capillary tube was 
complete, the probe was taken out from the source and the test sample was applied. 
The probe was re-introduced into the MS source and data acquisition re-started.  
5.4 Results and Discussion 
5.4.1 Application of DIP-MS to Analgesics/Antipyretics 
5.4.1.1 Analysis of Reference Samples for Common Analgesics/Antipyretics 
High purity/reference samples of paracetamol, aspirin and caffeine were subjected to 
the DIP process and the mass spectra recorded at the maximum TIC signal using 70eV 
electron ionisation (EI) are shown in Fig 5.4. Molecular ions for paracetamol and 
caffeine were detected at m/z 151 and 194 respectively whilst both compounds 
produced fragment ions at m/z 109 (Fig 5.4a and 5.4b). In samples stated to contain 
paracetamol and/or caffeine the detection of these ions would be sufficient confirmation 
of the presence of the correct API. 
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The molecular ion for aspirin at m/z 180 was also detected though in low relative 
abundance with more prominent fragment ions at m/z 138, 120 and 92 (Fig 5.4c). This 
is consistent with results obtained by Modick et al (2013), Sneha et al (2017) and 
Chonnker et al (2016) for paracetamol, caffeine and aspirin respectively. The m/z 
values obtained for paracetamol, caffeine and aspirin also agree with NIST Mass Spec 
data (NIST online). The presence of the three APIs can therefore be inferred by the 
detection of the characteristic peaks m/z 151 (paracetamol), m/z 194 (caffeine) and 
both m/z 138 and m/z 120 (aspirin). It should be noted how few peaks are present in 
the mass spectra compared to the complex traces obtained from the ATR-FTIR 
analyses. 
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Figure 5. 4 DIP-MS data for (a) Paracetamol reference (Molecular weight- 151 g/mol) (b) 
Caffeine reference (Molecular weight- 194 g/mol) (c) Aspirin reference (Molecular 
weight- 180 g/mol) 
 
Reference samples of paracetamol, aspirin and caffeine were also assessed using 
ambient ionisation ASAP-MS and mass spectra recorded. Figure 5.5 shows both 
positive (Fig 5.5a) and negative (Fig 5.5b) ion mass spectra of a mixture of reference 
samples of paracetamol, caffeine and aspirin obtained via ASAP-MS analysis. 
 
a 
    












Figure 5. 5 ASAP data for a mixture of reference samples of Paracetamol, Caffeine and 
Aspirin (a) Positive ion spectrum (b) Negative ion spectrum. 
Since ASAP-MS identifies the [M + H]+ ions of analytes, m/z 152 and 195 in Fig. 5.5a 
indicate the presence of paracetamol and caffeine respectively. The fragment at m/z 
110 is also the [M + H]+ ion of the fragment at m/z 109 common to both paracetamol 
and caffeine as indicated in Fig 5.4 and so further confirmed the presence of both APIs. 
Interestingly the (M + H)+ fragment ions for aspirin at m/z 121 and m/z 139 were  
detected in positive ion mode but in the negative ion mode (as highlighted in Fig 5.5b) 
the m/z values of 179 and 137 confirmed the presence of aspirin being the M-1 values 
for the molecular ion (m/z 180) and the fragment ion (m/z 138) respectively. The slight 
variation in mass spectral data (fragmentation patterns) between DIP-MS and ASAP-
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5.4.1.2 Paracetamol Tablet Results 
Paracetamol tablets cited in Table 5.2 were then assessed to confirm the presence of 
the API. The mass spectrum in Fig 5.6 confirms the presence of the molecular ion for 
paracetamol, from a UK tablet as seen with the reference in Fig 5.4a. Similar results 
were produced by ambient ASAP-MS analysis with [M + H]+ ions for paracetamol 
detected at m/z 110 and 152 for the fragment and molecular ion respectively (Fig 5.6b) 















Figure 5. 6 Mass spectrum for Paracetamol tablet from UK (Molecular weight- 151 
g/mol) (a) using high energy (EI) ionisation (b) using low energy ambient ionisation 
ASAP-MS. 
  Apart from the identification of APIs in test tablets, fragmentation patterns of analytes 
obtained using both ionisation methods for DIP-MS analysis might provide useful 
information for the characterisation of other compounds such as excipients and/or 
contaminants present in test tablets as well as valuable forensic data on the origin of 
the tablet samples.  
a 
b 
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Table 5.5 indicates the presence of paracetamol in the different test tablets obtained 
from different countries assessed via EI DIP-MS. 














Where n = number of tablets; Y = Yes/Paracetamol present; * = Suspect tablets based on ATR-FTIR study 
(Paracetamol detected along with other suspect components) 
The previously reported (Chapter 3) ATR analyses indicated unexpected components 
present in the 325mg paracetamol tablet samples obtained from India. The data from 
the DIP investigation of these tablets (Figure 5.7) confirmed the presence of 
paracetamol and also other components with m/z values greater than 151. Inspection 
of these data (Fig 5.7) shows a recurring gap of 2m/z values between pairs of ions, 
notably m/z 214/216, 242/244, 277/279 and 353/355. In most cases a gap of 2 mass 
units indicates the presence of a halogen atom in the molecule usually chlorine, with 
isotopic masses of 35 and 37.  
Tablet(s) 






UK  2 500 Y 
Cyprus  2 500 Y 
Switzerland  2 500 Y 
Spain  2 500 Y 
Spain  2 650 Y 
Spain  2 1000 Y 
Belgium  2 1000 Y 
India  16 500 Y 
India* 2 325 Y 
India  1 650 Y 
Pakistan  2 500 Y 
Nepal  8 500 Y 
China  4 500 Y 
UAE  4 500 Y 
Rwanda  6 500 Y 
Ghana  4 500 Y 
Jamaica  4 500 Y 
    




Figure 5. 7 Mass spectrum for suspect paracetamol tablet from India 
Two compounds are often used in combination with paracetamol, diclofenac and 
aceclofenac. The mass spectral data (NIST), in decreasing intensity, for these 
compounds is: 
Diclofenac m/z 214, 242, 295, 216, 297 molecular ions m/z 295, 297 
Aceclofenac m/z 214, 242, 277, 216, 279 molecular ions m/z 353, 355 
The mass spectral data is consistent with presence of aceclofenac in the tablet. White 
(2014), suggests this compound to be aceclofenac (nonsteroidal anti-inflammatory 
drug- NSAID) a common API used in combination with paracetamol generally used for 
rheumatoid arthritis and osteoarthritis. White (2014), also highlights that aceclofenac is 
not available over the counter in the US and is a prescription medication in countries 
like the UK, Italy and Spain though easily accessible through international internet 
purchases. White 2014, further points out that aceclofenac is widely utilised in India 
and some south-Asian countries and can be obtained over the counter or from street 
hawkers further confirming these results. White (2014), outlined the analytical profile of 
aceclofenac using several techniques including GC-MS. From the GC-MS study, the 
molecular ion was not detected but a fragment ion was detected at m/z 277. Other 
fragment ions were detected at m/z 242, 214 and 179 respectively.   
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The mass spectrum in Fig 5.7 confirms the presence of the fragment ions highlighted 
by White (2014), and the molecular ions at m/z 353/355 are also detected. The DIP-MS 
therefore provides a simpler and quicker method for detecting and identifying the 
compound which further highlights its potential in the authentication of medicines.  
Table 5.6 outlines the tablets assessed via ambient ionisation ASAP-MS indicating the 
presence of paracetamol in all tablets analysed. However, the tablet sample from Hong 
Kong (as highlighted in bold in table 5.6) was found to contain another component not 
present in other tablet samples. The mass spectrum in Fig 5.8 again accentuates the 
efficiency of DIP-MS in the characterisation of test tablets samples. Ambient ionisation 
ASAP-MS enabled the characterisation of the paracetamol tablet from Hong Kong 
which identified the presence of paracetamol at m/z 110 and 152 [M + H]+ but even 
more interestingly detected the presence of a chlorinated compound at m/z 230. This 
m/z value eliminates the presence of either diclofenac or aceclofenac and this could be 
a contaminant or undeclared constituent of the medication.  
Table 5. 6 List of test tablets analysed using DIP-MS with low energy ambient ionisation (ASAP-







* = Suspect tablets another compound detected at m/z 230 in addition to Paracetamol  
Contrastingly, though ATR-FTIR spectra confirmed the presence of paracetamol in the 
suspect tablet (PCM Hong Kong A), there was no noticeable difference in the tablet 
spectra indicative of the presence of another API, excipient or contaminant. 
 
 
Tablet(s) [M+H]+ Detected (m/z) 
API(s) Expected in 
Tablets  
PCM UK A 110, 152 Paracetamol 
PCM Nigeria A 110, 152 Paracetamol 
PCM India A 110, 152 Paracetamol 
PCM China A 110, 152 Paracetamol 
PCM Hong Kong A* 110, 152, 230* Paracetamol 
    















Figure 5. 8 ASAP-MS mass spectrum for suspect paracetamol tablet from Hong Kong. 
Therefore, DIP-MS potentially provides a simple method for the characterisation of 
contaminants/adulterants to medicines along the supply chain and could enhance the 
capacity to trace the origin (post-marketing surveillance) when/where the medicines 
were interfered with. It could also be employed in the quality control process for 
monitoring production lines in pharmaceutical companies by carrying out checks at 
different points within the process to ensure there are no defects/errors or to identify 
the points these errors occur if they do. In addition, DIP-MS could provide an important 
technique not just for regulatory purposes but also for forensic investigations in the 
pharmaceutical manufacturing industry. 
5.4.1.3 Evaluation of analgesic/antipyretic tablets containing multiple APIs  
In the results discussed above in 5.4.1.2, the DIP system by EI demonstrated the 
presence of two APIs (paracetamol and aceclofenac) in the suspect tablet samples 
from Indian identified by the ATR-FTIR analysis in Chapter 3. The DIP assessment of 
tablets containing multiple APIs was therefore investigated. This is important because 
there have been reports of some falsified medicines containing other APIs like 
paracetamol which was not indicated on the tablet packaging (Höllein et al, 2016; Li et 
Mostly paracetamol, but a chlorinated 
compound at m/z 230 detected 
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al, 2017). It is also important to ascertain the ability of DIP-MS to screen for all APIs in 
tablet formulations simultaneously. OTC tablet samples from the UK, containing either 
3 different APIs (Aspirin, Paracetamol and Caffeine) or 2 APIs (Paracetamol and 
Caffeine), as outlined in Table 5.3, were used for this study.  
Referring back to Fig 5.2 in section 5.2.1, the TIC is the summation of all ions detected 
in an MS scan and it is therefore possible to search the recorded data (TIC) to see 
where particular ions (extracted ions) occur. This process is shown in Fig 5.9 where the 
TIC data from the 3 APIs tablet (red) is searched, (green) for m/z 151 –paracetamol, 
(orange) m/z 180- aspirin and (blue) m/z 194- caffeine. Temperature of the sample 
increases from left to right on the diagram and these compounds are volatilised at 
different temperatures as indicated by the traces. 
 
 
Figure 5. 9 Total ion chromatogram (TIC) and extracted ion chromatograms (EICs) for 
UK tablet containing 3 APIs (m/z- Paracetamol- 151, Aspirin- 180, Caffeine- 194). 
Individual mass spectra will therefore vary depending on the time point selected within 
the total run time. Mass spectra recorded around the 2.0 minutes should contain ions 
from all the APIs as shown in Figure 5.9. This MS data is shown in Figure 5.10 where 
the ions from paracetamol (m/z 151) caffeine (m/z 194) and fragment ions from aspirin 
(m/z 138 and 120) are all visible. 
    




Figure 5. 10 Mass spectrum for UK tablet containing 3 APIs (m/z- Paracetamol- 151, 
Aspirin- 138, Caffeine- 194). 
Both DIP-MS and ASAP MS were able to detect individual API ions from other 
analgesic tablets containing only two APIs (paracetamol and caffeine) (Fig 5.11).  
 
Figure 5. 11 Mass spectrum for UK tablet containing Paracetamol and Caffeine (m/z: 
Paracetamol- 151, Caffeine- 194). 
 
Data in Table 5.7 represents details for individual test tablet samples with multiple APIs 
analysed via DIP-MS. In all cases, characteristic ions for individual APIs were detected 
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Table 5. 7 List of multiple API analgesic/antipyretic tablets containing paracetamol 
analysed using EI DIP-MS  
 
This is very important in the screening for counterfeit medicines since most of these 
medicines are complex mixtures containing several APIs, excipients and other 
materials used by counterfeiters (contaminants/impurities). Furthermore, this individual 
m/z detection capability of DIP-MS or ASAP-MS in a complex mixture also lends itself 
to addressing one of the limitations of the spectroscopic techniques outlined in chapter 
3 (ATR-FTIR spectroscopy) where there is difficulty in identifying individual 
components when the peaks are masked or overlap with those of other components.  
5.4.2 Antimalarial medicines study 
DIP-MS and ASAP-MS were used in the analysis of antimalarial tablet samples in order 
to avoid the limitations/difficultly encountered using the ATR-FTIR technique (Chapter 
3) where the IR peaks were not well defined due to the complex nature of the APIs in 
these tablets. This complexity makes it difficult to fully characterise and quantify more 
than one API in the tablet. 
Tablet(s) 
High energy DIP-MS data ASAP-MS Data API(s) Expected in 
Tablets  
PC A1  M+ (m/z 151 and 194 
observed for paracetamol 
and caffeine respectively); 
also fragment ion at m/z 
109 
- 
Paracetamol and Caffeine  
PC A2 
 
PC B1 M+ at m/z 151 and 194 
observed low abundance; 
fragment ion at m/z 109 
 
Paracetamol and Caffeine 
PC B2 
- 
PC C1  M+ at m/z 151 and 194 
observed low abundance; 
fragment ion at m/z 109 
 
Paracetamol and Caffeine 
PC C2 
- 
PCM UK B - 
M+1 (m/z 152 and 195 
observed for paracetamol 
and caffeine respectively); 
also fragment ion at m/z 
110 
Paracetamol and Caffeine 
PAC A1 Ions were at m/z 151, 194 
and 180 with other 
fragment ions at m/z 92, 
109, 120 and 138  
 
Paracetamol Aspirin, and 
Caffeine PAC A2 
- 
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Reference samples of two common APIs, sulfadoxine and chloroquine, found in 
antimalarial medicines were assessed using DIP-MS. Figure 5.12 (a and b) shows 
mass spectra of reference samples for the two APIs using ionisation at 70eV.  
 
 
Figure 5. 12 Mass spectra for (a) sulfadoxine reference (Molecular ion: m/z 310) (b) 
chloroquine reference (Molecular ions: m/z 319 and 321). 
 
For sulfadoxine (Mwt 310), the molecular ion was not detected but an intense peak was 
observed at m/z 246 and 245 with other fragment ions at m/z 227 and 228(Fig 5.12a). 
This was consistent with results obtained in previous studies (Florey, 1988) though 
there was no mass spectral data available for sulfadoxine in the NIST database. The 
molecular ion (M+) for chloroquine was detected in low relative abundance at m/z 319 
with the most abundant fragment ion at m/z 86 (Fig 5.12b) as observed in other studies 
a 
b 
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(Florey, 1984; Imran et al, 2016). The NIST data base also confirms mass spectral 
peaks at m/z 319 and 86 for chloroquine.  
Antimalarial tablets containing these APIs (sulfadoxine and chloroquine) were then 
analysed. In addition, other tablets (Table 5.4 and 5.5) containing other antimalarial 
APIs, for example, arthemether, lumefantrine, pyrimethamine, amodiaquine and 
artesunate were also assessed and DIP-MS data compared with data from literature 
and the NIST online database to check the potential of DIP-MS for the identification of 



















Figure 5. 13 Mass spectrum for Sulfadoxine and Pyrimethamine tablet 70eV- AM Ghana 
A (a) Delay time – 3.948min (b) Delay time – 6.561min.  
A pack of tablets (AM. Ghana A) expected to contain sulfadoxine and pyrimethamine 
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confirmed as indicated in the mass spectra in Fig 5.13a and Fig 5.13b. At a delay time 
of 6.561min the mass spectrum in Fig 5.13b was identical to the reference mass 
spectrum for sulfadoxine (Fig 5.12a) with similar delay time (6.485min). The base peak 
at m/z 246 and the fragment ion at m/z 227 were detected in the test tablet mass 
spectrum confirming the presence of sulfadoxine. The mass spectrum at delay time 
3.948min (Fig 5.13a), showed the presence of pyrimethamine with m/z values at 247, 
248, 249 and 250. The empirical formula of pyrimethamine is C12H13ClN4 and the two 
molecular ions are m/z 248 and 250 corresponding to the Cl 35 and 37 isotopes. The 
ions at m/z 247 and 249 correspond to the loss of a hydrogen atom from the molecular 
ions (Florey, 1983; Sandhya and Shijikumar, 2015). Again, these mass spectral data is 






Figure 5. 14 ASAP-MS mass spectrum for Sulfadoxine and Pyrimethamine tablet  
Interestingly, the 70eV DIP-MS mass spectral data in Fig 5.13 were noticeably different 
from those based on low energy ASAP-MS (Fig 5.14) for antimalarial tablet (AM. 
Zimbabwe C) expected to contain the same APIs (sulfadoxine and pyrimethamine). 
Low energy ASAP-MS confirmed the presence of the M+1 ion for sulfadoxine at m/z 
311 with other fragment peaks at m/z 156 and 108. There was only a very low signal at 
the expected m/z values 247, 248 and 249 for pyrimethamine. Poor detection of 
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not necessarily favour the production of the characteristic ions for pyrimethamine. 
Sensitivity of the equipment to the lower concentrations of API might be another point 
to note since the expected amount of pyrimethanime in the tablet is <5% w/w 
compared to about 80% w/w for sulfadoxine.  Although the ASAP-MS data for 
sulfadoxine varies from the DIP-MS data, the ASAP-MS data for sulfadoxine is also 
consistent with GC-MS mass spectral data for sulfadoxine on the Drugbank (Drugbank 
Online) and the PubChem open chemistry (PubChem Online) databases. Since there 
could be variation in the ionisation/ fragmentation sequence depending on the 
ionisation method used during the Probe-MS process, it is important that mass 
spectrometric data obtained for test tablet samples be compared to reference samples 
assessed by the same analytical method.  
Figure 5. 15 Mass spectrum for Artesunate and Amodiaquine tablet – 70eV 
For high energy EI DIP-MS analysis of the antimalarial tablet containing amodiaquine 
and artesunate (AM. Zimbabwe B- Table 5.4), the molecular ions (M+) for amodiaquine 
at m/z 355 and m/z 357 were observed (Fig 5.15) indicative of the presence of a 
chlorine atom. A fragment ion at m/z 282 was present. These results are similar to 
those obtained by Florey (1992), Rathod et al (2016) and data available in the NIST 
database further confirming the presence of amodiaquine. On the other hand, 
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molecular ion for artesunate was not detected. Mass spectral data for artesunate is 
also not available in the NIST and DrugBank databases. This could be due to thermal 
stability issues attributed to artemisinin and its derivatives where degradation occurred 
when stored above room temperature (Ansari et al, 2013). Artesunate is a derivative of 
artemisinin so extreme temperatures might have caused degradation of the API during 
analysis. Furthermore, it is also possible that artesunate is not present in the sample as 
no other fragments were detected.  
Two different packs of antimalarial tablets (AM. India A and AM. Zimbabwe A) with 
artemether and lumefantrine as the specified APIs were assessed using 70eV DIP MS. 
Under the current analytical conditions the APIs were volatilised between 6 and 8 
minutes into the run. Examples of mass spectra recorded over this period are shown in 
Figure 5.16. In positive ion mode, the only ions observed were at m/z 142 and 100 (Fig 
5.16a). Absence of any NIST mass spectral data for artemether and lumefantrine 
makes it difficult to characterise the individual APIs. However mass spectral data based 
on the Drugbank database identifies ions at m/z 142 and 100 as indicative of the 
presence of lumefantrine. Again, as observed with the tablet containing sulfadoxine 
and pyrimethamine, the difficulty in characterising API ions was found with the API of 
lower concentration (artemether). Expected concentration of artemether in each of 
these antimalarial tablets was about 8% w/w with much higher concentrations of 49% 
w/w expected for lumefantrine.  
Molecular ion for lumefantrine at m/z 528.9 (Fig 5.16b) was also detected in EI 
negative ion mode. Results for lumefantrine were similar to those obtained by Bernier 
et al (2016). In the negative mode, an ion at m/z 298 was observed at an increased 
delay time of 7.6 minutes suggesting the presence of artemether in the tablet.  
    




Figure 5. 16 Mass spectrum for antimalarial tablet containing artemether and 
lumefantrine -70eV (a) in positive ion mode (b) in negative ion mode showing molecular 
ion for lumefantrine at m/z 528.9 (c) ) in negative ion mode showing molecular ion for 
artemether at m/z 298 
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Contrastingly, Carrà et al (2014) and Bernier et al (2016) did not detect the molecular 
ion at m/z 298 but other fragments like the [M+ NH4] ion at m/z 316.21 and [M- OHCH3 
+ H]+ ion at m/z 267 which were not observed in this  DIP MS study.  
 
Figure 5. 17 ASAP mass spectrum for antimalarial tablet containing artemether and 
lumefantrine (a) showing molecular ion for lumefantrine at m/z 528 and 530 (b) showing 
fragment ion for artemether at m/z 267. 
However, using ASAP-MS analysis, lumefantrine was detected as highlighted by ions 
at m/z 528, 530 and 532 indicative of the presence of chlorine atoms in the compound 
(see Fig 5.17a).  Also, Fig 5.17b shows the ion at m/z 267 was detected suggesting the 
presence of the [M- OHCH3 + H]+ ion for artemether as highlighted by Bernier et al 
(2016). The difference in artemether data between both Probe-MS methods further 
suggests the ionisation methods employed could affect the fragmentation and hence, 
the ions produced because the mass spectral data for artemether based on ASAP-MS, 
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an ambient ionisation technique, are consistent with those obtained by Bernier et al 
(2016) who also used another ambient ionisation technique -DART-MS for analysis. 
5.4.3 Effects of Probe Tip Temperature Ramp Rate on Signal Intensity 
Since the rate of vaporisation of the sample is dependent on the temperature-
programmed mode of the probe, this temperature also affected the detection of the API 
(Paracetamol) and the signal intensity. The relationship between the probe temperature 
and signal intensity was investigated for temperature ranges between 30 - 325°C using 
the reference paracetamol standard. Fig 5.18 and 5.19 show total ion chromatograms 
(TICs) and mass spectra for paracetamol analysed with initial probe temperature at 













Figure 5. 18 Paracetamol reference- where temperature at TIC max is 165ºC (a) TIC 





    
























Figure 5. 19 Paracetamol reference - where temperature at TIC max is 152ºC  (a) TIC 
with initial probe temperature of 40ºC (b) Mass spectrum with initial probe temperature of 
40ºC. 
Comparing the TICs in Fig 5.18a and 5.19a, it is observed that at lower initial probe 
temperature (30ºC), paracetamol peak rises with a gentle slope to a maximum of about 
300 MCounts while at 40ºC, a peak which is more well defined and requires less time 
to arrive at a much higher count of about 500MCounts is observed. Analysis of 
paracetamol with initial probe temperature of 40ºC was found to be a more efficient 
method for the samples investigated and so was the preferred initial temperature of the 
probe for analysis. Delay time was also found to be quicker (3.736min) using 40ºC 
a 
b 
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initial probe temperature than with 30ºC (4.499min). In addition, considering the mass 
spectra in Fig 5.18b and 5.19b, the signal intensity showed progressive increase as 
temperature increased. For example the molecular ion at m/z 151 increased from 
4.758e+7 at 30ºC initial probe temperature to 7.725e+7 at 40ºC. This was the same 
situation for the fragment ion at m/z 109 from 1.106e+8 at 30ºC to 1.942e+8 at 40ºC. 
This suggests that higher temperatures may lead to more highly sensitive signal 
depending on the boiling point of the sample. 
On the other hand, temperature at TIC max for Fig 5.18 and 5.19 were 165ºC and 
152ºC respectively. Since the ramp rate was the same for both runs (30ºC/ min), it is 
expected that the TIC max for both runs would be the same regardless of the initial 
probe temperature. The slight difference in TIC max temperature for both runs could be 
due to the sensitivity of the equipment to the amount of sample introduced into the 
probe tip as approximate amounts of sample were used for each run and not the exact 
same mass of sample per run. The minute amount of sample needed in the vial for 
each run therefore made it difficult to obtain the same sample mass before analysis. 
Thus, this variability in the amount of powder sample affixed to the probe tip may have 
obscured the effects of a change in probe temperature on the signal intensity. 
Ramping however must be controlled to avoid the sample vaporising too quickly or 
saturation of the signal as mentioned earlier. It is also important that start temperature 
(when heating the probe) in the probe programme is lower than the actual boiling point 
of the solid sample to enable proper ionisation and enhance signal intensity. This is 
important in order to prevent a situation where most of the sample on the probe tip is 
vaporised before it is introduced into the ionisation chamber. 
5.4.4 Effects of electron voltage on the mass spectrum produced 
Electron energy at 70eV has been identified to provide optimum sensitivity in mass 
spectrometry analysis since at this electron energy, all atoms/molecules can be ionised 
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(Gross, 2011). Electron ionisation (EI) spectra recorded at 70eV have also been 
identified as being more informative owing to the large number of fragments presented 
and the fact that these spectra are reproducible providing library searchable fingerprint 
spectra (Drugbank; NIST Online).  
On the other hand, large number of fragments observed at 70eV could mean low 
abundance of the molecular ion making it more difficult to interpret spectra (Gross, 
2011). Using chloroquine as an example, decreasing electron energy to ≤ 20eV had a 
crucial effect on the final spectrum obtained as demonstrated by a comparison of the 
data in Figure 5.20. Most of the fragment ions observed using 70eV electrons (Fig 
5.20a) were no longer detected at 20eV leaving only the most characteristic fragment 
ions and the molecular ion for chloroquine at m/z 319 (Fig 5.20b). This is because 
electron energies higher than the ionisation energy of the test sample are required to 
facilitate its ionisation but subsequent fragmentation only reduces the level of the 
molecular ion signal but can provide some structural information concerning the 
molecule. In this research detection of the molecular ion is important. 
  
    
































Figure 5. 20 Mass spectrum for Chloroquine tablet UK (a) Electron energy- 70eV (b) 
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Table 5.8 is a list of tablets analysed and comments on the mass spectral data 
observed at different at 70ev and 20eV respectively. 























5.4.5 Limit of Detection (LOD) and Quantification Study 
The potential of DIP-MS in the quantification of APIs in tablet medication was 
considered. Standard calibration mixtures of paracetamol (API) in maize starch 
Tablet(s) 
70eV 20eV API(s) Expected in 
Tablets  
AM. UK A1 & A2 
M+ at m/z 319- low 
abundance; fragment 
at m/z 86 – high 
abundance 
 
M+ at m/z 319 
enhanced- high 
abundance; fragment 





A1 & A2 
For artemether: 
Ion(s) not detected.   
For lumefantrine:  
Ion at m/z 142 – high 
abundance; at m/z 
100 – low abundance   
For artemether: 
Ion(s) not detected.   
For lumefantrine:  
Ion at m/z 142 – high 
abundance; at m/z 




B1 & B2 
For artesunate: Ion(s) 
not detected.   
For amodiaquine:  
The molecular ion at 
m/z 355 and 357 were 
detected with the 
fragment ion at m/z 
282. 
For artesunate: 
Ion(s) not detected.   
For amodiaquine:   
The molecular ion at 
m/z 355 was detected 
but fragment ion at 
m/z 282 was not 
Artesunate and 
Amodiaquine 
AM. India A1 & 
A2 
For artemether: 
Ion(s) not detected.   
For lumefantrine:  
Ion at m/z 142 – high 
abundance; at m/z 
100 – low abundance   
For artemether: 
Ion(s) not detected.   
For lumefantrine:  
Ion at m/z 142 – high 
abundance; at m/z 
100 – not detected 
Artemether and 
Lumefantrine 
AM. Ghana A1 
& A2 
For sulfadoxine: 
Intense peaks at m/z 
246 and 245 were 
detected with the 
fragment ions at m/z 
227 and 228. 
For pyrimethamine:  
Molecular Ion at m/z 
248 indicative of the 
Cl 35 isotope was 
detected with ions at  
m/z 247 and 249 
indicating loss of 
hydrogen ion in 
molecular ions at  m/z 
248 and 250 (Cl 37 
isotope) respectively.  
Ion at  m/z 247 was 
the most prominent 
For sulfadoxine: Ion 
at m/z 246 detected 
with high abundance 
like 70eV but 
fragment ion was 
diminished/in low 
abundance. 
For pyrimethamine:  
Molecular Ion at m/z 
248 was detected 
with ions at  m/z 247 
and.  Ion at  m/z 248 
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(between 10-90% w/w) were employed for this study. These calibration mixtures 
covered the range of concentrations within which paracetamol was present in OTC 
medicines (See Chapter 3).  
The ion signal intensities at 70eV for each paracetamol standard mixture at the start, 
the apex and end of the peak (Fig 5.21) on the TIC were recorded as shown in Table 
5.9 for paracetamol m/z values at 151. The mean of the ion signal intensities based on 
the three points (start, apex and end) of the paracetamol peak was also deduced for 
each paracetamol in maize starch calibration mixture. Since the TIC is indicative of the 
vaporisation of the individual components of the sample as highlighted in section 5.2.1,   
area under the curve was not feasible as reproducibility was a challenge. These data in 
Table 5.9 was recorded in a bid to ascertain the point on the TIC for the API 
(paracetamol) where quantitative analysis based on the mass spectrum ion signal 
intensities might be most feasible. The start and end points were determined by the 
point where paracetamol ions where first observed on the mass spectra and the point 
just before it was completely vaporised respectively.  
 
Figure 5. 21 TIC of a paracetamol test sample showing 3 approximate points (start, apex 
and end) on the paracetamol peak where mass spectral data was collected for each 
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Table 5. 9 Ion signal intensities for calibration standard mixtures of paracetamol in maize 




Peak Start (Ion 
Signal Intensity) 
Peak Apex (Ion 
Signal Intensity) 
Peak End (Ion Signal 
Intensity) 
90 4.17E+06 6.67E+07 2.67E+07 
70 1.08E+07 7.38E+07 3.73E+06 
50 5.19E+06 9.81E+07 5.16E+06 
30 3.43E+06 3.68E+07 1.29E+06 
20 1.71E+06 1.16E+07 1.06E+06 
10 1.10E+06 8.52E+06 6.81E+05 
5 5.57E+05 4.73E+06 3.72E+05 
2 5.26E+05 1.99E+06 3.63E+05 
1 3.24E+05 1.15E+06 1.75E+05 
 
Figure 5.22 indicates that there was poor linear correlation between paracetamol 
concentration and ion signal intensity across all the points considered on the TIC for 
paracetamol. As stated earlier, minimal amounts of sample were required for analysis; 
hence, the amount of paracetamol test tablet powder in the sample vial was not exactly 
the same between measurements.  
 
Figure 5. 22 Calibration curve for paracetamol in maize starch standard mixtures (1-90% 
w/w) using ion signal intensity for molecular ion at m/z 151. 
Due to the high sensitivity and minimal amount of sample used for analysis with DIP-
MS, slight variations in the distribution or homogeneity of the components of the 






















Paracetamol Concentration (% w/w)
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API using DIP-MS could be a challenge. Therefore, to improve direct quantification of 
tablet samples, it might be important to ensure equal amounts of the crushed tablet 
samples are introduced into the vials each time and this could be achieved by 
suspending/dispersing known amounts of the powdered tablet sample in a medium that 
is heat stable.  
Despite the fact that there was poor linear correlation between paracetamol 
concentration and ion signal intensity, further analysis of the quantitative data for 
paracetamol calibration samples based on the ion signal intensities showed improved 
linear correlation between ion signal intensity and paracetamol concentrations ≤ 10% 
w/w (Fig 5.23). It is not clear why this is the case but standardising the amount of test 
sample introduced in the probe per run could provide more information regarding this 
phenomenon (improved linearity for lower paracetamol concentrations).  
 
Figure 5. 23 Calibration curve for paracetamol in maize starch standard mixtures (1-10% 
w/w) using ion signal intensity for molecular ion at m/z 151. 
The ion signal intensity at the apex of the peak represents data when paracetamol ions 
are most prevalent/fully ionised in the system during the run.  Therefore, calibration 
based on the ion signal intensity at the apex of the peak might be most useful/ efficient 
in the direct quantitative analysis of tablet medication but further investigations will be 
y = 8E+06x + 269355
R² = 0.9294
y = 8E+07x + 398418
R² = 0.998
y = 5E+06x + 176775
R² = 0.9007
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required to clarify this as data available so far are not enough to make any conclusive 
statements.  
Figure 5.24 shows that the presence of the API, paracetamol could be identified down 
to 0.1% w/w of the paracetamol/maize starch powder mixture. In addition, the amount 
of test sample powder used is much less than the amount needed for analysis in the 
spectroscopic techniques thereby further reducing contact and exposure to the 
samples/chemicals.  
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Figure 5. 24 0.1% w/w paracetamol in maize starch (a) Total ion chromatogram (b) 
Mass spectrum. 
 
The ability of DIP-MS to identify much lower levels of particular compounds in a mixture 
could even be more valuable in the detection of toxic impurities in pharmaceutical 
tablet samples. DIP-MS was therefore found to be much more sensitive than the 
MS Data Review Active Chromatogram and Spectrum Plots - 4/13/2017 4:45 PM
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spectroscopic techniques even when analysing the powder mixture directly without 
using any solvent extractive techniques and in full scan mode.  
Consequently DIP-MS shows its propensity in the simple and rapid analysis of tablet 
samples with concentrations much lower than the limit of detection of ATR-FTIR 
spectroscopy. It is also non-destructive since no treatment is required for samples 
before analysis safe crushing of the tablet. 
5.5 Conclusion  
DIP-MS therefore provides another simple and more sensitive option in the event that 
samples to be analysed exceed the limit of detection of the cheaper but less sensitive 
spectroscopic techniques. This is observed by its ability to identify individual 
components in analgesic and antimalarial tablets. The probe MS method was able 
characterise and identify unknown material in suspect tablets. Furthermore, samples 
were analysed directly without solvent extraction thereby saving time spent in sample 
preparation and the associated costs of solvent consumption. Probe MS data were 
obtained in less than 10 minutes. Its non-destructive feature and the speed of analysis 
compared to conventional solvent extraction techniques makes DIP-MS well-suited for 
assessing possible falsified and substandard medicines. The potential of DIP-MS in the 
direct quantification of APIs in pharmaceutical solid dosage forms can be further 
explored. 
Though the pharmacopoeia approved solvent extraction techniques are generally 
employed in the analysis of known chemicals (including APIs, excipients and possible 
impurites/contaminants) in pharmaceutical tablet formulations, these techniques might 
not be the most efficient for the forensic analysis of unknowns. DIP-MS on the other 
hand enables identification of unknowns as individual masses of the components 
molecular or fragment ions are recorded which further helps in elucidation of the 
structure of the compound.  
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Moreover, with the advent of mobile fibre optics spectrometers and their increasing 
availability, portable spectrometry based instruments can be deployed for in-field 
analysis of medicines. 
Operation of the DIP-MS instrument including spectral interpretation can be automated 
by comparing recorded mass spectra with those available in a local reference library 
which in turn helps to provide logical results/data to non-specialist personnel in the 
field.  
In addition to the simpler and quicker analytical techniques already proposed in 
Chapters 3 -5 for the screening of medicines in LMICs, conventional solvent extraction 
techniques were examined in order to validate results based on the rapid methods 
developed. Ultraviolet- visible (UV-vis) spectroscopy and Liquid Chromatography- 
Mass Spectrometry (LC-MS) will be the solvent extraction techniques considered in the 
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Spectrophotometry for validation 









    




Advancement in technology has made authentication of medicines and 
pharmacovigilance in general very complex as established in Chapter 2. Consequently, 
it is essential that methods employed in the screening of medicines facilitate the prompt 
removal of these medicines from the market (Dégardin et al, 2015).  
Quantification of the API is very crucial in the quality control of medicines since 
inconsistency in API content or absence of the API could pose a serious threat to 
public health as highlighted in Chapter 2 (Dégardin et al, 2014). This is because 
medicines are beneficial not just when the APIs are present but when the APIs are 
present in the right amount. Quantitative analysis of medicines will help guard against 
instances of drug toxicity due to higher than expected API or resistance to medication 
as a result of lower than expected API (under dosage) as seen with antimalarials and 
antibiotics (Kelesidis and Falagas, 2015; Koczwara and Dressman, 2017). It is 
therefore very important that measures be put in place (as part of the 
pharmacovigilance process) to determine drug content in medicines at every point in 
the pharmaceutical distribution chain. In Chapter 3, this study demonstrates the novel 
use of ATR-FTIR in the rapid quantification of APIs in tablet dosage forms and its 
potential in the screening of medicines in-field and in LMICs. It is therefore important 
that the data obtained via the proposed ATR-FTIR method be validated using 
conventional approaches or pharmacopoeia approved methods. An assessment of the 
correlation between the proposed ATR-FTIR method and conventional methods will 
help in providing more comprehensive data about tablet medicines sent for test in order 
to confirm if they are genuine.  
Ultraviolet-Visible (UV-Vis) spectrophotometry is one of the most commonly used 
techniques in pharmaceutical analysis (Behera et al, 2012; Ojeda and Rojas, 2013). 
Misiuk (2010), identifies UV-Vis spectrophotometry and the liquid chromatography as 
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the most frequently applied in pharmacopoeial monographs. This technique (UV-Vis), 
can be used for the quantification of the Active Pharmaceutical Ingredient (API) in 
medicines while screening for FSMs, since the absorbance patterns are indicative of 
the materials present and the intensity of the absorbance bands is directly proportional 
to the concentration of the API being assessed (Rote et al, 2012; Figueroa et al, 2015).  
Several studies have investigated the use of UV-Vis in the quantitative assessment of 
medicines (Kumar Talluri et al, 2012; Khanage et al, 2013; Islam et al, 2016). Kumar 
Talluri et al (2012) and Khanage et al (2013) considered the simultaneous 
determination of paracetamol in the presence of other APIs (Iornoxicam and Eperisone 
respectively) in pharmaceutical solid dosage forms. Islam et al (2016), on the other 
hand developed UV-Vis methods for the determination of calcium orotate in tablet 
dosage forms. UV-Vis has also been used together with chemometric methods in the 
quantitative determination of paracetamol in pharmaceutical tablet formulations 
(Khajehsharifi et al, 2010; Glavanović et al, 2016).  
Although UV-Vis has proven useful in the quantitative assessment of medicines, it is 
not as efficient as a qualitative analytical methodology since species are identified 
based on absorbance ranges (with maximum absorption- λmax) in the ultraviolet or 
visible region rather than a definite wavelength. This is because there could be shifts in 
the absorption maxima (characteristic wavelength) of the species being assessed and 
this has been linked to the use of different solvents or the ratios of the solvents 
employed in the investigation (Figueroa et al, 2015).  
Figueroa et al (2015) in their study using UV-Vis to detect counterfeit pharmaceuticals, 
also attribute the decrease in the absorption of paracetamol at 245nm and slight 
increase in other parts of the spectrum to contaminants which interact with the benzene 
ring of paracetamol. Although the use of UV-Vis spectrophotometry for simply 
identifying test species (analytes) is a challenge, Figueroa et al (2015) propose the 
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potential use of UV-Vis spectrophotometry in the identification of suspect samples 
based on the change in absorbance at particular wavelengths as well as the unique 
wavelength shifts observed  when different solvents are employed on a particular 
analyte.  
Although UV-Vis has been used extensively for analysis of medicines, the approach 
requires access to solvents and laboratory facilities which for the purpose of this study 
are considered beyond the reach of the people in the LMICs. In addition since UV-Vis 
is a solvent extraction technique, suggesting it requires a proper understanding of the 
analyte in question. This entails training which might be a challenge in areas where 
funds are not readily available.  
Hence, this chapter describes UV-Vis as a technique used in the validation of 
quantitative paracetamol data for tablet samples obtained via ATR-FTIR in Chapter 3. 
Since there were challenges quantifying chloroquine based on the proposed ATR-
FTIR, only the paracetamol tablet data were considered for UV-Vis validation.   
6.1.1 Ultraviolet-Visible Spectrophotometry Principle 
As a quantitative technique, UV-Vis estimates the amount of molecular species based 
on the radiation absorbed. UV-Vis use is however limited to the analysis of substances 
that can absorb light in the UV-Vis region (200-700nm) (Behera et al, 2012; Rote et al, 
2012). As such, UV-Vis spectrophotometry is not useful in the direct determination of 
substances with poor light-absorbing capacity (e.g. aminoglycosidic antibiotics) (Ojeda 
and Rojas, 2013). The groups within a molecule that are able to absorb light are 
referred to as chromophores (Almeling et al, 2012).  This technique is cheaper than 
other pharmacopoeia approved techniques like the LC-MS but is also a solvent 
extraction technique as mentioned earlier. Sample preparataion will therefore involve 
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lengthy processes. Quantitative UV-Vis spectrophotometric analysis of substances is 
fundamentally governed by the Beer-Lambert’s law which states that: 
When a beam of light is passed through a transparent cell containing a solution of an 
absorbing substance, attenuation of the intensity of light may occur (Behera et al, 
2012). Beer-Lambert’s law is expressed mathematically as; 
A = abc  
Where, A= absorbance or optical density, a= absorptivity/ extinction coefficient, b= 
radiation path length through sample (cm), c= concentration of solute in solution  
a and b are constant hence,  A (absorbance) is directly proportional to c 
(concentration). 
It is also important to note that solutions to be analysed have to be dilute enough as 
absorbance values are measured between 0 and 1.  
Therefore, to quantify pharmaceutical solid dosage forms using the UV-Vis 
spectrophotometer, a solution of the test tablet sample in transparent solvent is 
prepared and its absorbance is measured at a suitable wavelength. Normally, the 
wavelength of choice is the wavelength of maximum absorption (λmax) where there is 
negligible effect on the measured absorbance even in the event of small errors in 
setting the wavelength scale (Behera et al, 2012; Figueroa et al, 2015). To assay a 
single component sample containing other absorbing substances, the absorbance 
values of a range of standard solutions of the reference sample are recorded and used 
to produce a calibration curve. The concentration of the analyte in the test solution is 
then deduced from the calibration curve as the concentration corresponding to the 
measured absorbance of the solution. Figure 5.1 is UV-Vis spectra for paracetamol 
showing the λmax. 
    




Figure 6. 1 UV-Vis spectra of paracetamol standard showing λmax at 244nm 
6.2 Materials and Methods 
6.2.1 Materials and Reagents 
Reference sample of paracetamol was obtained from Sigma-Aldrich Company, Dorset 
UK. UV grade methanol was obtained from Fisher Scientific Ltd. Loughborough, UK.  
6.2.2 Test Tablet Samples 
OTC paracetamol tablets obtained from different countries around the world which had 
been quantitatively screened using ATR-FTIR (Chapter 3) were subjected to UV-Vis 
analysis for the purpose of validation. Table 6.1 provides a summary of the countries of 
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Table 6. 1 List of analgesic/antipyretic tablets containing paracetamol analysed using 



















6.2.3.1 UV-Vis Analysis 
UV spectra were collected using UV-Visible spectrophotometer, Helios Gamma 
(Thermo Electron Corporation England). The studied spectral range was 190-400nm 
with a scan interval of 0.5nm. Quantitative readings for paracetamol were taken at 
244nm. The UV-Visible spectrophotometer was piloted using the VisionLite software 
2.2 (Ueberlingen, Germany). 
6.2.4 Methods 
Pulverized and properly homogenised paracetamol tablet samples already used for 
ATR-FTIR analysis were subjected to UV-Vis analysis to verify results obtained by the 
Tablet(s) 




UK  2 500 
Belgium  2 1000 
Spain  2 500 
Spain  2 650 
Spain  2 1000 
Cyprus  2 500 
Switzerland  2 500 
Pakistan  2 500 
China  4 500 
UAE  4 500 
Rwanda  6 500 
Ghana  4 500 
India  16 500 
India  2 325 
India  1 650 
Jamaica  4 500 
Nigeria 4 500 
Nepal  8 500 
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ATR-FTIR. The protocol used by Behera et al (2012) was adopted for this part of the 
study.  
6.2.4.1 Preparation of paracetamol standard solutions for calibration graph 
10mg Paracetamol standard was dissolved in 15ml methanol. 85ml double-distilled 
water was then added to make up the volume to 100ml (100ppm). From the 100ppm 
solution, 2ml was taken and made up to 20ml (10ppm) with diluent. UV grade methanol 
and double-distilled water (15:85 v/v) was used as the diluent. Further dilutions of the 
10ppm paracetamol standard were made to obtain concentrations between 2ppm and 
10pmm (2, 4, 6, 8, and 10ppm) for paracetamol. 
6.2.4.2 Test Tablet Sample Preparation for UV analysis 
Each tablet was weighed and pulverised. 10mg of the pulverised paracetamol tablet 
was weighed and dissolved in 15ml methanol in a 100ml volumetric flask. 85ml double-
distilled water was added to make up the volume to 100ml. The solution was also 
filtered using Whatman® filter paper and 2ml was taken out of the filtered solution and 
made up to 20ml with diluent in a 20ml volumetric flask (10ppm). Working solutions of 
each tablet sample along with the paracetamol standard solutions were then subjected 
to UV-Vis analysis.  
6.2.4.3 Recording UV-Vis Spectra 
All UV spectra were measured in absorbance mode. The solution to be analysed was 
placed in a quartz cuvette and scanned across the range 190-400nm in the UV-Vis 
spectrophotometer. Each test sample solution was analysed in triplicate to ensure 
reproducibility and blanks were run after every sample. The cuvette was cleaned after 
each measurement with diluent and dried with paper tissue before placing the next 
sample in the cuvette to avoid contamination or sample carry over.  
    
226 | P a g e  
 
 
6.2.4.4 Quantitative analysis of test tablet samples and calculations 
All quantitative data was processed using Microsoft Excel 2016. Measured levels of 
paracetamol in working solution were obtained by substituting absorbance values for 
the samples in the calibration equation. The measured levels were indicative of the 
amount of the API in the 10ppm working solution of the test sample.   
Sample calculation for the amount of paracetamol in mg for each tablet is outlined in 
section 6.2.3.4.1. 
6.2.4.4.1 Sample Calculation for amount of Paracetamol based on portion of 
tablet 
Considering a 10ppm solution of a solvent extracted portion (10mg) of a paracetamol 
tablet with mean absorbance found to be 0.558 for instance,  
Mean absorbance reading= 0.558, calibration equation: y= 0.0635x + 0.0122 
Substituting the absorbance value for y in the calibration equation, 0.558= 0.0635x + 
0.0122 
x = (0.558 – 0.0122)/0.0635 = 8.59ppm 
10ppm tablet solution = 8.59ppm paracetamol and 10ppm=10mg/l 
Therefore, 
10mg of tablet powder contains 8.59mg paracetamol 
Actual amount of paracetamol in tablet = (Tablet weight/10)* Amount in 10mg of the 
tablet 
For tablet investigated, Tablet weight before crushing = 557.4mg 
Actual amount of paracetamol in tablet = (557.4/10) * 8.59= 55.74* 8.59 = 479mg 
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6.2.4.5 Validation of method  
The adopted method for paracetamol was validated in terms of linearity, limit of 
detection (LOD), limit of quantification (LOQ), accuracy and precision.  
6.2.4.5.1 Linearity 
Linearity was assessed based on the correlation coefficient (R2 - value) of the 
calibration curve for the mean absorbance versus the paracetamol standard 
concentrations. LOD and LOQ were determined based on the 3.3 σ/s and 10 σ/s 
criteria, respectively; where σ refers to the standard deviation of peak area and ‘s’ is 
the slope of the calibration curve. Paracetamol showed good linearity for the 
concentration range assessed  
6.2.4.5.2 Accuracy 
To check accuracy of the method, an incurred sample analysis was employed in 
assessing recovery for paracetamol standards based on the calibration curve. 
Absorbance values, for test samples, were substituted into the calibration curve 
equation to obtain measured concentrations of paracetamol standards and these were 
compared to expected concentrations of the paracetamol standards.    
6.2.4.5.3 Precision 
Precision of the method was based on repeatability and variation in terms of the level 
of the expected API shown by the relative standard deviation (%RSD). 
6.3 Results and Discussion 
6.3.1 UV Spectra 
Maximum absorbance was at 244nm±1 which was in agreement with Behera et al 
(2012) and Nnadi et al (2013) suggesting the presence of paracetamol in the samples 
analysed. 
    
228 | P a g e  
 
 
6.3.2 Quantification data: Linearity, Limit of Detection (LOD) and Limit of 
Quantification (LOQ) 
Calibration curves were plotted for paracetamol based on data shown in Table 6.2. 
Linearity of paracetamol data obtained using the method is highlighted by correlation 
coefficients ≥ 0.998. Relative standard deviation (RSD) values are also highlighted in 
addition to the mean and standard deviation (SD). Figure 6.2 shows the calibration 
curve with data points representing the mean±SD of 3 replicates. Correlation coefficient 
of the mean reading is also indicated.  




Replicate 1 Replicate 2 Replicate 3 Mean±SD RSD 
2 0.113 0.110 0.112 0.112±0.002 1.79 
4 0.229 0.228 0.229 0.229±0.001 0.45 
6 0.364 0.363 0.364 0.364±0.001 0.27 
8 0.496 0.490 0.493 0.493±0.004 0.81 
10 0.631 0.635 0.633 0.633±0.003 0.47 
 
 
Figure 6. 2 UV-Vis calibration curve for paracetamol standards over the range 2-10ppm 
(Data points represent the mean±SD of 3 replicates. 
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The data in Table 6.2 highlights the reproducibility of the data obtained. Using the 
equations mentioned earlier in section 6.2.3.5.1, LOD and LOQ for the method were 
1.0ppm and 3.0ppm respectively. 
6.3.3 Accuracy/ Incurred sample analysis 
Reference standards were analysed using the developed protocol. Mean absorbance 
values obtained were resubstituted in the calibration equation to check closeness of the 
measured concentration values based on the method to the expected concentrations 
as outlined in section 7.2.4.5.2. Results obtained were satisfactory as shown by the 
data in Table 6.3. Mean recovery of measured concentration values compared to 
expected concentrations was 99±3%. 
Table 6. 3 Comparison of measured versus expected concentrations of paracetamol in 







1. 2.0 2.0 100.0 
2. 4.0 3.8 95.0 
3. 6.0 5.9 98.3 
4. 8.0 8.0 100.0 
5. 10.0 10.2 102.0 
 
6.3.4 Precision of UV-Vis Data 
The data obtained using UV-Vis showed good precision with relative standard deviation 
(RSD) for calibration measurements found to be between 0.27-1.79 percent (Table 
6.2). 
6.3.5 UV-Vis Quantitative Data for Paracetamol Tablet Samples 
The actual concentration of working solutions for each tablet were calculated by 
substituting measured absorbance values in the calibration equation. The amount of 
paracetamol in each tablet was calculated following the steps outlined in section 
6.2.3.4.1. The amount of paracetamol in each tablet assessed is recorded in Table 6.4. 
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Table 6. 4 Summary of UV-Vis quantitative data for paracetamol tablets from around the 













 UK (n=2) 
UK P1T1 532±4 
500 
UK P1T2 479±3 
 Cyprus (n=2) 
Cyp P1T1 438±6 




Swz P1T1 523±6 
Swz P1T2 508±5 
  
Spn P1T1 529±7 
Spn P1T2 515±6 
Europe (n=14) Spain (n=6) 
Spn P2T1 678±8 
650 
Spn P2T2 648±5 
  
Spn P3T1  1005±13 
1000 
Spn P3T2 1008±10 
 Belgium (n=2) 
Bel P1T1 1031±11 
Bel P1T2 1090±11 
Asia & Middle 
East (n=37) 
India (n=19) 
Ind P1T1  480±3 
500 
Ind P1T2 545±5 
Ind P2T1 521±5 
Ind P2T2 539±3 
Ind P3T1 464±4 
Ind P3T2 499±4 
Ind P3T3 528±4 
Ind P4T1 478±3 
Ind P4T2 550±5 
Ind P5T1 504±3 
Ind P5T2 539±4 
Ind P5T3 485±3 
Ind P6T1 487±7 
Ind P6T2 463±6 
Ind P7T1 502±7 
Ind P7T2 442±6 
Ind P8T1 365±3 
325 
Ind P8T2 358±3 
Ind P9T1  660±6 650 
Pakistan (n=2) 
Pak P1T1  449±6 
500 
Pak P1T2 453±8 
Nepal (n=8) 
Nep P1T1  501±5 
Nep P1T2 498±6 
Nep P2T1 497±7 
Nep P2T2 475±7 
Nep P3T1 450±4 
Nep P3T2 494±3 
Nep P4T1 517±6 
Nep P4T2 552±5 
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Chn P1T1 541±4 
 
Chn P1T2 495±3 
Chn P2T1  488±3 
Chn P2T2 548±4 
UAE (n=4) 
UAE P1T1 525±7 
UAE P1T2  513±6 
UAE P2T1 484±5 





Rwa P1T1 543±4 
500 
Rwa P2T1  476±3 
Rwa P3T1  511±4 
Rwa P3T2 581±4 
Rwa P4T1  503±3 
Rwa P4T2 519±4 
Ghana (n=4) 
Gha P1T1 476±5 
Gha P1T2 504±5 
Gha P2T1 508±6 
Gha P2T2 479±6 
Jamaica (n=4) 
Jam P1T1 510±5 
Jam P1T2  515±6 
Jam P2T1  533±6 
Jam P2T2 511±7 
 
Nigeria (n=4) 
Nig P1T1 463±2  
 Nig P1T2 479±4  
 Nig P2T1 516±10  
 Nig P2T2 547±3  
 
Results shown in Table 6.4 confirm UV quantitative results for all the tablets generally 
fell within the allowed limits by the British Pharmacopoeia (85-115% of expected 
amount) (BP, 2017) and well within the global threshold limits (FDA, 2014). These 
generally agree with the ATR-FTIR data in Chapter 3.  
    




Figure 6. 3 Ratio of measured to expected amounts of Paracetamol in tablet samples 
from around the world using UV-analysis (a) 14 tablet samples from Europe (b) 37 tablet 
samples from Asia and the Middle East (c) 18 tablet samples from Africa and the 
Caribbean Islands 
 
    
233 | P a g e  
 
 
Just like with the ATR-FTIR data, the UV-Vis data is presented as a plot of the ratio of 
measured to expected amounts of paracetamol versus the tablet sample origin in Fig 
6.3(a-c). The diagrams showing paracetamol data from three regions (Europe; Asia 
and the Middle East; Africa and the Caribbean Islands) clearly indicates that all 
samples generally fall within the accepted limits as observed in Table 6.4. However, 
some significant differences were noted. High values were obtained for some tablets 
from Cyprus (Cyp P1T1, Cyp P1T2) and India (Ind P8T1, Ind P8T2) using ATR-FTIR 
when compared to UV-Vis data for the same tablets. On the other hand, low 
paracetamol levels were obtained from both ATR-FTIR and UV-Vis analysis for tablets 
from Pakistan (Pak P1T1, Pak P1T2). Results based on probe mass spectrometry in 
Chapter 4 identified a second API (aceclofenac) in addition to the paracetamol in the 
Ind P8 tablets. Therefore, lower paracetamol values with UV-Vis further suggests that 
although paracetamol is present in these tablets (Ind P8) as identified by the ATR-FTIR 
technique, the second API could be the reason for higher paracetamol values in the 
region of the ATR-FTIR spectra assessed. A detailed comparison of the techniques 
employed in the study and possible reasons for variation in the data are discussed in 
Chapter 8. In addition, the significance of the proposed rapid analytical methods in the 
screening process for FSMs (especially in LMICs) is highlighted.    
General agreement between ATR-FTIR further highlights the potential of ATR-FTIR in 




    




The quantitative determination of paracetamol in pharmaceutical tablet formulations 
using UV-Vis spectrophotometry as outlined in this chapter produced some findings 
worthy of note. UV-Vis results obtained for paracetamol test tablets confirmed the 
presence of paracetamol in all the tablets analysed via ATR-FTIR in Chapter 3 further 
validating the data obtained. UV-Vis spectrophotometry involves a lengthy (solvent 
extraction) sample preparation process and would require adequate training of the 
technician handling the equipment. Training of the technician or operator is also 
important because sample specific method development (involving solvent extraction of 
the analyte) is required in order to obtain reproducible data and this has to be done 
manually.   
With UV-Vis data indicating paracetamol levels for all the tablet samples assessed fell 
within acceptable limits (and mostly in agreement with ATR-FTIR), it was therefore 
important to reassess tablets samples where significant differences were observed 
between the two techniques. Further tests will provide understanding on the reason for 
the variance in data for the identified tablets. Therefore, investigations based on liquid 
chromatography, identified as the pharmacopoeia gold standard was necessary. The 
tablet samples with inconclusive paracetamol data based on UV-Vis and ATR-FTIR 
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As established in previous chapters, the intent of falsifiers of medicine is to deceive and 
anonymity allows falsifiers of medicines to thrive. As a result, the differences between 
FSMs and genuine medicines need to be subtle to avoid being detected. 
Comprehensive data is therefore needed in order to discriminate a falsified or 
substandard medicine from a genuine one (Dégardin et al, 2015). It is difficult to find 
one technique that provides all the necessary information when screening for FSMs. As 
observed with the techniques employed in Chapters three to six, each technique 
provides unique and valuable information about the medicines being analysed.  A good 
understanding of what information is needed at each stage of the screening process 
will then inform the approach to be taken (Dégardin et al, 2014). Just as speed of 
analysis is crucial in the forensic analysis of FSMs, sensitivity cannot be overlooked 
especially if this information is to form the basis for criminal investigations. It is 
important that cases of false positive or negative results are ruled out. This is to avoid a 
situation where either genuine medicines are identified as falsified thereby denying the 
patients access to these medicines or falsified medicines are identified as genuine 
posing a threat to public health. Validation of data obtained during preliminary 
analytical screening of medicines is therefore necessary in order to make conclusive 
statements about the genuineness of medicines. Identification of an FSM is usually a 
two stage process where rapid screening tests are used on site followed by 
confirmatory tests using more sophisticated laboratory based equipment such as the 
liquid chromatography mass spectrometer combination (LC-MS). 
Liquid chromatography is one of those techniques identified as a gold standard for the 
analysis of medicines (Kovacs et al, 2014; Zou et al, 2017; Montaseri and Forbes, 
2018) as explained in detail in chapter two. Prior to LC analysis solvent extraction of 
medicines from the tablet is required and so sampling time is much longer than with 
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simpler techniques such as the spectroscopic techniques (in chapters three and four) 
and probe mass spectrometry (chapter five). However, LC can also be combined with 
mass spectrometers to provide more information about the medicine in one study. 
Liquid chromatography- mass spectrometry (LC-MS) combines the separation 
capabilities of liquid chromatography with the mass detection capabilities of mass 
spectrometry. Consequently, several studies have used (LC-MS) in the analysis of 
medicines (Lohmann and Karst, 2006; Van Quekelberghe et al, 2008; Lou et al, 2010). 
Fenk et al (2010) employed LC-MS in the quantitative analysis of paracetamol, 
acetylsalicylic acid and caffeine. Fiori and Andrisano (2014) developed LC-MS 
methods for quantifying six glucocorticoids in pharmaceutical formulations. 
The aim of this study was to further validate data for the API (paracetamol) obtained via 
ATR-FTIR spectroscopy in addition to the UV-Vis data presented in the previous 
chapter. LC-MS is therefore proposed as a second check or second line validation 
especially where there is variation in results between initial simple authentication 
techniques and the first confirmatory techniques used (UV-Vis spectroscopy).  
Beyond the validation of ATR-FTIR data for paracetamol, LC-MS results will also allow 
a comparison of the performance of both the UV-Vis and LC-MS quantitative 
techniques approved by the British Pharmacopoeia. Details of the performance of 
different techniques forms the basis for the next Chapter. An assessment of the data 
provided by different techniques will provide information on the choice of analytical 
technique to be used during different stages of screening for falsified and substandard 
medicines.  
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7.2 Materials and Methods 
7.2.1 Materials and Reagents 
Reference paracetamol standard was obtained from Sigma-Aldrich Company, Dorset 
UK. Formic acid and LC-MS grade methanol and water were obtained from Fisher 
Scientific Ltd, Loughborough, UK.  
7.2.2 Test Tablet Samples 
Selected tablet formulations containing paracetamol already analysed via ATR-FTIR 
spectroscopy and UV-Vis Spectroscopy in earlier chapters were subjected to LC-MS 
analysis in order to further assess the performance of the techniques and validate the 
results obtained. LC-MS analysis is costly to run both in terms of the instrumentation, 
the quality of the solvents needed and the time taken for each individual analysis. The 
initial samples were selected for analysis either because the doses covered the 
therapeutic range or earlier work had suggested the tablets might be suspect. Details 
of the tablets analysed including the expected dose of each tablet and country of origin 
are outlined in Table 7.1. 
Table 7. 1 Paracetamol Tablet Samples analysed and their origin 
Country (n) Tablet* Expected Amount (mg) 
UK (2) UK P1T1, UK P1T2 500 
Cyprus (2) Cyp P1T1, Cyp P1T2 500 
Pakistan (2) Pak P1T1, Pak P1T2 500 
Belgium (2) Bel P1T1, Bel P1T2 1000 
India (2) Ind P8T1, Ind P8T2 325 
Note: n = number of samples, *P1T1= Pack 1 Tablet 1 and so on.  
7.2.3 Instrumentation 
The Agilent 6120 Quadrupole LC/MS system with its accompanying OpenLab CDS 
Chemstation Edition C.01.09 software for data acquisition and analysis was used. The 
LC-MS conditions for the separation of paracetamol were as follows: 
LC conditions: 
Column- Gemini C18 (250 x 4.60mm, 5µm) (Phenomenex) 
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Mobile Phase: (A) 0.1% formic acid in water (B) 0.1% formic acid in Methanol;  
A:B = 60:40 
Flow rate: 0.7ml/min 
Run time: 10mins 
Sample injection volume: 20µl 
MS conditions: 
Ionisation: Atmospheric Pressure Ionisation- Electrospray (API-ES) positive ion mode 
m/z range: 100-350 
Fragmentor: 100V 
Drying gas flow: 11l/min 
Nebulizer pressure: 60psig 
Drying gas temperature: 310°C 
The Agilent 6120 Quadrupole LC/MS system comes with an autosampler that permits 
the instrument to be set to run multiple injections of all the standard solutions and the 
test samples in one go with experimental data collected and processed when all 
analysis is completed. For this analysis, the instrument was programmed to run three 
injections per sample with a blank run at the start and after each sample. No carry over 
was observed from one sample to the next. 
7.2.4 Methods 
As mentioned earlier in the review chapter (Chapter 2), liquid chromatography (LC) is 
one of the pharmacopoeial gold standards for analysis of medicines. Consequently, 
already established LC methods for quantifying medicines were adopted and modified 
for this validation study (Attimarad, 2011; Chandra et al, 2012; Akgeyik et al, 2016).  
7.2.4.1 Preparation of Test Tablet Samples for LC-MS analysis 
To determine the paracetamol content of the test tablet samples, an amount of powder 
for each tablet (already crushed and used for ATR-FTIR and UV-Vis analysis) 
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equivalent to 15.1 mg of paracetamol, based on the stated dose, was accurately 
weighed out and dissolved in 100ml of diluent in a 100ml volumetric flask. LC-MS 
grade methanol and water (40:60 v/v) was used as the solvent. The solution was 
sonicated for 30 minutes to make sure paracetamol in the tablet powder had dissolved 
completely. Filtration was done with 0.45µm nylon syringe filters and the filtered 
solution was further diluted to obtain working solutions of 50µM paracetamol for each 
tablet. These working solutions for each tablet were then subjected to LC-MS analysis 
along with calibration standard solutions using parameters mentioned earlier in section 
7.2.3.  
7.2.4.2 Preparation of paracetamol standard solutions and calibration graphs  
A stock solution was prepared by dissolving 15.1mg of paracetamol reference standard 
in 40ml methanol in a 100ml volumetric flask. This was shaken properly and made up 
to the mark with water to obtain a 1mM solution of paracetamol. The solution was then 
filtered with a 0.45µm nylon syringe filter. Serial dilutions of the 1mM stock solution 
were made to obtain concentrations in the range of 5-80µM (5, 7.5, 10, 25, 50, 60, 75 
and 80 µM) for paracetamol.  
7.2.4.3 Chromatograms and Mass spectra- Qualitative analyses 
All chromatograms and spectral data were collected for each sample in positive 
ionisation mode using parameters as outlined in the instrumentation section. 
Characteristic paracetamol peak was present and reproducibility of data in terms of 
retention time of paracetamol was assessed. Data was collected in both scan mode 
and single ion monitoring (SIM) mode for the protonated molecular ion [MH]+ of 
paracetamol at m/z 152. In scan mode, characteristic ions for paracetamol were 
identified from the mass spectra recorded.  
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7.2.4.4 Quantitative analysis of test tablet samples and calculations 
All quantitative data was processed using Microsoft Excel 2016. Measured levels of 
paracetamol in working solution were obtained by substituting peak area values for the 
samples in the calibration equation. The measured levels were indicative of the amount 
of the API in 50µM working solution of the test sample.  Since working solution was a 
20 fold dilution of the 1mM stock, actual concentration of paracetamol in stock was 20 
times the amount in the 50µM solution. Test tablet sample equivalent of 15.1mg was 
dissolved to obtain 1mM (1000µM) stock solution. Therefore,  
If 15.1mg …………. 1000µM 
Amount of API dissolved (mg) = (15.1 x Measured concentration (µM) x 20) /1000 
Consequently, 
Actual dosage of API in tablet (mg) = (W/AT) x AP 
Where W = Total weight of the tablet; AT = Amount of tablet powder dissolved in 
solvent and AP = Amount of API in tablet powder dissolved (mg). 
7.2.4.5 Validation of method  
The adopted method was validated in terms of linearity, limit of detection (LOD), limit of 
quantification (LOQ), accuracy and precision.  
7.2.4.5.1 Linearity 
Linearity was assessed based on the correlation coefficient (R2 - value) of the 
calibration curve for the mean peak area versus the paracetamol standard 
concentrations. LOD and LOQ were determined based on the 3.3 σ/s and 10 σ/s 
criteria, respectively; where σ refers to the standard deviation of peak area and ‘s’ is 
the slope of the calibration curve. Paracetamol was found to obey Beer Lambert’s law 
for these concentrations as it showed good linearity.  
    




To check accuracy of the method, recovery for paracetamol standards based on the 
calibration curve was assessed using an incurred sample analysis protocol. Peaks 
areas, for test samples, were substituted into the calibration curve equation to obtain 
measured concentrations of paracetamol standards and these were compared to 
expected concentrations of the paracetamol standards.    
7.2.4.5.3 Precision 
Precision of the method was assessed based on repeatability and variation in terms of 
the level of the expected API shown by the relative standard deviation (%RSD). 
7.3 Results and Discussion 
7.3.1 Qualitative analysis - Chromatograms 
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Figure 7. 2 LC-MS traces for paracetamol tablet (a) TIC scan mode (b) SIM mode at m/z 
152  
Figures 7.1 and 7.2 show the total ion chromatogram for a paracetamol standard and 
test tablet sample respectively. Chromatograms for each sample were recorded in both 
scan and SIM m/z 152 as shown. The presence of the single peak with similar retention 
times (4mins) in both the standard and the test sample suggests the presence of the 
API (paracetamol) in the tablets. In all test tablets analysed, paracetamol was found to 
be present.  
 
Figure 7. 3 LC-MS traces for paracetamol tablet (Ind P8) (a) TIC scan mode (b) SIM 
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Figure 7.3 is the chromatogram for the paracetamol tablet sample identified as suspect 
and needing further analysis based on ATR-FTIR data in Chapter three (Ind P8). There 
was no obvious difference in the chromatograms with Fig 7.3 showing similarities with 
Fig 7.1 and 7.2. The mass spectra were then considered for extra information about the 
tablets. 
7.3.2 Qualitative analysis - Mass spectra 
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Figure 7. 5 Mass spectrum for paracetamol tablet (a) scan mode (b) SIM mode at m/z 
152 
In Figs 7.4 and 7.5, the [M + H]+ ions of analytes are highlighted. Ions at m/z 152 and 
110 confirm the presence of paracetamol in both the standard and the paracetamol 
tablet. These results are same as those observed with the ASAP probe MS in Chapter 
five further validating the probe MS data.  
Based on the mass spectral data, the presence of paracetamol was also confirmed for 
all selected tablets assessed.  
The mass spectra for the sample (Ind P8) identified as suspect using ATR-FTIR was 
studied in scan mode. Paracetamol ions were confirmed at m/z 152 and 110 as shown 
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in Fig 7.6a. In addition, ions at m/z 289 and 215, identified as fragment ions for 
aceclofenac, were also detected at a retention time of 2.586min (Fig 7.6b). This result 
also agrees with probe MS data in Chapter five confirming the presence of another API 
(aceclofenac) in the Ind P8 tablets assessed. 
Figure 7. 6 Mass spectrum for suspect paracetamol tablet using scan mode at (a) 
3.875minutes retention time (b) 2.586 minutes retention time  
7.3.3 Quantification data: Linearity, Limit of Detection (LOD) and Limit of 
Quantification (LOQ) 
Calibration curves were plotted for paracetamol based on data shown in Table 7.2. 
Relative standard deviation (RSD) values are also highlighted in addition to the mean 
    
249 | P a g e  
 
 
and standard deviation (SD). Linearity of paracetamol data obtained using the method 
is highlighted by correlation coefficients ≥ 0.997. Fig 7.7 shows the calibration curve 
with all data points (including replicate readings for each concentration) and correlation 
coefficient of the mean reading.  




Replicate 1 Replicate 2 Replicate 3 Mean±SD RSD 
5 24087 24079.5 23877.3 24014.6±119 0.50 
7.5 32979.8 32246.6 32802.5 32676.3±383 1.17 
10 36145.8 36511 36108 36254.9±227 0.61 
25 74944.5 75757.8 75734.6 75479.0±463 0.61 
40 125417 122499 125657 124524.3±1758 1.41 
50 138961 138978 138311 138750.0±380 0.27 
60 166498 165109 166399 166002.0±775 0.47 
75 202910 201497 203973 202793.3±1242 0.61 
80 212561 216584 214618 214587.7±2012 0.94 
 
 
Figure 7. 7 LC-MS Calibration curve for paracetamol standards over the range 5-80µM 
All three replicates per paracetamol standard analysed are displayed in Fig 7.7 
indicating reproducibility of the data. Using the equations mentioned earlier, LOD and 
LOQ for the method were calculated to be 3.0µM and 9.1µM respectively. 
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7.3.4 Accuracy/ Incurred sample analysis 
Reference standards were analysed using the developed protocol. Mean peak area 
values obtained were resubstituted in the calibration equation to check closeness of the 
measured concentration values based on the method to the expected concentrations 
as outlined in section 7.2.4.5.2. Results obtained were satisfactory as shown by the 
data in Table 7.3. Mean recovery of measured concentration values compared to 
expected concentrations was 98±7%. 
Table 7. 3 Comparison of measured versus expected concentrations of paracetamol in 







1. 5 4.3 85.6 
2. 7.5 7.7 102.5 
3. 10 9.1 90.9 
4. 25 24.5 98.0 
5. 40 43.8 109.4 
6. 50 49.4 98.7 
7. 60 60.1 100.1 
8. 75 74.5 99.4 
9. 80 79.2 99.0 
 
7.3.5 Precision of Data 
The data obtained using LC-MS showed good precision with relative standard deviation 
(RSD) for calibration measurements found to be between 0.27-1.41percent (Table 7.2). 
7.3.6 Quantitative Data for Test Tablet Samples 
Actual concentration of working solution for test tablets (expected to be 50µM) was 
deduced by substituting the peak area for each sample in the calibration equation. 
Actual amount of paracetamol in tablet mixture dissolved and total paracetamol dosage 
in the whole tablet were calculated using details explained in section 7.2.4.6. Total 
paracetamol dosages for all test tablets assessed are shown in Table 7.4. 
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Table 7. 4 Quantitative results for paracetamol tablet samples analysed and their origin 
 






UK P1T1 499.2±9 
500 
 
UK P1T2 502.3±3 
Cyprus (2) 
Cyp P1T1 494.6±9 
Cyp P1T2 520.1±13 
Pakistan (2) 
Pak P1T1 496.9±8 
Pak P1T2 499.0±6 
Belgium (2) 
Bel P1T1 1001.9±7 
1000 
Bel P1T2 989.4±19 
India (2) 
Ind P8T1 329.4±3 
325 
Ind P8T2 324.8±5 
**  Results are the mean±SD of three replicates 
Results shown in Table 7.4 confirm results for all the ten tablets assessed to be well 
within allowed limits by the British Pharmacopoeia (85-115% of expected amount). 
Tablets which were initially identified as questionable or at the threshold limit (using the 
quick spectroscopic technique - ATR-FTIR) and needing further analysis, were found to 
have passed screening based on the quantitative LC-MS paracetamol data obtained. 
These were also in agreement with UV-Vis data obtained in chapter six.  
7.4 Conclusion 
In screening for falsified and substandard medicines, time of analysis is very crucial but 
sensitivity of the technique employed is also important in order to obtain correct 
information. In this work sample extraction and the analytical run can take up-to 20 
minutes per sample and a balance between speed of analysis and sensitivity is 
therefore necessary to facilitate efficient screening for falsified and substandard 
medicines.  
Results obtained for selected paracetamol tablets using LC-MS clarifies data obtained 
via spectroscopic techniques by confirming paracetamol was present in the right 
amounts. However, it does not provide information about possible contaminants or 
additional APIs present. The LC-MS results further validate data obtained using MS 
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and solvent extraction techniques. Data based on LC-MS analysis together with data 
already acquired using other techniques (in Chapters three to six) also support the call 
for a sequential approach to screening medicines highlighted by the authentication 
pyramid in Chapter two. Simpler techniques can be used identify suspect samples in 
the field thereby cutting down the number of samples that need to be assessed in the 
laboratories. LC-MS is therefore very useful as a confirmatory technique in reassessing 
questionable samples identified based on simpler authentication techniques while 
screening for FSMs.  
Variation in data between the techniques can be linked to several factors including the 
sensitivity of the technique which will be discussed in more detail in the next chapter 
(Chapter eight).  A more efficient approach to screening for falsified and substandard 
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In previous chapters, analytical methods were assessed individually for their potential 
in the investigation of FSMs. Each analytical method employed provided unique and 
relevant information about the test tablets analysed. Therefore, cumulative assessment 
of these analytical methods and the corresponding data obtained will allow for an in-
depth understanding of the tablets samples and the analytical strategy required for the 
control of FSMs (Mackey et al, 2015; Shore, 2015; Rebiere et al, 2017). As mentioned 
in Chapter 2, the analytical strategy employed in the control of FSMs depends on 
several factors. The principal factor will be the country in which the analysis takes 
place, in this work, low and middle income countries (LMICs) are the concern. Within 
these countries other factors include, time and location of analysis, availability of funds, 
the purpose for the testing and the expertise of the operator (Martino et al, 2010; 
Dégardin et al, 2014; Rebiere et al, 2017).  
Based on the factors mentioned above, this chapter assesses the performance of the 
different analytical methods employed and the context within which each one can be 
applied to facilitate an efficient approach to the screening of FSMs. Furthermore, the 
development of an analytical strategy combining data from several techniques to arrive 
at conclusive decision about a suspect medicine is also outlined. 
8.2 Cost of Technique/Analysis 
The overall cost of using a particular analytical technique plays a major role in its 
feasibility in the screening of FSMs (Davison, 2011; Hamilton et al, 2016; Zou et al, 
2017). The gold standard confirmatory technique LC-MS (highlighted in Chapter 7) is a 
pharmacopoeia approved method for the qualitative and quantitative analysis of 
pharmaceutical formulations but is expensive. UV-Vis provides pharmacopoeia 
approved quantitative data but both these techniques require solvent extraction and 
trained technical staff and access to these confirmatory techniques will therefore be a 
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challenge in areas where funds are not readily available like the LMICs. In such regions 
these techniques might only be used in one or two regulatory or quality control 
laboratories located centrally. In countries like the UK, such instruments are available 
at the county analyst. There is also the high cost of analyses due to the need for 
trained staff, the use of solvents and the maintenance of the instrument since they are 
laboratory based equipment requiring a controlled environment (Dégardin et al, 2014).  
On the other hand, with IR based spectroscopic techniques like the ATR-FTIR and 
Raman (in Chapters 3 and 4) overall cost of analyses is much less since the equipment 
is considerably cheaper and test tablet samples can be analysed directly without 
solvent extraction thereby eliminating the cost of solvents (Nuhu, 2011; Custers et al, 
2016). They are also handy and easy to maintain making them good options for the 
analysis of test tablet samples in regions with limited funds. Furthermore, techniques 
such as Probe MS (Chapter 5) are cheaper than the LC-MS systems and comparable 
to the IR based systems but with better detection abilities than the spectroscopic 
techniques. Detection ability of the DIP-MS is discussed in section 8.6. Cost of analysis 
is also reduced compared to LC-MS because samples are analysed more quickly 
without solvent extraction. Table 8.1 summarizes estimated costs in pound sterling 
(GBP) of the equipment used in this study for the analysis of tablet medicines. 
Table 8. 1 Equipment costs – new purchase 
Type Lab based Portable Cost (GBP) 
UV-Vis Yes - 5,000-10,000 
Raman Yes - 30,000-100,000 
Raman - Yes 30,000-60,000 
ATR-FTIR Yes - 30,000-60,000 
ATR-FTIR - Yes 15,000-30,000 
ASAP-MS Yes - 60,000 
Probe MS Yes - 70,000-120,000 
LC-MS Yes - 80,000-120,000 
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8.3 Sampling time and sample throughput 
As established earlier, time is of essence in the detection of FSMs since unlike any 
other falsified goods; they pose a huge risk to public health. Analytical strategies for the 
detection of FSMs must therefore be able to spot these medicines within the shortest 
possible time in order to facilitate their immediate withdrawal from the market and 
improve patient safety (Fernandez et al, 2011).   
Considering the techniques employed, the ATR-FTIR and Raman techniques allowed 
rapid analysis of test tablet samples with results obtained in less than five minutes. 
ASAP Probe MS results were also obtained within the same time frame as with ATR-
FTIR and Raman spectroscopy. These techniques therefore provide an avenue for 
quick pass/fail tests on tablet samples and so many samples can be assessed within a 
short period of time. The requirements for these rapid techniques are similar to the 
airport scanners where the aim is to get as many individuals through the system 
retaining only those who are suspect.  
However, the pharmacopoeia approved techniques (UV-Vis and LC-MS) took much 
longer to obtain results which involved solvent extraction of the API before analysis of 
the sample to obtain data. These techniques were therefore more useful as second line 
confirmation for tablet samples identified as suspect by the IR based techniques 
(Chapters 6 and 7). Rapid pass/fail tests reduce the number of samples requiring 
analysis via solvent extraction techniques thereby saving time and the cost of running 
all samples available. 
8.4 Ease of use  
The ease of use determines the where and by whom the technique can be used in the 
detection of FSMs. This cuts across the sample preparation phase to the analysis of 
the test tablet sample. The rapid techniques employed in Chapters 3 -5 (ATR-FTIR, 
Raman spectroscopy and probe MS) are considered easy to use since tablet samples 
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(whole or crushed) are analysed directly without any need for solvent extraction. 
Eliminating the solvent extraction phase also helps in maintaining the integrity of the 
original tablet sample (non-destructive). The simplicity of the rapid techniques implies 
that they can be run by operators with minimal training if adequate software based 
identification is incorporated into the software. Quantitative UV-Vis and LC-MS on the 
other hand requires operators with advanced scientific training to correctly solvent 
extract APIs for analysis and also ensure analysis proceeds under the right 
experimental conditions. 
8.5 Complexity of Data Output  
Beyond the ease of use of the device, interpretation of experimental data is also 
important in the analysis of FSMs. Results obtained showed that though the 
spectroscopic techniques were quick and easy to use, data obtained using these 
techniques were more challenging to interpret. Spectra obtained for samples using 
ATR-FTIR and Raman spectroscopy (Chapters 3 and 4) had several peaks for the 
same analyte providing a fingerprint which could be used to identify the API as long as 
there was only one API present in the tablet. Multiple APIs produced complex 
overlapping spectra difficult to interpret.  
Conversely, Probe MS, and LC-MS were more specific with results showing peaks 
unique to the API being assessed.  
8.6 Detection Capability 
It is one thing for a technique to be able to identify the target API. It is another thing for 
that same technique to detect the API in the concentration at which it is present in the 
test tablet or indeed the presence of multiple APIs. 
Given the complexity of the spectral data obtained using IR based techniques (as 
discussed above), analyses of tablet medicines was most feasible with simpler single 
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API tablets (as with paracetamol). The difficulty in quantifying chloroquine using ATR-
FTIR PCA algorithm highlights the challenges that abound in the analysis of such APIs 
in tablets with spectral peaks that are not well defined or separated. In Chapter 4, 
Raman spectroscopy with PCA was employed in successfully discriminating 
paracetamol and chloroquine tablet samples into different groups depending on their 
formulation. However, the inability to discriminate the paracetamol tablets, Ind P4, 
(coloured and containing a second API), suggests that there might be a limit in the 
degree of difference detectable by the PCA algorithm. Due to the specificity of the 
probe MS, and LC-MS techniques, they are able to analyse complex/multiple API 
samples more effectively (Jonahnsson et al, 2014; Rebiere et al, 2017). The specificity 
of probe MS is evidenced by its use in this study for the characterisation of suspect 
tablet samples identified using ATR-FTIR (Ind P8T1 and Ind P8T2) and confirming the 
presence of another API in addition to paracetamol. However, there were challenges 
using probe MS for the direct quantification of paracetamol (Chapter 5) due to the 
negligible amounts of crushed tablet powder required for analysis. 
Figure 8.1 assesses the performance of the rapid ATR-FTIR method developed in the 
determination of paracetamol content of tablets versus the pharmacopoeia approved 
UV-Vis analysis. 
    




Figure 8. 1 Comparing the ratio of measured to expected amounts of paracetamol in 
tablet samples based on ATR-FTIR and UV-Vis showing agreement data from both 
techniques and the ability of the ATR-FTIR to spot suspect samples.  
Results based on ATR-FTIR and UV-Vis confirmed the presence of paracetamol in all 
tablets assessed. Quantitative results indicate two paracetamol tablet samples which 
were identified as suspect using ATR-FTIR but found to be within the accepted range 
using UV-Vis. These are the same tablets from India (Ind P8T1 and Ind P8T2) found to 
contain a second and undeclared API, aceclofenac. Aceclofenac could therefore be 
responsible for the overestimation of paracetamol concentration using ATR-FTIR 
compared to the UV-Vis data for the same tablets. Therefore, the novel ATR-FTIR 
method was able to identify these as suspect paracetamol tablets. Other techniques 
were used to identify the API (aceclofenac) which was not declared on the blister pack. 
Quantitative ATR-FTIR data also indicated that five other tablets were outside the 
general allowed limits (85-115% of expected) but within the threshold limits (75-125% 
of expected). These five tablets in addition to the IndP8 tablets and UK P1 tablets 
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Table 8.2 and Fig 8.2 assess the performance of ATR-FTIR, UV-Vis and LC-MS 
techniques based on the quantitative data for the selected paracetamol tablets.  
Table 8. 2 Comparing quantitative results for a selected range of paracetamol tablets 









UK P1T1 514±15 532±4 499±9 
500 
UK P1T2 505±15 479±3 502±3 
Cyprus 
Cyp P1T1 594±14 438±6 495±9 
Cyp P1T2 591±5 442±6 520±13 
Pakistan 
Pak P1T1 373±14 449±6 497±8 
Pak P1T2 451±8 453±8 499±6 
Belgium 
Bel P1T1 1196±55 1031±11 1002±7 
1000 
Bel P1T2 1178±24 1090±11 989±19 
India 
Ind P8T1 464±12 365±3 329±3 
325 
Ind P8T2 472±4 358±3 325±5 
                  
The results in Figure 8.2 are intriguing demonstrating that the most compound selective 
methods confirms the care taken to deliver the correct dosage level. The scatter 
observed from the other two techniques is derived from the decreasing specificity of the 
chosen quantification methodologies. UV-Vis requires solvent extraction, providing 
limited specificity, followed by measurement at a single wavelength whilst ATR-FTIR 
requires a crushed sample and measurement at a single wavelength. 
    




Figure 8. 2 Comparing the performance of ATR-FTIR, UV-Vis and LC-MS in the 
quantitative analysis of selected paracetamol tablets (showing increasing selectivity of 
the techniques). 
 
LC-MS and UV-Vis results for the selected tablets suggest paracetamol content falls 
within the expected range for all tablets analysed. Although ATR-FTIR overestimation 
of paracetamol in Ind P8 tablets could be linked to the presence of a second API, the 
reason for variation of quantitative data in Cyp P1, Pak P1 and Bel P1 is not clear. 
Rebiere et al (2017) highlights the use of PCA in checking for homogeneity in batches 
of tablet samples. Since PCA was used for ATR-FTIR quantification of test tablets, the 
variation in the data for Cyp P1, Pak P1 and Bel P1 might be due to differences in 
homogeneity of the samples. Unlike the suspect samples which showed variation in 
quantitative data using the three techniques, UK P1 tablets (used as control) showed 
close agreement in quantitative data based on ATR-FTIR, UV-Vis and LC-MS (Fig 8.2). 
This could be an indication of differences in the formulation of these tablets collected 
from different parts of the world. 
8.7 Site where analyses takes place 
Finally, a crucial question to be answered when developing a strategy for rapid 
detection of FSMs is “do you take the sample to the machine or the machine to the 
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sample?” In other words, it is important to decide if in-field or laboratory analysis of 
medicines would provide the required information. This will inform the technique of 
choice for analysis (Dégardin et al, 2015; Fadlallah et al, 2016).  
Spectroscopic techniques like ATR-FTIR and Raman can be manufactured as portable 
devices that can easily be moved around making them good choices for in-field 
analyses. The speed of analysis with the spectroscopic techniques implies that 
valuable information about tablet samples can be obtained within a short time and in 
the field. This will enhance the availability of data at every stage of the authentication 
process rather than waiting for data obtained in batches after test tablet samples must 
have been taken to laboratories for analysis. For instance, there are only ten WHO 
prequalified quality control laboratories in Africa (WHO, 2018). This implies that these 
ten quality control laboratories serve the 54 countries in the continent. If all samples for 
authentication in these countries are sent to these quality control laboratories to obtain 
primary data for the test samples, a backlog of samples would mean long waiting times 
in order to obtain any valuable information about the samples. 
There is also the question of whether bench-top or handheld devices should be used. 
This is also dependent on the data required. Zheng et al (2014) in their comparative 
study, assert that bench-top Raman spectrometers were found to be ten times more 
sensitive than the handheld devices. 
Techniques like probe MS, UV-Vis and LC-MS require a controlled environment to 
work effectively and so are laboratory based. Therefore, samples to be assessed using 
these techniques have to be taken to the laboratory for analyses since the devices are 
not rugged enough to be used on the field. A constant smooth electricity supply is also 
needed for these devices to operate whereas some of the portable spectroscopic 
techniques can be battery powered.  
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In deciding whether to analyse tablet samples on field or take them to the laboratory, 
some important factors need to be considered such as: 
 Likelihood of damaging samples while in transit 
 Storage conditions for samples  
 The kind of analysis required 
 Time frame during which results need to be delivered  
An analytical strategy can then be chosen after reviewing the requirements for the test 
tablet samples to be analysed. The analytical strategy outlines successive analytical 
steps required to arrive at the conclusion that a test tablet sample could be falsified or 
substandard. The analytical strategy could also be a standalone test that provides the 
information needed at the time. For instance, in a situation where there is adverse 
reaction due to FSMs and the patients’ life is at risk, conclusive results need to be 
delivered within the shortest time possible. Consequently, the analytical strategy 











    




Figure 8. 3 Analytical Strategy for the detection of Falsified and Substandard Medicines 
(FSMs) 
As mentioned earlier, simple and rapid analytical methods used for initial screening do 
not negate the use of the laboratory based pharmacopoeia approved methods since 
each method provides unique data. Analysis based on the rapid and pharmacopoeia 
methods identified in the analytical strategy can proceed simultaneously. It is important 
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to note that the analytical strategy can be re-adjusted or modified at each step to 
ensure valuable data is obtained. If a particular analysis does not provide enough 
information needed to help characterise the test tablet samples in question, an 
additional method may be employed to help validate initial results. 
8.8 Conclusion 
A good and efficient analytical strategy is required to effectively control FSMs. As such, 
a proper assessment of the situation has to be made for this to be achieved since there 
is difficulty in defining a general methodology for the rapid detection of FSMs (Rebiere 
et al, 2017; Zou et al, 2017). Based on data obtained from previous experimental 
Chapters (3-7), this chapter highlights scenarios in which the analytical techniques 
employed are most feasible. As mentioned earlier, this study is targeted at LMICs 
where facilities are not readily available. Rapid analytical methods developed in the 
study hold great potential in the quick screening and identification of FSMs especially in 
LMICs for a number of reasons: 
 They are cheaper than the solvent extraction LC-MS method which is the gold 
standard for analysis of medicines since funds spent in purchasing solvents and 
training technicians are saved. 
 They are quicker which implies that more tablet samples can be assessed 
within a short period of time with suspect samples sent for further analysis.  
 Data produced by the ATR-FTIR and Raman spectroscopy might be complex 
but these can be addressed by software programs for data analysis being part 
of the equipment set up. This will allow operators with little or no experience to 
run quick test on tablet samples with the equipment producing the data and the 
analysis of the data in one go. They are therefore, simple and easy to use. 
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 Although some of the rapid techniques (ATR-FTIR and Raman) may not be as 
selective as the UV-Vis and LC-MS, they provide quick YES/NO answers which 
is most important in the first line screening of medicines. 
 Portable versions of the ATR-FTIR and Raman equipment exist making these 
techniques suitable for in-field analysis of medicines especially in LMICs where 
rural areas are not easily accessible. A summary of major findings based on the 
rapid techniques employed are highlighted in Table 8.3. 
Table 8. 3 Key features and findings from rapid analytical techniques employed in the 








Tablet sample analysed directly x   x 
Crushed Tablet sample       
Identification of Single API       
Identification of Multiple APIs   x   
Quantification of API   x x 
 
Development of the analytical strategy used in this research that combines valuable 
data obtained from different techniques employed in order to produce robust analytical 
results in the authentication of medicines is also discussed. Analytical strategies for the 
detection of FSMs are therefore dependent on the context of the analyses and as such 
can be approached in different ways. This can be observed in the approach adopted in 
this study focusing on identification of FSMs in LMICs. 
A summary of the main findings in this research and future directions of the study are 
contained in the next chapter. 
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Falsified and substandard medicines are a menace which if not curbed could lead to 
devastating public health issues. It could occur at any point in the pharmaceutical 
distribution chain; from the manufacturers of medicines until just before it gets to the 
final consumer. Therefore, safeguarding of medicines is important in ensuring 
medicines dispensed or sold to patients are what they say on the pack. Hence, 
authentication of medicines is becoming an important area of research, especially with 
the recent increase in reports of all kinds of FSMs across the globe. 
Pharmacopoeia approved analytical methods like the HPLC have generally been used 
for the assessment of medicines but these methods are expensive, involve lengthy 
solvent extraction procedures and operate optimally in a controlled environment 
(laboratory). Control of FSMs is dependent on their early detection and withdrawal from 
the market. Thus, the speed of analyses and the availability of these analytical 
techniques at every point in the pharmaceutical distribution chain are important for 
effective screening of medicines. The high cost of these techniques implies that they 
might not be feasible in LMICs. 
For many years the ‘mini-lab’ which is a combination of simple liquid chromatography 
and colorimetric analyses has been used in LMICs for the identification of FSMs. These 
investigations did however require the use of solvent extraction prior to analysis. 
The work reported here demonstrated the novel use of ATR-FTIR spectroscopy as a 
simple, rapid and solvent free method for the determination of API content in 
pharmaceutical tablet formulations. Previous research in this area considered the use 
of conventional FTIR spectroscopy for the determination of API content. Conventional 
analyses using FTIR involve a rigorous and lengthy sample preparation protocol 
(Chapter 3) where KBr discs, containing the sample, are made for analysis. Maintaining 
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spectral reproducibility between disc samples is a huge challenge requiring a certain 
skill level from the analyst. Most studies using IR spectroscopy have also required 
manipulation of raw spectral data via baseline correction or normalisation. 
 The novel ATR-FTIR method in this study proposed a more simplified process; directly 
using raw spectral data for analysis. The performance of this method was investigated 
using paracetamol and chloroquine test tablets from around the world with a local 
reference library created consisting a range of APIs and excipients for identification of 
samples. Paracetamol identification and quantification was feasible with the method 
identifying suspect samples needing further investigation. Based on the characteristic 
peak identified, paracetamol could be detected in tablets down to 5% w/w. The whole 
process from crushing each test tablet to spectral analysis was done within five 
minutes. Paracetamol concentrations down to 10%w/w were quantified using a partial 
least square (PLS) regression approach and were found to be dependent on the 
excipient used in the preparation of standard paracetamol/excipient mixtures for 
calibration. Chloroquine on the other hand could be identified but performed poorly 
using the quantitative methods. Nevertheless, the ATR-FTIR method could still identify 
suspect chloroquine tablet by spectral comparison. Difficulty in quantifying chloroquine 
could be attributed to complexity in spectral fingerprint of the antimalarial API where 
peaks were less intense and not as well-separated/defined as with paracetamol. 
Raman spectroscopy is another rapid IR spectroscopic technique and one of the most 
commonly used for analysis of FSMs. However, just as with FTIR, most Raman studies 
have been based on manipulated spectra. Following the successful application of raw 
ATR-FTIR spectra for analyses of test tablets, raw Raman spectra were also used for 
the characterisation of paracetamol and chloroquine tablet samples. This work 
demonstrates that Raman spectroscopy with PCA is able to discriminate between 
different groups of tablet medicines without any manipulation of the raw spectra. This 
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novel Raman method could potentially be used in forensic/criminal investigations for 
discriminating tablet samples from the same origin or source and acquisition of data 
that is tenable in a law court. 
Furthermore, as mentioned in Chapter 2 and 5, there are no known studies on the use 
of probe MS for screening FSMs in the literature. This research highlights the use of 
probe MS for the rapid analysis of tablet dosage forms. Due to its specificity probe MS 
was used as a second-line rapid screening technique for further assessment of 
paracetamol and antimalarial tablet samples. Probe MS techniques were applied to 
tablets identified as suspect by the spectroscopic techniques and also to those with API 
levels lower than the limit of the detection for the IR based methods. Probe MS was 
able to confirm the presence of multiple APIs and also detect and identify a compound 
(API-aceclofenac) not declared on the blister pack of some suspect tablets identified by 
IR spectroscopy. However there was difficulty in the direct quantification of 
paracetamol with probe MS since calibration was non-linear.  
The use of UV-Vis spectroscopy and LC-MS for validation of ATR-FTIR quantitative 
data in this research suggests individual analytical techniques provide unique data 
which contributes towards detection of FSMs. However, the context of the analysis will 
determine what technique(s) should be used. Furthermore, this research also 
demonstrates that a combination of data acquired via different analytical techniques 
allows the investigator to arrive at a more informed decision about the tablet sample in 
question. Therefore the investigator is able to develop an efficient analytical strategy 
using techniques which when combined provide more conclusive data about the tablet 
sample being investigated within the shortest time possible. 
Finally, the potential use of the simple, rapid and solvent free analytical methods 
developed in this research, in addition to the pharmacopoeia approved methods, could 
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facilitate identification of FSMs on the field and even in the LMICs where sophisticated 
analytical facilities are not readily available. 
9.2 Recommendations and Future work 
Based on the findings of this study, the following recommendations for further work on 
the rapid identification of FSMs are suggested: 
 With respect to quantitative screening of APIs using ATR-FTIR spectroscopy, 
the method applied was successful for simpler API tablets with well-defined 
spectra such as paracetamol. However, there was difficulty in the direct 
quantification of chloroquine using the method developed. Therefore it is 
recommended the ATR-FTIR quantitative methods be modified to account for 
more complex/multiple API tablets. Modification of the method can be done by 
using more complex API/excipient mixtures for calibration. For example, the API 
can be mixed with more than one excipient in order to prepare a mixture that is 
even more representative of the pharmaceutical tablet formulation rather than 
the binary API/ excipient mixtures used in the current method. In addition, the 
potential of ATR-FTIR in the discrimination of chiral compounds via shifts in the 
IR band could also be investigated. This will enable the detection of falsified 
medicines where an enantiomer is used instead of the required API.  
 Raman spectroscopy in combination with PCA was successful in the 
discrimination of tablet samples into groups without spectral manipulation. It will 
therefore be interesting to consider the potential of Raman spectroscopy and 
PCA in the quantitative analyses of tablets samples using their corresponding 
raw spectra and not the manipulated spectra which is more common in the 
literature. 
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 Direct quantification of the API (paracetamol) was a challenge using both probe 
MS analyses. This is because calibration was not linear for higher 
concentrations of standard paracetamol/excipient mixtures. Non-linearity of 
calibration data could be due to inconsistency in amount of tablet powder used 
for analysis since minimal (µg) amounts were used for each run. Nevertheless, 
some linearity was observed for paracetamol in excipient concentrations less 
than or equal to 10% w/w. Paracetamol in excipient concentrations less than or 
equal to 10% w/w does not cover the range in which this API generally occurs 
in tablet medicines. This is, however, a common level for many APIs in tablet 
formulations and a proper understanding of the linearity observed at lower 
concentrations might provide a basis for improving the quantitative capabilities 
of the probe MS to cover this concentration range. Another way forward might 
be dispersing exact amounts of tablet powder in a matrix to eliminate slight 
variations between each run. 
In the grand scheme of things, efforts towards serialisation and traceability of 
medicines will go a long way in addressing FSMs. A central database providing real 
time monitoring of medicines from the manufacturer to the final consumer (including 
results of screening tests conducted while in transit) will help provide more valuable 
data about FSMs worldwide. The use of digital health in patient engagement could be 
useful in the fight against FSMs. Miniaturisation of analytical methods for screening 
medicines such that they can be incorporated in mobile phone applications, will allow 
the patient a final check on the medicine at the point of purchase. This will in turn 




    





A3.1 Calibration curve for Paracetamol in Maize starch for the range 1236 - 1210cm-1 
and peak centred at 1225cm-1 
 
A3.2 Calibration curve for Paracetamol in Maize starch for the range 1524 – 1210cm-1  
    




A3.3 Calibration curve for Paracetamol in Maize starch for the full spectral range 4000 
– 400cm-1 
 
